書籍詳細

I / 消化器疾患

P.44 掲載の参考文献

• 1) Nakajima S, Graham DY, Hattori T, et al.:Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000. Curr. Pharm. Des. 6:1503-1514, 2000
  pubmed

• 2) Enerback L:Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol. Microbiol. Scand. 66:289-302, 1966
  pubmed

• 3) Kitamura Y, Shimada M, Hatanaka K, et al.:Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 268:442-443, 1977
  pubmed

• 4) Enerback L, Miller HRP, Mayrhofer G:Methods for the identification and characterization of mast cells by light microscopy. In:MAST Cell Differentiation and Heterogeneity. ed by Befus AD, Bienenstock J, Denburg JA, Raven Press, New York, 1986, pp.405-417

• 5) Nakajima S, Krishnan B, Ota H, et al.:Mast cell involvement in gastritis with or without Helicobacter pylori infection. Gastroenterology 113:746-754, 1997
  pubmed

• 6) Kurose I, Granger DN, Evans DJ Jr, et al.:Helicobcater pylori-induced microvascular protein leakage in rats:role of neutrophils, mast cells, and platelets. Gastroenterology 107:70-79, 1994

• 7) Yamamoto J, Watanabe S, Hirose M, et al.:Role of mast cells as a trigger of inflammation in Helicobacter pylori infection. J. Physiol. Pharmacol. 50:17-23, 1999

• 8) Bechi P, Dei R, Di Bello MG, et al.:Helicobacter pylori potentiates histamine release from serosal rat mast cells in vitro. Dig. Dis. Sci. 38:944-949, 1993
  pubmed

• 9) Masini E, Bechi P, Dei R, et al.:Helicobacter pylori potentiates histamine release from rat serosal mast cells induced by bile acids. Dig. Dis. Sci. 39:1493-1500, 1994
  pubmed

• 10) Lutton DA, Bamford KB, O'Loughlin B, et al.:Modulatory action of Helicobacter pylori on histamine release from mast cells and basophils in vitro. J. Med. Microbiol. 42:386-393, 1995
  pubmed

• 11) Walls AF, He S, Teran LM, et al.:Granulocyte recruitment by human mast cell tryptase. Int. Arch. Allergy Immunol. 107:372-373, 1995
  pubmed

• 12) Serafin WE, Austen KF:Current concepts:mediators of immediate hypersensitivity reactions. N. Engl. J. Med. 317:30-34, 1987

• 13) Galli SJ:New concepts about the mast cell. N. Engl. J. Med. 328:257-265, 1993
  pubmed

• 14) Marshall JS, Bienenstock J:The role of mast cells in inflammatory reactions of the airways, skin and intestine. Curr. Opin. Immunol. 6:853-859, 1994
  pubmed

• 15) Goetzl EJ, Derian CK, Tauber AI, et al.:Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorylcholine mediators on human leukocyte function:delineation of the specific roles of the acyl substituents. Biochem. Biophys. Res. Commun. 94:881-888, 1980

• 16) Wershil BK, Furuta GT, Wang ZS, et al.:Mast cell-dependent neutrophil and mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. Gastroenterology 110:1482-1490, 1996
  pubmed

• 17) Nilsson G, Butterfield JH, Nilsson K, et al.:Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 153:3717-3723, 1994
  pubmed

• 18) Gruber BL, Marchese MJ, Kew RR:Transforming growth factor-β1 mediates mast cell chemotaxis. J. Immunol. 152:5860-5867, 1994

• 19) 中島滋美, 馬場忠雄, 服部隆則:胃炎と胃潰瘍における肥満細胞の役割と動態. Ther. Res. 20 (Suppl.1):S91-S94, 1999

• 20) Nakajima S, Arizono N, Hattori T, et al.:Increase in mucosal and connective tissue-type mast cells in the stomach with acetic acid-induced ulcer in rat. APMIS 104:19-29, 1996

• 21) Bamba N, Nakajima S, Hattori T, et al.:Stem cell factor expressed in human gastric mucosa in relation to mast cell increase in Helicobacter pylori-infected gastritis. Gastroenterology 120 (Suppl.1):A709, 2001

• 22) Saito H, Ebisawa M, Sakaguchi N, et al.:Characterization of cord-blood-derived human mast cells cultured in the presence of of steel factor and interleukin 6. Int. Arch. Allergy Immunol. 107:63-65, 1995
  pubmed

• 23) Gionchetti P, Vaira D, Campieri M, et al.:Enhanced mucosal interleukin 6 and 8 in Helicobacter pylori-positive dyspeptic patients. Am. J. Gastroentero. 89:883-887, 1994

• 24) Denburg JA:Basophil and mast cell lineages in vitro and in vivo. Blood 79:846-860, 1992
  pubmed

• 25) Tufano MA, Rossano F, Catalanotti P, et al.:Immunobiological activities of Helicobacter pylori porins. Infect. Immun. 62:1392-1399, 1994
  pubmed

P.54 掲載の参考文献

• 1) Bochner BS, Schleimer RP:Mast cells, basophils, and eosinophils:distinct but overlapping pathways for recruitment. Immunol. Rev. 179:5-15, 2001
  pubmed

• 2) Yoshikawa H, Tasaka K:Suppression of mast cell activation by glucocorticoid. Arch. Immunol. Ther. Exp. (Warsz) 48:487-495, 2000
  pubmed

• 3) Terada T, Matsunaga Y:Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Hepatol. 33:961-966, 2000
  pubmed

• 4) Matsunaga Y, Terada T:Mast cell subpopulations in chronic inflammatory hepatobiliary diseases. Liver 20:152-156, 2000
  pubmed

• 5) Yamashiro M, Kouda W, Kono N, et al.:Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study. Virchows Arch. 433:471-479, 1998
  pubmed

• 6) Koda W, Harada K, Tsuneyama K, et al.:Evidence of the participation of peribiliary mast cells in regulation of the peribiliary vascular plexus along the intrahepatic biliary tree. Lab. Invest. 80:1007-1017, 2000
  pubmed

• 7) Tsuneyama K, Kono N, Yamashiro M, et al.:Aberrant expression of stem cell factor on biliary epithelial cells and peribiliary infiltration of c-kit-expressing mast cells in hepatolithiasis and primary sclerosing cholangitis:a possible contribution to bile duct fibrosis. J. Pathol. 189:609-614, 1999
  pubmed

• 8) Nakanuma Y, Hoso M, Sanzen T, et al.:Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc. Res. Tech. 38:552-570, 1997
  pubmed

• 9) Galli SJ:New concepts about the mast cell. N. Engl. J. Med. 328:257-265, 1993
  pubmed

• 10) Kobayashi S, Nakanuma Y, Matsui O:Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases:a histological survey. Hum. Pathol. 25:940-946, 1994
  pubmed

• 11) Feldman MJ, Morris GP, Dinda PK, et al.:Mast cells mediate acid-induced augmentation of opossum esophageal blood flow via histamine and nitric oxide. Gastroenterology 110:121-128,1996
  pubmed

• 12) Sayama S, Iozzo RV, Lazarus GS, et al.:Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. J. Biol. Chem. 262:6808-6815, 1987
  pubmed

• 13) Foreman JC:Neuropeptides and the pathogenesis of allergy. Allergy 42:1-11, 1987
  pubmed

• 14) Akiyoshi H, Terada T:Mast cell, myofibroblast and nerve terminal complexes in carbon tetrachloride-induced cirrhotic rat livers. J. Hepatol. 29:112-119, 1998
  pubmed

• 15) Nakamura A, Yamazaki K, Suzuki K, et al.:Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am. J. Gastroenterol. 92:2245-2249, 1997
  pubmed

• 16) Omori M, Evarts RP, Omori N, et al.:Expression of alpha-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats. Hepatology 25:1115-1122, 1997
  pubmed

• 17) Uddin Ahmed AF, Ohtani H, Nio M, et al.:Intrahepatic mast cell population correlates with clinical outcome in biliary atresia. J. Pediatr Surg. 35:1762-1765, 2000
  pubmed

• 18) Sedlaczek N, Jia JD, Bauer M, et al.:Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am. J. Pathol. 158:1239-1244, 2001

• 19) Farrell DJ, Hines JE, Walls AF, et al.:Intrahepatic mast cells in chronic liver diseases. Hepatology 22:1175-1181, 1995
  pubmed

• 20) Kawada N:The hepatic perisinusoidal stellate cell. Histol. Histopathol. 12:1069-1080, 1997
  pubmed

P.59 掲載の参考文献

• 1) Friedman SL:The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328:1828-1835, 1993
  pubmed

• 2) Olaso E, Friedman SL:Molecular regulation of hepatic fibrogenesis. J. Hepatol. 29:836-847, 1998
  pubmed

• 3) Ginsburg H, Ben-Shahar D, Ben-David E:Mast cell growth on fibroblast monolayers:two-cell entities. Immunology 45:371-380, 1982
  pubmed

• 4) Atkins FM, Friedman MM, Subba Rao PV, et al.:Interaction between mast cells, fibroblasts and connective tissue components. Int. Arch. Allergy Appl. Immunol. 77:96-102, 1985
  pubmed

• 5) Levi-Schaffer F, Austen KF, Gravallese PM, et al.:Co-culture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc. Natl Acad. Sci. USA 83:6485-6488, 1986

• 6) Gaca MDA, Pickering JA, Arthur MJ, et al:Human and rat hepatic stellate cells produce stem cell factor:a possible mechanism for mast cell recruitment in liver fibrosis. J. Hepatol. 30:850-858, 1999

• 7) Murata K, Okudaira M, Akashio K:Mast cells in human liver tissue. Acta. Derm. Venereol. Suppl. (Stockh) 73:157-165, 1973
  pubmed

• 8) 黒川 晋:肝疾患における肝内組織肥満細胞の意義に関する検討. 日消誌 73:226-236, 1976

• 9) 斉藤孝治, 山川光徳, 伊藤正尚ほか:各種肝疾患における線維増生と細胞反応-特に肥満細胞の局在を中心として-. 消化器と免疫 27:172-177, 1992

• 10) Armbrust T, Batusic D, Ringe B, et al.:Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J. Hepatol. 26:1042-1054, 1997
  pubmed

• 11) Yamashiro M, Kouda W, Kono N, et al.:Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study. Virchows Arch. 433:471-479, 1998
  pubmed

• 12) Matsunaga Y, Kawasaki H, Terada T:Stromal mast cells and nerve fibers in various chronic liver diseases:relevance to hepatic fibrosis. Am. J. Gastroenterol. 94:1923-1932, 1999
  pubmed

• 13) Matsunaga Y, Terada T:Mast cell subpopulations in chronic inflammatory hepatobiliary diseases. Liver 20:152-156, 2000
  pubmed

• 14) Farrell DJ, Hines JE, Walls AF, et al.:Intrahepatic mast cells in chronic liver diseases. Hepatology 22:1175-1181, 1995
  pubmed

• 15) Nakamura A, Yamazaki K, Suzuki K, et al.:Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am. J. Gastroenterol. 92:2245-2249, 1997
  pubmed

• 16) Rioux KP, Sharkey KA, Wallace JL, et al.:Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis. Hepatology 23:888-895, 1996
  pubmed

• 17) Akiyoshi H, Terada T:Mast cell, myofibroblast and nerve terminal complexes in carbon tetrachloride-induced cirrhotic rat livers. J. Hepatol. 29:112-119, 1998
  pubmed

• 18) Okazaki T, Hirota S, Xu ZD, et al.:Increase of mast cells in the liver and lung may be associated with but not a cause of fibrosis:demonstration using mast cell-deficient Ws/Ws rats. Lab. Invest. 78:1431-1438, 1998

• 19) Sugihara A, Tsujimura T, Fujita Y, et al.:Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. J. Hepatol. 30:859-867, 1999
  pubmed

• 20) Ramos SG, Montenegro AP, Goissis G, et al.:Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol. Int. 44:655-661, 1994
  pubmed

P.65 掲載の参考文献

• 1) 松田修:アレルギー. 栄養免疫学-病態疾患と治療-, 渡辺明治編, 医歯薬出版, 東京, 1996, pp. 136-142

• 2) Kiyono H, Bienenstock J, McGhee JR, et al.:The mucosal immune system:features of inductive and effector sites to consider in mucosal immunization and vaccine development. Reg. Immunol. 4:54-62, 1992
  pubmed

• 3) Kato T, Owen RL:Structure and function of intestinal mucosal epithelium. In:Handbook of Mucosal Immunology, ed. by Ogra PL, Mestecky J, Lamm ME, et al., Academic Press, San Diego, 1994, pp.11-26

• 4) Croitou K, Bienenstock J:Characteristics and functions of mucosal-associated lymphoid tissue. In:Handbook of Mucosal Immunology ed. by Ogra PL, Mestecky J, Lamm ME, et al., Academic Press, San Diego, 1994, pp.141-148

• 5) 後藤真生, 好田正, 八村敏志ほか:腸管免疫系における食物アレルゲンの認識機構. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.46-50

• 6) 矢島知治, 渡辺守:抗原投与量による oraltolerance 誘導機序の違い. Oral toleranceとは?-腸管免疫応答のトピックス (別冊医学のあゆみ), 石井祐正編, 医歯薬出版, 東京, 1997, pp.34-36

• 7) 南野昌信, 石川博通:腸管上皮間T細胞と腸管粘膜免疫応答. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.16-19

• 8) 下条直樹, 河野陽一:食物アレルゲン特異的T細胞の機能. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.20-24.

• 9) de Jong EC, Spanhaak S, Martens BP, et al.:Food allergen (peanut)-specific TH2 clones generated from the peripheral blood of a patient with peanut allergy. J. Allergy Clin. Immunol. 98:73-81, 1996
  pubmed

• 10) McMenamin C, Holt PG:The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+T cell-mediated but MHC class II-restricted CD4+T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 178:889-899, 1993

• 11) 三浦総一郎, 藤森斉:腸管リンパ球のmigrationと腸管アレルギー. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.25-29

• 12) 寺井格, 小林邦彦:IgA, IgEの食物抗原への抗体活性. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編医歯薬出版, 東京, 1999, pp.57-62

• 13) 平澤典保, 大内和雄:肥満細胞におけるヒスタミン放出機序. 医学のあゆみ 184:961-964, 1998
  Medical*Online

• 14) 藤山佳秀, 内原啓次:アラキドン酸カスケードと粘膜障害. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.39-45

• 15) 向山徳子:食物アレルギーの診断. 食物アレルギーの最前線 (別冊医学のあゆみ), 名倉宏編, 医歯薬出版, 東京, 1999, pp.81-85

P.73 掲載の参考文献

• 1) 杉本道代, 豊田 茂:小児期アレルギー性胃腸症の病態に関する検討. 日本小児栄養消化器病学会雑誌 12:126-138, 1998
  Medical*Online

• 2) 篠原公一, 山城雄一郎:新生児の消化管機能の発達-早期授乳は消化管機能の発達を促進. 周産期医学 31:301-306, 2001

• 3) 豊田 茂:食物アレルギーと消化管免疫. 医薬の門 32:32-37, 1992

• 4) Foreman J, Jordan C:Histamine release and vascular changes induced by neuropeptides. Agents Actions 13:105-116, 1983
  pubmed

• 5) Payan DG, Levine JD, Goetzl EJ:Modulation of immunity and hypersensitivity by sensory neuropeptides. J. Immunol. 132:1601-1604, 1984
  pubmed

• 6) Sampson HA:Food allergy. Part 1:immunopathogenesis and clinical disorders. J. Allergy Clin. Immunol. 103:717-728, 1999
  pubmed

• 7) 位田 忍, 高橋まり, 吉村文一ほか:十二指腸粘膜生検でヒスタミン陽性マスト細胞の著明な浸潤を示した重症食物アレルギーの女児例. 日小児アレルギー会誌 13:133, 1999

• 8) 藤澤隆夫:好酸球の構造. 細胞 30:294-299, 1998

• 9) Gounni AS, Lamkhioued B, Ochiai K, et al.:High-af finity IgE receptor on eosinophils is involved in defence against parasites. Nature 367:183-186, 1994

• 10) 茄原順一, 中島重徳, Capron M:アレルギー反応における好酸球の傷害性とサイトカイン. 臨床免疫 23:692-702, 1991

• 11) 大野典子, 杉本道代, 田原卓浩ほか:Milk-induced Proctitisにおける直腸粘膜の組織学的検討. 日本小児栄養消化器病学会雑誌 9:161-165, 1995

• 12) Bischoff SC, Mayer JH, Manns MP:Allergy and the gut. Int. Arch. Allergy Immunol. 121:270-283, 2000
  pubmed

P.79 掲載の参考文献

• 1) Yonei Y, Oda M, Tsuchiya M, etal.:Alterations of mast cells and autonomic nerves in the colonic wall in patients with ulcerative colitis. J. Clin. Electron Microscopy 25:249-260, 1992

• 2) Paull A, Hislop IG:Etiologic factor in ulcerative colitis. Birth, death, and symbolic equivalents. Int. J. Psychiatry. Med. 5:57-64, 1976

• 3) Macauley RL, Sommers SC:Mast cells in nonspecific ulcerative colitis. Am. J. Dig. Dis. 6:233-236, 1961

• 4) Hiatt RB, Katz L:Mast cells in inflammatory conditions of the gastrointestinal tract. Am. J. Gastroenterol. 37:541-545, 1962
  pubmed

• 5) Bercovitz ZT, Sommers SC:Altered inflammatory reaction in nonspecific ulcerative colitis. Arch. Intern. Med. 117:504-510, 1966
  pubmed

• 6) Sommers SC:Mast cells and Paneth cells in ulcerative colitis. Gastroenterology 51:841-850, 1966
  pubmed

• 7) Tsuchiya M, Munakata Y, Hibi N, et al.:Immediate hypersensitivity in the ulcerative colitis and effect of adrenocortical steroids. Jpn. J. Gastroenterol. 76:2400-2409, 1979

• 8) Dvorak AM, Osage JE, Monahan RA, et al.:Crohn's disease:transmission electron microscopic studies. 3. Target tissues. Proliferation of and injury to smooth muscle and the autonomic nervous system. Hum. Pathol. 11:620-634, 1980

• 9) Stead RH, Dixon MF, Bramwell NH, et al.:Mast cells closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 97:575-585, 1989
  pubmed

• 10) Yonei Y:Autonomic nervous alterations and mast cell degranulation in exacerbation of ulcerative colitis. Jpn. J. Gastroenterol. 84:1045-1056, 1987

• 11) Dvorak AM, McLeod RS, Onderdonk AB, et al.:Human gut mucosal mast cells:ultrastructural observations and anatomic variation in mast cell-nerve associations in vivo. Int. Arch. Allergy Immunol. 98:158-168, 1992
  pubmed

• 12) Bienenstock J, Perdue M, Blennerhassett M, et al.:Inflammatory cells and the epithelium. Mast cell/nerve interactions in the lung in vitro and in vivo. Am. Rev. Respir. Dis. 138:S31-S34, 1988
  pubmed

• 13) Marshall JS, Bienenstock J:Mast cells. Springer Semin. Immmunopathol. 12:191-202, 1990
  pubmed

• 14) Keranen U, Kiviluoto T, Jarvinen H, et al.:Changes in the substance P-immunoreactive innervation of the human colon associated with ulcerative colitis. Dig. Dis. Sci. 40:2250-2258, 1995
  pubmed

• 15) Raithel M, Schneider HT, Hahn EG:Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand. J. Gastroenterol. 34:496-503, 1999
  pubmed

P.85 掲載の参考文献

• 1) 八木田旭邦, 立川 勲:活動性クローン病と潰瘍性大腸炎に対するステロイドとウリナスタチンの併用動注療法. 医学のあゆみ 142:963-964, 1987

• 2) 多田正大, 磯 彰格, 大塚弘友ほか:難治性潰瘍性大腸炎の新しい治療の試み ウリナスタチンの応用. 日本大腸肛門病会誌 42:578-582, 1989

• 3) 成澤林太郎, 吉田 豊, 棟方昭博ほか:潰瘍性大腸炎に対するウリナスタチン (MR-20) の用量比較試験. 薬理と治療 28:199-209, 1998

• 4) Raithel M, Matek M, Baenkler HW, et al.:Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int. Arch. Allergy Immunol. 108:127-133, 1995
  pubmed

• 5) Lloyd G, Green FH, Fox H, et al.:Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 16:861-866, 1975
  pubmed

• 6) Sarin SK, Malhotra V, Sen Gupta S, et al.:Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig. Dis. Sci. 32:363-367, 1987
  pubmed

• 7) Fox CC, Lazenby AJ, Moore WC, et al.:Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 99:119-124, 1990
  pubmed

• 8) King T, Biddle W, Bhatia P, et al.:Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig. Dis. Sci. 4:490-495, 1992
  pubmed

• 9) Bischoff SC, Wedemeyer J, Herrmann A, et al.:Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 28:1-13, 1996
  pubmed

• 10) Craig SS, DeBlois G, Schwartz LB:Mast cells in human keloid, small intestine, and lung by immunoperoxidase technique using a murine monoclonal antibody against tryptase. Am. J. Pathol. 124:427-435, 1986

• 11) Murase K, Hewlett BR, Kohno S, et al.:Diagnosis of duodenal involvement in systemic mastocytosis. Gastroenterology 114:A237, 1998

• 12) 中村達也:潰瘍性大腸炎の消化管外合併症:肝疾患, 胆道疾患. 日本臨牀 557:2549-2554, 1999

• 13) 稲葉 均, 溝田雅洋, 大沢伸雄:副腎皮質ホルモン作用に及ぼすUlinastatinの効果. 薬理と治療 14:6871-6889, 1986

• 14) Nishida Y, Murase K, Furusu H, et al.:Response to urinary trypsin inhibitor therapy in ulcerative colitis is associated with a disease in mast cell count in the colonic mucosa. Acta Medica Nagasakiensia 44:39-43, 1999

• 15) 吉川敏一, 村上正志, 瀬戸 治ほか:蛋白分解酵素阻害薬ウリナスタチンによる実験的DICの防御と白血球トロンボプラスチン活生遊離阻止効果. 麻酔 36:1281-1285, 1987

• 16) Bochner BS, Scleimer RP:Mast cells, basophils, and eosinophils:distinct but overlapping pathways for recruitment. Immunol. Rev. 179:5-15, 2001

• 17) Echtenacher B, Mannel DN, Hulther L:Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996

• 18) 伊藤 久, 丸山正二, 福嶋健一ほか:潰瘍性大腸炎における直腸粘膜血流の臨床的検討. 杏林医会誌 25:423-425, 1994

• 19) Kido H, Yokogoshi Y, Katunuma N:Kunitz type protease inhibitor found in rat mast cells. Purification, properties and amino acid sequence. J. Biol. Chem. 263:18104-18107, 1988
  pubmed

• 20) Furusu H, Murase K, Nishida Y, et al.:Accumulation of mast cells and macrophages in focal active gastritis of patients with Crohn's disease. Hepatogastroenterology (in press.)

II / 循環器疾患

P.95 掲載の参考文献

• 1) 奥西秀樹:心血管系キマーゼとアンジオテンシン II. 日薬理誌 112:203-212, 1998
  Medical*Online

• 2) Okunishi H, Miyazaki M, Toda N:Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J. Hypertens. 2:277-284, 1984

• 3) Reilly CF, Tewksbury DA, Schechter NM, et al.:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteases. J. Biol. Chem. 257:8619-8622, 1982
  pubmed

• 4) Okunishi H, Miyazaki M, Okamura T, et al.:Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem. Biophys. Res. Commun. 149:1186-1192, 1987
  pubmed

• 5) Urata H, Kinoshita A, Misono KS, et al.:Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265:22348-22357, 1990

• 6) Caughey GH, Zerweck EH, Vanderslice P:Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J. Biol. Chem. 266:12956-12963, 1991
  pubmed

• 7) Shiota N, Miyazaki M, Okunishi H:Increase of angiotensin-converting enzyme gene expression in the hypertensive aorta. Hypertension 20:168-174, 1992
  pubmed

• 8) Jin D, Takai S, Shiota N, et al.:Roles of vascular angiotensin-converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J. Hypertens. 16:657-664, 1998
  pubmed

• 9) Powell JS, Clozel JP, Muller RK, et al.:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186-188, 1989
  pubmed

• 10) MERCATOR Study Group:Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study:a multicenter, randomized, double-blind placebo-controlled trial. Circulation 86:100-110, 1992

• 11) Le Trong H, Neurath H, Woodbury RG:Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc. Natl. Acad. Sci. USA 84:364-367, 1987
  pubmed

• 12) Okunishi H, Oka Y, Shiota N, et al.:Marked species-difference in the vascular angiotensin II-forming pathways:humans versus rodents. Jpn. J. Pharmacol. 62:207-210, 1993
  pubmed

• 13) Takai S, Shiota N, Yamamoto D, et al.:Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 58:591-597, 1996
  pubmed

• 14) Shiota N, Fukamizu A, Takai S, et al.:Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J. Hypertens. 15:431-440, 1997

• 15) Shiota N, Fukamizu A, Okunishi H, et al.:Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2, and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts. Biochem. J. 333:417-424, 1998
  pubmed

• 16) Sadoshima J:Cytokine actions of angiotensin II. Circ. Res. 86:1187-1189, 2000
  pubmed

• 17) Ruiz-Ortega M, Lorenzo O, Ruperez M, et al.:Angiotensin II activates nuclear transcription factor ｓｙそB through AT1 and AT2 in vascular smooth muscle cells:molecular mechanisms. Circ. Res. 86:1266-1272, 2000

• 18) Barnes PJ, Karin M:Nuclear factor-そB-A pivotal transcription factor in chronic inflammatory disease. N. Engl. J. Med. 336:1066-1071, 1997

• 19) Chandrasekharan UM, Sanker S, Glynias MJ, et al.:Angiotensin II-forming activity in a reconstituted ancestral chymase. Science 271:502-505, 1996

• 20) Caughey GH, Raymond WW, Wolters PJ:Angiotensin II generation by mast cell α-and β-chymases. Biochim. Biophys. Acta 1480:245-257, 2000

• 21) Weber KT:Fibrosis, a common pathway to organ failure:angiotensin II and tissue repair. Semin. Nephrol. 17:467-491, 1997
  pubmed

• 22) Caughey GH:Mast cell chymases and tryptases:Phylogeny, family relations and biogenesis. In:Mast Cell Proteases in Immunology and Biology. ed. by Caughey GH, Marcel-Dekker, New York, 1995, pp.305-329

• 23) 奥西秀樹, 塩田直孝:新しいアンジオテンシンII 産生酵素キマーゼ. 血管と内皮 5:440-448, 1995

• 24) 奥西秀樹, 柿添栄一:キマーゼ. Vascular Biology ナビゲーター. メディカルレビュー社, 大阪, 2001, pp.66-67

• 25) Lindstedt KA, Wang Y, Shiota N, et al.:Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells:a novel function for chymase. FASEB J. 15:1377-1388, 2001

• 26) Hara M, Matsumori A, Ono K, et al.:Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443-1449, 1999
  pubmed

• 27) Leskinen M, Wang Y, Leszczynski D, et al.:Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arteroscler. Thromb. Vasc. Biol. 21:516-522, 2001
  pubmed

• 28) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997
  pubmed

• 29) Muramatsu M, Katada J, Hayashi I, et al.:Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J. Biol. Chem. 275:5545-5552, 2000

• 30) Kakizoe E, Shiota N, Tanabe Y, et al.:Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J. Invest. Dermatol. 116:118-123, 2001
  pubmed

P.102 掲載の参考文献

• 1) Arakawa K:Serine protease angiotensin II systems. J. Hypertens. 14:S3-S7, 1996

• 2) Urata H, Hoffmann S, Ganten D:Tissue angiotensin II system in the human heart. Eur. Heart J. 15:68-78, 1994
  pubmed

• 3) Wei CC, Meng QC, Palmer R, et al.:Evidence for angiotensin-converting enzyme-and chimase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99:2583-2589, 1999

• 4) Mangiapane ML, Rauch AL, MacAndrew JT, et al.:Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (proll, D-Ala12)-angiotensin I. Hypertens. 23:857-860, 1994

• 5) Nishimura H, Buikema H, Boltatu O, et al.:Functional evidence for alternative ANGII-forming pathways in hamster cardiovascular system. Am. J. Physiol. 275:H1307-H1312, 1998

• 6) Jin D, Takai S, Shiota N, et al.:Roles of vascular angiotensin converting enzyme and chymase in two-kidney, on clip hypertensive hamsters. J. Hypertens. 16:657-664, 1998
  pubmed

• 7) Kaartinen M, Penttila A, Kovanen PT, et al.:Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90:1669-1678, 1994
  pubmed

• 8) Kovanen PT, Kaatinen M, Paavonen T:Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92:1084-1088, 1995
  pubmed

• 9) Ihara M, Urata H, Kinoshita A, etal.:Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33:1399-1405, 1999
  pubmed

• 10) Kovanen PT:Mast cell granule-mediated uptake of low density lipoproteins by macrophages:a novel carrier mechanism leading to the formation of foam cells. Ann. Med. 23:551-559, 1991

• 11) Nakano A, Kishi F, Minami K, et al.:Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J. Immunol. 159:1987-1992, 1997
  pubmed

• 12) Mizutani H, Schechter N, Lazarus G, et al.:Rapid and specific conversion of precursor interleukin I beta (IL-I beta) to an active IL-I species by human mast cell chymase. J. Exp. Med. 174:821-825, 1991

• 13) Hokimoto S, Yasue H, Fujimoto K, et al.:Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardia I infarction. Circulation 94:1513-1518, 1996
  pubmed

• 14) Ihara M, Urata H, Shirai K, et al.:High cardiac angiotensin II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 94:47-253, 2000

• 15) Takai S, Shiota N, Yamamoto D, et al.:Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 58:591-597, 1996
  pubmed

• 16) Shiota N, Fukamizu A, Takai S, et al.:Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J. Hypertens. 15:431-440, 1997

• 17) Pitt B, Soga IR, Martinez FA, etal.:Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349:747-752, 1997

• 18) Tetlow LC, Wooley DE:Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann. Rheum. Dis. 54:549-555, 1995

• 19) Toth T, Toth-Jakatics R, Jimi S, et al.:Mast cells in rapidly progressive glomerulonephritis. J. Am. Soc. Nephrol. 10:1498-1505, 1999
  pubmed

P.110 掲載の参考文献

• 1) Shimokama T, Haraoka S, Watanabe T:Immunohistochemical and ultrastructural demonstration of the lymphocyte-macrophage interaction in human aortic intima. Mod. Pathol. 4:101-107, 1991
  pubmed

• 2) Kaartinen M, Penitila A, Kovanen PT:Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase-and tryptase/chymase containing mast cells in normal intimas, fatty streaks and the shoulder region of atheromas. Arterioscler. Thromb. 14:966-972, 1994
  pubmed

• 3) Kovanen PT:Chymase-containing mast cells in human arterial intima:implications for atherosclerotic disease. Heart Vessels (Suppl.) 12:125-127, 1997

• 4) Church MK, Levi-Schaffer F:The human mast cell. J. Allergy CIin. Immunol. 99:155-160, 1997

• 5) Jeziorska M, MoCollum C, Woolley DE:Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J. Pathol. 182:115-122, 1997

• 6) Fuster V, Bodimon L, Badimon JJ, et al.:The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J. Med. 326:242-250, 1992

• 7) Kovanen P, Kaartinen M, Paavonen T:Infiltrates of activated mast cell at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92:1084-1088, 1995
  pubmed

• 8) Li Z, Li L, Zielke HR, et al.:Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol. 148:121-128, 1996

• 9) Matsumoto S, Kobayashi T, Katoh M, et al.:Expression and localization of matrix metallo-proteinase-12 in the aorta of cholesterol-fed rabbits:relationship to lesion development. Am. J. Pathol. 153:109-119, 1998

• 10) Galis ZS, Sukhova GK, Lork MW, et al.:Increased expression of matrix metallo-proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503, 1994

• 11) Sato T, Takebayashi S, Kohchi K:Increased subendothelial infiltration of the coronary arteries with monocytes/macrophages in patients with unstable angina. Atherosclerosis 68:191-197, 1987
  pubmed

• 12) Blair RJ, Meng H, Morchese MJ, et al.:Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J. Clin. Invest. 99:2691-2700, 1997

• 13) Kohchi K, Takebayashi S, Hiroki T, et al.:Significance of adventitial inflammation of the coronary artery in patients with unstable angina:results at autopsy. Circulation 71:709-716, 1985
  pubmed

• 14) Urata H, Strobel F, Gonten D, et al.:Widespread tissue distribution of human chymase. J. Hypertens. 12 (Suppl.9):S17-S22, 1994

• 15) Yamamoto Y, Tomoike H, Egashira K, et al.:Attenuation of endothelium-related relaxation and enhanced responsiveness of vascular smooth muscle to histamine in spastic coronary arterial segments from miniature pigs. Circ. Res. 61:772-778, 1987
  pubmed

• 16) Shimokawa H, Ito A, Fukumoto Y, et al.:Chronic treatment with interleukin-1 β induces coronary intimal lesions and vasospastic responses in pigs in vivo. J. Clin. Invest. 97:769-776, 1996

• 17) Atkinson JB, Harlan CW, Harlan GC, et al.:The association of mast cells and atherosclerosis:a morphologic study of early atherosclerotic lesions in young people. Hum. Pathol. 25:154-159, 1994
  pubmed

• 18) 坂田則行, 孟 晶, 立川 裕ほか:血管病変. 渡辺明治, 岡崎 勲編, 細胞外マトリックス-臨床医学への応用-. メディカレビュー社, 大阪, 1996, pp.361-373

• 19) Lopez-Candales A, Holmes DR, Liao S, et al.:Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am. J. Pathol. 150:993-1007, 1997
  pubmed

• 20) Leskinen M, Wong Y, Leszcznski D, et al.:Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:516-522, 2001

• 21) Borkerud S, Borkerud B:Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am. J. Pathol. 149:367-380, 1996

• 22) Kugiyama K, Sugiyama S, Ogata N, et al.:Burst production of superoxide anion in human endothelial cells by lysophosphatidylcholine. Atherosclerosis 143:201-204, 1999
  pubmed

• 23) Meng J, Sakata N, Takebayashi S, et al.:Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis 136:355-365, 1998
  pubmed

• 24) Sakata N, Miyamoto K, Meng J, et al.:Oxidative damage of vascular smooth muslce cells by glycated protein-cupric ion system. Atherosclerosis 136:263-274, 1998

• 25) Siow RC, Riohards JP, Pedley KC, et al.:Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. Arterioscler. Thromb. Vasc. Biol. 19:2387-2394, 1999

P.118 掲載の参考文献

• 1) Ohishi M, Ueda M, Rakugi H, etal.:Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J. Hypertens. 17:547-553, 1999
  pubmed

• 2) Mitani Y, Ueda M, Maruyama K, et al.:Mast cell chymase in pulmonary hypertension. Thorax 54:88-90, 1999
  pubmed

• 3) Yamada M, Ueda M, Naruko T, et al.:Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 59:1374-1381, 2001
  pubmed

• 4) Glenner GG, Cohen LA:Histochemical demonstration of a species-specific trypsin-like enzyme in mast cells. Nature 185:846-847, 1960
  pubmed

• 5) Schwartz LB, Lewis RA, Austen KF:Tryptase from human pulmonary mast cells. J. Biol. Chem. 256:11939-11943, 1981
  pubmed

• 6) Molino M, Bamathon ES, Numerof R, et al.:Interactions of mast cell tryptase with thrombin recepters and PAR-2. J. Biol. Chem. 272:4043-4049, 1997

• 7) Akers IA, Parsons M, Hill MR, et al.:Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell Mol. Physiol. 278:L193-L201, 2000
  pubmed

• 8) Cairns JA, Walls AF:Mast cell tryptase stimulates the synyhesis of type I collagen in human fibroblasts. J. Clin. Invest. 99:1313-1321, 1997

• 9) Thabrew H, Cairns JA, Walls AF:Mast cell tryptase is a growth factor for human airway smooth muscle. J. Allergy Clin. Immunol. 97:969, 1996

• 10) Cairns JA, Walls AF:Mast cell tryptase is a mitogen for epithelial cells:stimulation of IL-8 production and ICAM-1 expression. J. Immunol. 156:275-283, 1996
  pubmed

• 11) McEuen AR, Sharma B, Walls AF:Regulation of the activity of human chymase during storage and release from mast cells:the contributions of inorganic cations, pH, heparin and histamine. Biochim. Biophys. Acta 1267:115-121, 1995
  pubmed

• 12) Schechter NM, Sprows JL, Schoenberger OL, et al.:Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J. Biol. Chem. 264:21308-21315, 1989
  pubmed

• 13) Walter M, Plotnick M, Schechter NM:Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor:enhancement of the interaction by heparin. Arch. Biochem. Biophys. 327:81-88, 1996
  pubmed

• 14) Wei CC, Meng QC, Palmer R, et al.:Dell'Italia. Evidence for angiotensin-converting enzyme-and chymase-mediated angiotensin II formation in the interstitial fluid space in vivo. Circulation 99:2583-2589, 1999
  pubmed

• 15) Mizutani H, Schechter N, Lazarus G, et al.:Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174:821-825, 1991

• 16) Tetlow LC, Woolley DE:Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann. Rheum. Dis. 54:549-555, 1995
  pubmed

• 17) Atkinson JB, Harlan CW, Harlan GC, et al.:The association of mast cells and atherosclerosis:a morphologic study of early atherosclerotic lesions in young people. Hum. Pathol. 25:154-159, 1994
  pubmed

• 18) Kaartinen M, Penttila A, Kovanen PT:Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase-and tryptase/chymase-containing mast cells n normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler. Thromb. 14:966-972, 1994

• 19) Kaartinen M, Penttila A, Kovanen PT:Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90:1669-1678, 1994
  pubmed

• 20) Kovanen PT:The mast cell-a potential link between inflammation and cellular cholesterol deposition in a herogenesis. Eur. Heart J. 14 (Suppl. K):105-117, 1993

• 21) Kokkonen JO, Kovanen PT:Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro. J. Biol. Chem. 264:10749-10755, 1989
  pubmed

• 22) Gibbons GH, Pratt RE, Dzau VJ:Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest. 90:456-461, 1992
  pubmed

• 23) Shiota N, Okunishi H, Fukamizu A, et al.:Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 323:239-242, 1993
  pubmed

• 24) Heath D, Yacoub M:Lung mast cells in plexogenic pulmonary arteriopathy. J. Clin. Pathol. 44:1003-1006, 1991
  pubmed

• 25) Lajoie G, Nadasdy T, Laszik Z, et al.:Mast cells in acute cellular rejection of human renal allografts. Mod. Pathol. 9:1118-1125, 1996
  pubmed

• 26) Yanagida M, Fukamachi H, Ohgami K, et al.:Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86:3705-3714, 1995
  pubmed

• 27) Toru H, Eguchi M, Matsumoto R, et al.:Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998
  pubmed

• 28) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997
  pubmed

• 29) Pimentel JL Jr, Sundell CL, Wang S, et al.:Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int. 48:1233-1246, 1995
  pubmed

• 30) Oikawa T, Freeman M, Lo W, et al.:Modulation of plasminogen activator inhibitor-1 in vivo:a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 51:164-172, 1997
  pubmed

P.126 掲載の参考文献

• 1) 渡辺重行, 杉下靖郎:心臓過敏症 (Cardiac anaphylaxis) 別冊日本臨牀 15:560-563, 1996

• 2) Auer J, Lewis PA:The physiology of the immediate reaction of anaphylaxis in the guinea-pig. J. Exp. Med. 12:151-175, 1910
  pubmed

• 3) Auer J, Robinson GC:An electrocardiographic study of the anaphylactic rabbit. J. Exp. Med. 18:450-460,1913 .

• 4) Foster RF, Layman Jr JF:Generalized urticaria with electrocardiographic changes simulating myocardial infarction. JAMA 19:203-205, 1952

• 5) Wegmann A, Renker H, Hubscher H:Electrocardiographic changes in anaphylactic shock of the rabbit. Experientia 28:655-656,1972
  pubmed

• 6) Capurro N, Levi R:The heart as a target organ in systemic allergic reactions. Circ. Res. 36:520-528, 1975
  pubmed

• 7) Dvorak AM:Mast-cell degranulation in human hearts. N. Engl. J. Med. 315:969-970,1986
  pubmed

• 8) Marone G, Patella V, de Crescenzo G, et al.:Human heart mast cells in anaphylaxis and cardiovascular disease. Int. Arch. Allergy Immunol. 107:72-75, 1995
  pubmed

• 9) del Balzo UH, Levi R, Polley MJ:Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc. Natl. Acad. Sci. USA 82:886-890, 1985
  pubmed

• 10) Levi R:Cardiac anaphylaxis:models, mediators, mechanisms and clinical considerations. In:Human Inflammatory Disease, Clinical Immunology, ed. by Marone G, Lichtenstein LM, Condorelli M, et al., BC Decker, Toronto, 1988, pp.93-105

• 11) Feigen GA, Prager DJ:Experimental cardiac anaphylaxis:physiologic, pharmacologic and biochemical aspects of immune reactions in the isolated heart. Am. J. Cardiol 24:474-491, 1969
  pubmed

• 12) Wolff AA, Levi R:Histamine and cardiac arrhythmias. Circ. Res. 58:1-16, 1986
  pubmed

• 13) Vigorito C, Poto S, Picotti GB, et al.:Effect of activation of the H1 receptor on coronary hemodynamics in man. Circulation 73:1175-1182, 1986
  pubmed

• 14) DeFily DV, Kuo L, Chilian WM:PAF attenuates endothelium-dependent coronary arteriolar vasodilation. Am. J. Physiol. 270:H2094-H2099, 1996
  pubmed

• 15) Hattori Y, Levi R:Effect of PGD2 on cardiac contractility:a negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action. J. Pharmacol. Exp. Ther. 237:719-724, 1986
  pubmed

• 16) Levi R, Burke JA, Guo ZG, et al.:Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ. Res. 54:117-124, 1984
  pubmed

• 17) Woodman OL, Dusting GJ:Coronary vasoconstriction induced by leukotrienes in the anesthetized dog. Eur. J. Pharmacol. 86:125-128, 1983

• 18) Montrucchio G, Alloatti G, Camussi G:Role of platelet-activating factor in cardiovascular pathophysiology. Physiological Reviews 80:1669-1699, 2000
  pubmed

• 19) Allan G, Levi R:Pharmacological studies on the role of prostaglandins in cardiac hypersensitivity reactions. In:Prostaglandins in Cardiovascular and Renal Function, ed. by Scriabine A, Lefer AM, Kuehl FA, New York, Spectrum Publication, 1980, pp. 223-237

• 20) Allan G, Levi R:The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164. J. Pharmacol Exp Ther. 214:45-49, 1980
  pubmed

• 21) Heller LJ, Regal JF:Effect of adenosine on histamine release and atrioventricular conduction during guinea pig cardiac anaphylaxis. Circ. Res. 62:1147-1158, 1988
  pubmed

III / 呼吸器疾患

P.133 掲載の参考文献

• 1) 泉高英 :特発性肺線維症の臨床. 日内会誌 84:1396-1406, 1995

• 2) Kawanami O, Ferrans VJ, Fulmer JD, et al.:Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab. Invest. 40:717-734, 1979
  pubmed

• 3) Goto T, Befus D, Low R, et al.:Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. Am. Rev. Respir Dis. 130:797-802, 1984
  pubmed

• 4) Wagner MM, Edwards RE, Moncrieff CB, et al.:Mast cells and inhalation of asbestos in rats. Thorax 39:539-544, 1984
  pubmed

• 5) Suzuki N, Horiuchi T, Ohta K, et al.:Mast cells are essential for the full development of silica-induced pulmonary inflammation :a study with mast cell-deficient mice. Am. J. Respir. Cell Mol. Biol. 9:475-483, 1993
  pubmed

• 6) Horiuchi T, Ohta K, Yamaguchi M, et al.:Mast cell involvement in bleomycin induced lung injury of mice. Am. Rev. Respir. Dis. 141:A498, 1990

• 7) Ruoss SJ, Hartmann T, Caughey GH :Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 88:493-499, 1991
  pubmed

• 8) Gruber BL, Kew RR, Jelaska A, et al.:Human mast cells activate fibroblasts :tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol. 158:2310-2317, 1997
  pubmed

• 9) Schwartz LB, Bradford TR :Regulation of tryptase from human lung mast cells by heparin, stabilization of the active tetramer. J. Biol. Chem. 261:7372-7379, 1986
  pubmed

• 10) Schwartz LB, Bradford TR, Rouse C, et al.:Development of a new, more sensitive immunoassay for human tryptase :use in systemic anaphylaxis. J. Clin. Immunol. 14:190-204, 1994
  pubmed

• 11) Dvorak AM, Kissell S:Granule changes of human skin mast cells characteristic of piecemeal degranulatin and associated with recovery during wound healing in situ. J. Leukoc. Biol. 49:197-210, 1991

• 12) Cocks TM, Fong B, Chow JM, et al.:A protective role for protease-activated receptors in the airways. Nature 398:156-160, 1999
  pubmed

• 13) Akres I, Parsons M, Hill MR, et al.:Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol Lung Cell Mol. Physiol. 278:L193-L201, 2000
  pubmed

• 14) Dery O, Corvera CLI, Steinhoff M, et al.:Protease-activated receptors :novel mechanisms of signaling by serine proteases. Am. J. Physiol. 274:C1429-C1452, 1998.

P.140 掲載の参考文献

• 1) Inoue Y, King TE Jr, Tinkle SS, et al.:Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol. 149:2037-2054

• 2) Suzuki N, Horiuchi T, Ohta K, et al.:Mast cells are essential for the full development of silica-induced pulmonary inflammation :a study with mast cell-deficient mice. Am. J. Respir Cell Mol. Biol. 9:475-483, 1993
  pubmed

• 3) Kleeberger SR, Seiden JE, Levitt RC, et al.:Mast cells modulate acute ozone-induced inflammation of the murine lung.Am. Rev. Respir. Dis. 148:1284-1291, 1993
  pubmed

• 4) Takizawa H, Ohta K, Hirai K, et al.:Mast cells are important in the development of hypersensitivity pneumonitis. A study with mast-cell-deficient mice. J. Immunol. 143:1982-1988, 1989
  pubmed

• 5) Jordana M :Mast cells and fibrosis-who's on first? Am. J. Respir. Cell Mol. Biol. 8:7-8, 1993
  pubmed

• 6) Ando M, Miyazaki E, Fukami T, et al.:Interleukin-4-producing cells in idiopathic pulmonary fibrosis :an immunohistochemical study. Respirology 4:383-391, 1999
  pubmed

• 7) Reed JA, Albino AP, McNutt NS :Human cutaneous mast cells express basic fibroblast growth factor. Lab. Invest. 72:215-222, 1995
  pubmed

• 8) Qu Z, Huang X, Ahmadi P, et al.:Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor. Int. Arch. Allergy Immunol. 115:47-54, 1998
  pubmed

• 9) Kawanami O, Ferrans VJ, Fulmer JD, et al.:Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab. Invest. 40:717-734, 1979
  pubmed

• 10) Qu Z, Kayton RJ, Ahmadi P, et al.:Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules. Morphological evidence for bfgf release through degranulation. J. Histochem. Cytochem. 46:1119-1128, 1998
  pubmed

• 11) Henke C, Fiegel V, Peterson M, et al.:Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury. Clin. Invest. 88:1386-1395, 1991
  pubmed

• 12) Florkiewicz RZ, Sommer A :Human basic fibroblast growth factor gene encodes four polypeptides :three initiate translation from non-AUG codon. Proc. Natl, Acad, Sci. USA 86:3978-3981

• 13) Henke C. Marinelli W. JESSURUN J. et al.:Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am. J. Pathol. 143:1189-1199, 1993

• 14) Liebler JM, Picou MA, Qu Z, et al.:Altered immuno histochemical localization of basic fibroblast growth factor after bleomycin-induced lung injury. Growth Factors 14:25-38, 1997

• 15) Bashkin P, Doctrow S, Klagsbrun M, et al.:Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-1743, 1989
  pubmed

• 16) Friedl A, Chang Z, Tierney A, et al:Differential binding of fibroblast growth factor-2 and-7 to basement membrane heparan sulfate :comparison of normal and abnormal human tissues. Am. J. Pathol. 150:1443-1455, 1997
  pubmed

• 17) Inoue Y, Barker EA, King TE Jr, et al.:Immuno histochemistry of basic fibroblast growth factor receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 157:A74, 1998

• 18) Hamada H, Vallyathan V, Cool CD, et al.:Mast cell basic fibroblast growth factor in silicosis. Am. J. Respir. Crit. Care Med. 161:2026-2034, 2000
  pubmed

• 19) Mason RJ, Schwarz M, Hunninghake GW, et al.:Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am. J. Respir. Crit Care. Med. 160:1771-1777,1999
  pubmed

P.145 掲載の参考文献

• 1) Djukanovic R, Wilson JW, Britten KM, et al.:Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am. Rev. Respir. Dis. 142:863-871, 1990
  pubmed

• 2) Bradley BL, Azzawi M, Jacobson M, et al.:Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma :comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 88:661-674, 1991
  pubmed

• 3) Laitinen LA, Laitinen A, Haahtela T:Airway mucosal inflammation even in patients with newly diagnosed asthma. Am. Rev. Respir. Dis. 147:697-704, 1993
  pubmed

• 4) Pesci A, Foresi A, Bertorelli G, et al.:Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and control subjects. Am. Rev. Respir. Dis 147:684-689, 1993
  pubmed

• 5) Tomioka M, Ida S, Shindoh Y, et al.:Mast cells in bronchoalveolar lumen of patents with bronchial asthma. Am. Rev. Respir. Dis. 129:1000-1005, 1984

• 6) Beasley R, Roche WR, Roberts JA, et al.:Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis. 139:806-817, 1989
  pubmed

• 7) Frint KC, Leung KB, Hudspith BN, et al.:Bronchoalveolar mast cells in extrinsic asthma :a mechanism for the initiation of antigen specific bronchoconstriction. Br. Med. J. 291:923-926, 1985

• 8) Wardlaw AJ, Dunnette S, Gleich GT, et al.:Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma :relationship to bronchial hyperreactivity. Am. Rev. Respir. Dis. 137:62-69, 1988

• 9) Casale TB, Wood D, Richerson HB, et al.:Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine and bronchial hyperresponsiveness. J. Clin. Invest. 79:1197-1203, 1987
  pubmed

• 10) Liu MC, Bleecker ER, Lichtenstein LM, et al.:Evidence for elevated levels of histamine, prostaglandin D2 and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am. Rev. Respir. Dis. 142:126-132, 1990
  pubmed

• 11) Jarjour NN, Calhoun WJ, Schwartz LB, et al.:Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am. Rev. Respir. Dis. 144:83-87, 1991
  pubmed

• 12) Wardlaw AJ, Hay H, Cromwoll O, et al.:Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J. Allergy Clin. Immunol. 84:19-26, 1989

• 13) Wenzel SE, Larsen GL, Johnston K, et al.:Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142:112-119, 1990
  pubmed

• 14) Wenzel SE, Fowler AA3rd, Schwartz LB, et al.:Activation of pulmonary mast cells by bronchoalveolar allergen challenge :in vivo release of histamine and tryptase in atopic subjects with and without asthma. Am. Rev. Respir. Dis. is 137:1002-1008, 1988
  pubmed

• 15) 中村 豊, 星野 誠, 福島保喜 :気管支喘息の病型と気管支粘膜の細胞浸潤について. 日胸疾誌 33:403-409, 1995

• 16) Hoshino M, Nakamura Y :The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics. Eur. Respir. J. 10:858-865, 1997
  pubmed

• 17) Bradding P, Roberts JA, Britten KM, et al.:Interleukin-4,-5,-6, and tumor necrosis factor-ain normal and asthmatic airways :evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10:471-480, 1994

• 18) Bradding P, Feather IH, Howarth PH, et al.:Interleukin 4 is localised to and released by human mast cells. J. Exp. Med. 176:1381-1386, 1992
  pubmed

• 19) Grauchat JF, Henchoz S, Mazzei G, et al.:Induction of human IgE synthesis in B cells by mast cells and basophis. Nature 365:340-343, 1993

P.153 掲載の参考文献

• 1) Kuwano K, Bosken CH, Pare PD, et al.:Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 148:1220-1225, 1993
  pubmed

• 2) Carroll NG, Cooke C, James AL :Bronchial blood vessel dimension in asthma. Am. Rev. Respir. Dis. 155:689-695, 1997

• 3) Li X, Wilson JW:Increased vascularity of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Care Med. 156:229-233, 1997
  pubmed

• 4) Kumar SD, Emery MJ, Atkins ND, et al.:Airway mucosal blood flow in bronchial asthma. Am. J. Respir. Crit. Care Med. 158:153-156, 1998
  pubmed

• 5) Vrugt B, Wilson S, Bron A, et al.:Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur. Respir. J. 15:1014-1021, 2000
  pubmed

• 6) 山田 玄, 伊藤峰幸, 阿部庄作 :拡大気管支鏡による診断. 呼吸器疾患最新医療と21世紀への展望. 先端医療技術研究所, 東京, 2001, pp. 81-85

• 7) Tanaka H, Yamada G, Itoh T, et al.:Airway hypervascularity in asthmatic patients assessed by side-viewing high-magnified bronchoscopy :a new point of view. Am. J. Respir. Crit. Care Med. 163:A787, 2001

• 8) Orsida BE, Li X, Hickey B, et al.:Vascularity in asthmatic airways :relation to inhaled steroid dose. Thorax 54:289-295, 1999
  pubmed

• 9) Foschi D, Castoldi L, Corsi F, et al.:Inhibition of inflammatory angiogenesis in rats by locoregional administration of hydrocortisone and protamine. Agents Actions 42:40-43, 1994
  pubmed

• 10) Nauck M, Karakiulakis G, Perruchoud AP, et al.:Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341:309-315, 1998
  pubmed

• 11) Conway EM, Collen D, Carmeliet P :Molecular mechanisms of blood vessel growth. Cadiovasc. Res. 49:507-521, 2001
  pubmed

• 12) Hoshino M, Takahashi M, Aoike N :Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationshp to angiogenesis. J. Allergy Clin. Immunol. 107:295-301, 2001

• 13) Redington AE, Roche WR, Madden J, et al.:Basic fibroblast growth factor in asthma :measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J. Allergy Clin. Immunol. 107:384-387, 2001
  pubmed

• 14) Tanaka H, Miyazaki N, Oashi K, et al.:Sputum matrix metalloproteinase-9 :tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J. Allergy Clin. Immunol. 105:900-905, 2000
  pubmed

• 15) Tanaka H, Miyazaki N, Oashi K, et al.:IL-18 might reflect disease activity in mild and moderate asthma exacerbatio. J. Allergy Clin. Immunol. 107:331-336, 2001

• 16) Bocchino, V, Bertorelli G, Zanini A, et al.:Integrin αvβ3 is incresed in the airways of atopic asthmatic patients. Am. J. Respir. Crit. Care Med. 163:A785, 2001

• 17) Hashimoto M, Tanaka H, Teramoto S, et al.:Bronchial angiogenensis and vascular endoth-elial growth factor in bronchial asthma :pathological examination. Am. J. Respir. Crit. Care Med. 163:A786, 2001

P.159 掲載の参考文献

• 1) International consensus report on the diagnosis and management of asthma. Clin. Exp. Allergy 22 (Suppl.):1-72, 1992

• 2) Karnam U, Rogers A :Systemic mastocytosis. Dig. Dis. 17:299-307, 1999
  pubmed

• 3) Mochizuki H, Shigeta M, Morikawa A:Development of bronchial hyperresponsiveness during childhood. J. Asthma 38:1-21, 2001
  pubmed

• 4) Eggleston PA :Upper airway inflammatory diseases and bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 81:1036-1041, 1988
  pubmed

• 5) van Herwerden L, Harrap SB, Wong ZYH, et al.:Linkage of high-affinity IgE receptor gene with bronchial hyperreactivity, even in absence of atopy. Lancet 346:1262-1265, 1995

• 6) Postma DS, Bleecker ER, Amflung PJ, et al.:Genetic susceptivity to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl. J. Med. 333:894-900, 1995

• 7) Alvarez MJ, Olaguibel JM, Acero S, et al.:Effect of current exposure to Der p 1 on asthma symptoms, airway inflammation, and bronchial hyperresponsiveness in mite-allergic asthmatics. . Allergy 55:185-190, 2000
  pubmed

• 8) Berger P, Compton SJ, Molimard M, et al.:Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin. Exp. Allergy 29:804-812, 1999
  pubmed

• 9) Krishna MT, Chauhan A, Little L, et al.:Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol. 107:1039-1045, 2001
  pubmed

• 10) Matsuoka T, Hirata M, Tanaka H, et al.:Prostaglandin D2 as a mediator of allergic asthma. Science 287:2013-2017, 2000
  pubmed

• 11) Temann UA, Geba GP, Rankin JA, et al.:Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J. Exp. Med. 188:1307-1320, 1998
  pubmed

• 12) Kobayashi H, Ishizuka T, Okayama Y :Human mast cells and basophils as sourses of cytokines. Clin. Exp. Allergy 30:1205-1212, 2000

• 13) Power C, Screenan S, Hurrson B, et al.:Distribution of immunocompetent cells in the bronchial wall of clinical healthy subjects showing bronchial hyperresponsiveness. Thorax 48:1125-1129, 1993

• 14) Kanbe N, Tanaka A, Kanbe M, et al.:Human mast cells produce matrix metalloproteinase 9. Eur. J. Immunol. 29:2645-2649, 1999
  pubmed

• 15) Wolters PJ, Laig-Webster M, Caughey GH:Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways. Am. J. Respir. Cell Mol. Biol. 22:183-190, 2000
  pubmed

• 16) 福田健 :喘息における気道炎症. 日内会誌 85:189-193, 1996

• 17) Valent P, Escribano L, Parwaresch RM, et al.:Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int. Arch. Allergy Immunol. 120:1-7, 1999
  pubmed

• 18) Akin C, Schwartz LB, Kitoh T, et al.:Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis :relationship to disease severity and bone marrow pathology. Blood 96:1267-1273, 2000
  pubmed

• 19) Barrios VE, Middleton SC, Kashem MA, et al.:Tryptase mediates hyperresponsiveness in isolated guinea pigs bronchi. Life Sci. 63:2295-2303, 1998
  pubmed

IV / 泌尿器疾患

P.167 掲載の参考文献

• 1) Reilly CF, Tewsbury DA, Schechter NM, et al.:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J. Biol. Chem. 257:8619-8622, 1982

• 2) Reilly CF, Schechter NB, Travis J:Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem. Biophys. Res. Commun. 127:443-449, 1985
  pubmed

• 3) Nakano A, Kishi F, Minami K, et al.:Selective conversion of big endothelins to tracheal smooth muscle- 31-amino acid-1ength endothelins by chymase from human mast cells. J. Immunol 159:1987-1992, 1997
  pubmed

• 4) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril for mation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997

• 5) Taipale J, Lohi J, Saarinen J, et al.:Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270:4689-4696, 1995
  pubmed

• 6) Pavone-Macaluse M:Tissue mast cells in renal diseases. Acta Pathol. 50:337-347, 1960

• 7) Lajoie G, Nadasdy T, Laszik Z, et al.:Mast cells in acute cellular rejection of human renal allografts. Mod. Pathol. 9:1118-1125, 1996
  pubmed

• 8) Ruger BM, Hasan Q, Greenhill NS, et al.:Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 39:1215-1222, 1996
  pubmed

• 9) Hiromura K, Kurosawa M, Yano S, et al.:Tubulointerstitial mast cell infiltration in glomerulonephritis. Am. J. Kidey Dis. 32:593-599, 1998

• 10) Ehara T, Shigematsu H:Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int. 54:1675-1683, 1998

• 11) 村上円人, 池田栄二:腎臓におけるACEとキマーゼの役割. 血管と内皮 9:53-60, 1999

• 12) Toth T, Toth-Jakatics R, Jimi S, et al.:Mast cells in rapidly progressive glomerulonephritis. J. Am. Soc. Nephrol. 10:1498-1505, 1999
  pubmed

• 13) Yamada M, Ueda M, Naruko T, et al.:Mast cells chymase expression and mast cell phenotyps in human rejected kidneys. Kidney Int. 59:1374-1381, 2001

• 14) Dzau VJ:Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (suppl. I):1-4, 1988

• 15) Kokkonen JO, Saarinen J, Kovanen PT:Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 95:1455-1463, 1997
  pubmed

• 16) Urata H, Kinoshita A, Misono KS, et al.:Identification of a highly specific chymase as the major angiotensin II- forming enzyme in the human heart. J. Biol. Chem. 265:22348-22357, 1990

• 17) 木下昭生, 笹栗学, 出石宗仁ほか:ヒト各組織におけるACEとchymase様活性の比率. 日本高血圧学会総会抄録集 64:1995

• 18) Schwarz LB:Heterogeneity of human mast cells. In:The Mast Cells in Health and Disease, ed. by Kaliner MA, Metcalfe DD, Dekker, New York, 1993, pp.219-235

• 19) Taugner R, Hackenthal E, Helmchen U, et al.:The intrarenal renin-angiotensin-system:an immunocytochemical study on the localization of renin, angiotensinogen, converting enzyme and the angiotensins in the kidney of mouse and rat. Klin. Wochensche. 60:1218-1222, 1982

• 20) Shiota N, Okunishi H, Fukamizu A, et al.:Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 323:239-2342, 1993
  pubmed

• 21) Kovanen PT:Chymase-containing mast cells in human arterial intima:implications for atherosclerotic disease. Heart Vessels 12 (Suppl. 1):125-127, 1997

• 22) Murakami M, Matsuda H, Kubota E, et al.:Role of angiotensin II generated by angiotensin converting enzyme- independent pathways in canine kidney. Kidney Int. (Suppl.) 52:S132-S135, 1997

• 23) Mangiapane ML, Rauch AL, MacAndrew JT, et al.:Vasoconstrictor activity of angiotensin-I-convertase and the synthetic substrate [Pro11, D-Ala12] angiotensin I. Hypertension 23:857-860, 1994

• 24) Weidner N, Austen KF:Heterogeneity of mast cells at multiple body sites:fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase and carboxypeptidase content. Pathol. Res. Pract. 189:156-162, 1993
  pubmed

• 25) Kitamura Y:Heterogeneity of mast cells and phenotypic change between subpopulations. Annu. Rev. Immunol. 7:9-76, 1989

• 26) Church MK, Levi-Schaffer F:The human mast cells:updates on cells and cytokines. J. Allergy Clin. Immunol. 99:155-160, 1997

• 27) Anderson J, Rennke HG, Bronner BM:Therapeutic advantage of converting enzyme inhibitors in arresting Progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77:1993-2000, 1986

• 28) Kaneto H, Morrissey J, McCracken R, et al.:Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int. 45:1637-1647, 1994
  pubmed

P.175 掲載の参考文献

• 1) Pavone-Macaluso M:Tissue mast cells in renal diseases. Acta Pathol. Microbiol. Scand. 50:337-346, 1960
  pubmed

• 2) Colvin RB, Dvorak HF:Letter:Basophils and mast cells in renal allograft rejection. Lancet i:212-214, 1974
  pubmed

• 3) Colvin RB, Dvorak AM, Dvorak HF:Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum. Pathol. 5:315-326, 1974
  pubmed

• 4) Ruger BM, Hasan Q, Greenhill NS, et al.:Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 39:1215-1222, 1996
  pubmed

• 5) Lajoie G, Nadasdy T, Laszik Z, et al.:Mast cells in acute cellular rejection of human renal allografts. Mod. Pathol. 9:1118-1125, 1996
  pubmed

• 6) Ehara T, Shigematsu H:Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis Kidney Int. 54:1675-1683, 1998

• 7) Hiromura K, Kurosawa M, Yano S, et al.:Tubulointerstitial mast cell infiltration in glomerulonephritis. Am. J. Kidney Dis. 32:593-599, 1998
  pubmed

• 8) Toth T, Toth-Jakatics R, Jimi S, et al.:Mast cells in rapidly progressive glomerulonephritis. J. Am. Soc. Nephrol. 10:1498-1505, 1999
  pubmed

• 9) Toth T, Toth-Jakatics R, Jimi S, et al.:Increased density of interstitial mast cells in amyloid A renal amyloidosis. Mod. Pathol. 13:1020-1028, 2000
  pubmed

• 10) Roberts IS, Brenchley PE:Mast cells:the forgotten cells of renal fibrosis. J. Clin. Pathol. 53:858-862, 2000
  pubmed

• 11) Yamada M, Ueda M, Naruko T, et al.:Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 59:1374-1381, 2001
  pubmed

• 12) Becker GJ, Hewitson, TD:The role of tubulointerstitial injury in chronic renal failure. Curr. Opin. Nephrol. Hypertens. 9:133-138, 2000
  pubmed

• 13) Eddy AA:Molecular basis of renal fibrosis. Pediatr. Nephrol. 15:290-301, 2000
  pubmed

• 14) Church MK, Levi-Schaffer F:The human mast cell. J. Allergy Clin. Immunol. 99:155-160, 1997
  pubmed

• 15) Pardo J, Diaz L, Errasti P, et al.:Mast cells in chronic rejection of human renal allografts. Virchows Arch. 437:167-172, 2000
  pubmed

• 16) Weidner N, Austen KF:Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol. Res. Pract. 189:156-162, 1993
  pubmed

• 17) D' Amico G, Ferrario F, Rastaldi MP:Tubulointerstitial damage in glomerular diseases:its role in the progression of renal damage. Am. J. Kidney Dis. 26:124-132, 1995
  pubmed

• 18) Cairns JA, Walls AF:Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997
  pubmed

• 19) Abe M, Kurosawa M, Ishikawa O, et al.:Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J. Allergy Clin. Immunol. 106:S78-S84, 2000
  pubmed

• 20) Urata H, Boehm KD, Philip A, et al.:Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J. Clin. Invest. 91:1269-1281, 1993

• 21) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997
  pubmed

• 22) Galli SJ:New concepts about the mast cell. N. Engl. J. Med 328:257-265, 1993
  pubmed

• 23) Kobayashi H, Ishizuka T, Okayama Y:Human mast cells and basophils as sources of cytokines. Clin. Exp. Allergy 30:1205-1212, 2000
  pubmed

• 24) Inoue Y, King TE Jr, Tinkle SS, et al.:Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorder. Am. J. Pathol. 149:2037-2054, 1996
  pubmed

• 25) Kanbe N, Kurosawa M, Nagata H, et al.:Cord blood-derived human cultured mast cells produce transforming growth factor beta 1. Clin. Exp. Allergy 29:105-113, 1999
  pubmed

• 26) Bhattacharyya SP, Drucker I, Reshef T, et al.:Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. J. Leukoc. Biol. 63:337-341, 1998
  pubmed

• 27) Furitsu T, Saito H, Dvorak AM, et al.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 28) Trautmann A, Krohne G, Brocker EB, et al.:Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4. J. Immunol. 160:5053-5057, 1998
  pubmed

• 29) Mori H, Kawada K, Zhang P, et al.:Bleomycininduced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int. Arch. Allergy Appl. Immunol. 95:195-201, 1991
  pubmed

• 30) Suzuki N, Horiuchi T, Ohta K, et al.:Mast cells are essential for the full development of silica-induced pulmonary inflammation:a study with mast cell-deficient mice. Am. J. Respir. Cell Mol. Biol 9:475-483, 1993
  pubmed

• 31) Okazaki T, Hirota S, Xu ZD, et al.:Increase of mast cells in the liver and lung maybe associated with but not a cause of fibrosis:demonstration using mast cell-deficient Ws/Ws rats. Lab. Invest. 78:1431-1438, 1998

• 32) Yamamoto T, Takahashi Y, Takagawa S, et al.:Animal model of sclerotic skin II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J. Rheumatol. 26:2628-2634, 1999

P.181 掲載の参考文献

• 1) Irani AM, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986

• 2) Urata H, Kinoshita A, Misono KS, et al.:Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265:22348-22357, 1990

• 3) Church MK, Levi-Schaffer F:The human mast cell:updates on cells and cytokines. J. Allergy Clin. Immunol. 99:155-160, 1997

• 4) Sasatomi Y, Kiyoshi Y, Takebayashi S:A clinical and pathological study on the characteristics and factors influencing the prognosis of crescentic glomerulonephritis using a cluster analysis. Pathol. Intern. 49:781-785, 1999

• 5) Toth T, Toth-Jakatics R, Jimi S, et al.:Mast cells in rapidly progressive glomerulonephritis. J. Am. Soc. Nephrol. 10:1498-1505, 1999
  pubmed

• 6) Couser WG:Rapidly progressive glomerulonephritis:classification, pathogenetic mechanisms and therapy. Am. J. Kidney Dis. 11:449-464, 1988
  pubmed

• 7) Claman HN:Mast cells, T cells and abnormal fibrosis. Immunol, Today 6:192-195, 1985
  pubmed

• 8) Metcalfe DD, Costa JJ, Burd PR:Mast cells and basophils. In:Inflammation:Basic Principles and Clinical Correlates, 2nd Ed, ed. by Gallin JI, Goldstein IM, Snyderman R, New York, Raven Press, 1992, pp. 709-725

• 9) Ambrust T, Batusic D, Ringe B, et al.:Mast cell distribution in human liver disease and experimental rat liver fibrosis. indications for mast cell participation in development of liver fibrosis. J. Hepatol. 26:1042-1054, 1997

• 10) Nabel G, Galli SJ, Dvorak AM, et al.:Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature 291:332-334, 1981
  pubmed

• 11) Bhattacharyya SP, Drucker I, Reshef T, et al.:Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cel-to-cell contact. J. Leukoc. Biol. 63:337-341, 1998

• 12) Baghestanian M, Hofbauer R, Kiener HP, et al.:The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood 90:4438-4449, 1997

• 13) Davidson S, Mansour A, Gallily R, et al.:Mast cell differentiation depends on T cells and granule synthesis on fibroblasts. Immunology 48:439-452, 1983

• 14) Russel JD, Russell SB, Trupin KM:The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J. Cell. Physiol. 93:389-393, 1977

• 15) Norrby K:Effect of heparin, histamine and serotonin on the density-dependent inhibition of replication in two fibroblastic cell lines. Virchows Arch. B Cell Pathol. 15:75-93, 1973
  pubmed

• 16) Hatamochi A, Fujiwara K, Ueki H:Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch. Dermatol. Res. 277:60-64, 1985
  pubmed

• 17) Young JD, Liu CC, Butler G, etal.:Identification, purification, and characterization of a mast cell-associated cytolytic factor related to tumor necrosis factor. Proc. Natl. Acad. Sci. USA 84:9175-9179, 1987
  pubmed

• 18) Sugarman BJ, Aggarwal BB, Hass PE, et al.:Recombinant human tumor necrosis factor-α:effects on proliferation of normal and transformed cells in vitro. Science 230:943-945, 1985

• 19) Cairns JA, Walls AF:Mast cell stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997
  pubmed

• 20) Desmouliere A, Rubbia-Brandt L, Grau G, et al.:Heparin induces α-smooth muscle actin expression in cultured fibroblasts and in granuation tissue myofibroblasts. Lab. Invest. 67:716-726, 1992

• 21) Colvin RB, Dvorak AM, Dvorak HF:Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum. Pathol. 5:315-326, 1974
  pubmed

• 22) Pavone-Macalusco M:Tissue mast cells in renal diseases. Acta Pathol. 50:337-346, 1960

• 23) Harrison DJ, Neary C, Wathen CG:Distribution of IgE-bearing cells in renal biopsies in Wegener's granuloma. Nephrol. Dial. Translant. 3:24-27, 1988

• 24) Lajoie G, Nadasdy T, Laszik Z, et al.:Mast cells in acute cellular rejection of human renal allografts. Mod. Pathol. 9:1118-1125, 1996
  pubmed

• 25) Yamada M, Ueda M, Naruko T, et al.:Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 59:1374-1381, 2001
  pubmed

• 26) Ehara T, Shigematsu H:Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int. 54:1675-1683, 1998

• 27) Ruger BM, Hasan Q, Greenhill NS, et al.:Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 39:1215-1222, 1996
  pubmed

• 28) Alpers CE, Hudkins KL, Floege J, et al.:Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J. A m. Soc. Nephrol. 5:201-209, 1994

• 29) Goumenos D, Tsomi K, Iatrou C, et al.:Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol. Dial. Transplant. 13:1652-1661, 1998
  pubmed

• 30) Rubinchik E, Levi-Schaffer F:Mast cells and fibroblasts:two interacting cells. Int. J. Clin. Lab. Res. 24:139-142, 1994
  pubmed

• 31) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997
  pubmed

P.187 掲載の参考文献

• 1) Gillenwater JY, Wein AJ:Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis. J. Urol. 140:203-206, 1988
  pubmed

• 2) Simmons JL:Interstitial cystitis. J. Urol. 85:149-155, 1961

• 3) Larsen S, Thompson SA, Hald T, et al.:Mast cells in interstitial cystitis. Br. J. Urol. 54:283-286, 1982
  pubmed

• 4) Kastrup J, Hald T, Larsen S, et al.:Histamine content and mast cell count of detrusor muscle in patiets with interstitial cystitis and other types of chronic cystitis. Br. J. Urol. 55:495-500, 1983

• 5) Aldenborg F, Fall M, Enerback L:Proliferation and transepithelial migration of mucosal mast cells in interstitial Cystitis. Immunology 58:411-416, 1986
  pubmed

• 6) Aldenborg F, Fall M, Enerback L, et al.:Mast cells in interstitial cystitis. Ann. Urol. 23:165-166, 1989
  pubmed

• 7) Christmas TJ, Rode J:Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 68:473-478, 1991
  pubmed

• 8) Newson B, Dahlstrom A, Enerback L, et al.:Suggestive evidence for a direct innervation of mucosal mast cells. Neuroscience 10:565-570, 1983
  pubmed

• 9) Lundeberg T, Liedberg H, Nordling L, et al.:Interstitial cystitis:correlation with nerve fibers, mast cells and histamine. Br. J. Urol. 711 427-429, 1992

• 10) Letourneau R, Pang X, Sant GR, et al.:Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. Br. J. Urol. 77:41-54, 1996
  pubmed

• 11) Pang X, Cotreau-Bibbo MM, Sant GR, et al.:Bladder mast cell expression of high affinity strogen receptors in patients with interstitial cystitis. Br. J. Urol. 75:154-161, 1995

• 12) 山田哲夫, 田口裕功:間質性膀胱炎のアレルギー 学的検討(1). 日泌尿会誌 76:1843-1847, 1985

• 13) 山田哲夫, 村山鉄郎, 田口裕功:尿中好酸球の臨床的意義. 泌尿紀要 38:173-176, 1992

• 14) Theoharides TC, Sant GR:Bladder mast cell activation in interstitial cystitis. Semin. Urol. 11:74-87, 1991

• 15) Theoharides TC, Flaris N, Cronin CT, et al.:Mast cell activation in sterile bladder and prostate inflammation. Int. Arch. Allergy Appl. Immunol. 92:281-286, 1990
  pubmed

• 16) Holgate ST, Church MK:Allergy part 1. In:Mast Cell and Basophil Functions, ed. by Church MK, Caulfield JP, 5.1-5. 9, Gower Medical Publishing, London, UK.

• 17) Yamada T, Murayama T, Mita H, Subtypes of bladder mast cells in cystitis. Int. Urol. 7:292-297, 2000
  pubmed

V / 皮膚科疾患

P.197 掲載の参考文献

• 1) Irani AA, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neural protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986

• 2) Cairns JA, Wall AF:Mast cell tryptase is a mitogen for epitheial cells. Stimulation of IL-8 production and ICAM-1 expression. J. Immunol. 156:275-283, 1996

• 3) Caughey GH, Leidig F, Viro NF, et al.:Substance P and vasoactive intestinal polypeptide degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. 244:133-137, 1988
  pubmed

• 4) Tunon De Lara JM, Okayama Y, McEuen Ar, et al.:Release and inactivation of interleukin-4by mast cells. Ann. NY Acad. Sci. 725:50-58, 1994

• 5) Kubota Y:The effect oh human anaphylatoxins and neutrophils oh histamine release from isolated human skin mast cells. J. Dermatol. 19:19-26, 1992

• 6) Bradding P, Okayama Y, Howarth PH, et al.:Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155:297-307, 1995

• 7) Walsh LJ, Trinchieri G, Waldorf HA, et al.:Human dermal mast cells contain and release tumor necrosis factor alpha, which induces ELAM-1. Proc. Natl. Acad. Sci. USA 88:4220-4224, 1991
  pubmed

• 8) Valent P, Bevec D, Maurer D, et al.:IL-4 promotes expression of mast cell ICAM-1 antigen. Proc. Natl. Acad. Sci. USA 88:3339-3342, 1991
  pubmed

• 9) Damsgaard TE, Olesen AB, Sorensen FB, et al.:Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal skin. Arch. Dermatol. Res. 289:256-260, 1997
  pubmed

• 10) Algermissen B, Bauer F, Schadendorf D, et al.:Analysis of mast cell subpopulations (MCT, MCTc) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp. Dermatol. 3:290-297, 1994
  pubmed

• 11) Jarvikallio A, Naukkarinen A, Harvima IT, et al.:Quantitative analysis of tryptase-and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br. J. Dermatol. 136:871-877, 1997
  pubmed

• 12) Imayama S, Shibata Y, Hori Y:Epidermal mast cells in atopic dermatitis. Lancet 346:1559, 1995
  pubmed

• 13) Mao XQ, Shirakawa T, Enomoto T, et al.:Association between variants of mast cell chymase gene and serum IgE levels in eczema. Hum. Hered. 48:38-41, 1998
  pubmed

• 14) Amon U, Menz U, Wolff HH:Investigation on plasma levels of mast cell mediators in acute atopic dermatitis. J. Dermatol. Sci. 7:63-67, 1994
  pubmed

• 15) Ackermann L, Harvima IT:Mast cells of psoriatic and atopic dermatitis skin are positiv for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res. 290:353-359, 1998

• 16) Horsmanheimo L, Harvima IT, Jarvikallio A, et al.:Mast cells are one major source of interleukin-4 in atopic dermatitis. Br. J.Dermatol. 131:348-353, 1994
  pubmed

• 17) Fox CC, Jewell SD, Whitacre CC:Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell. Immunol. 158:253-264, 1994
  pubmed

• 18) Lipski S, Grabbe J, Henz BM:Absence of MHC class II antigen on mast cells at sites of inflammation in human skin. Exp. Dermatol. 5:120-124, 1996

• 19) Toyoda M, Morohashi M:Morphological assessment of the effects of cyclosporin A on mast cell-nerve relationship in atopic dermatitis. Acta Derm. Venereol. 78:321-325, 1998
  pubmed

• 20) Di-Marco-E, Marchisio-PC, Bondanza-S, et al.:Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J. Biol. Chem. 266:21718-21722, 1991

• 21) Rukwied R, Lischetzki G, Mcglone F, et al.:Mast cell mediators other than histamine indu e pruritis in atopic dermatitis patients:a dermal microdialysis study. Br. J. Dermatol. 142:1114-1120, 2000

• 22) Shishibori T, Oyama Y, Matsushita O, et al.:Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem. J. 338:583-589, 1999
  pubmed

• 23) Cohan VL, Undem BJ, Fox CC, et al.:Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am. Rev. Respir. Dis. 140:951-954, 1989
  pubmed

P.202 掲載の参考文献

• 1) Kitamura Y, Shimada M, Hatanaka K, etal.:Development of mast cells from grafted bone marro cells in irradiated mice. Nature 268:442-443, 1977

• 2) Furitsu T, Saito H, Dvorak AM, etal.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 3) Flanagan JG, Leder P:The kit ligand:a cell surface molecule altered in steel mutant fibroblasts. Cell 63:185-194, 1990
  pubmed

• 4) Nakahata T, Tsuji K, Tanaka R:Synergy of stem cell factor and other cytokines in mast cell development. In:Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function, ed. by Kitamura Y, Yamamoto S, Galli SJ, et al., Elsevier Science Publishers, USA, 1995, pp. 13-24

• 5) Levi-Schaffer F, Austen KF, Gravallese PM, et al.:Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc. Natl. Acad. Sci. USA 83:6485-6488, 1986

• 6) Morita E, Hiragun T, Tanaka T, et al.:Mouse bone marrow-derived mast cells acquire responsiveness to substance P after co-culture with 3T3 fibroblasts in the presence of stem cell factor. Allergol. Int. 47:205-212, 1998

• 7) Morita E, Lee DG, Sugiyama M, et al.:Expression of c-kit ligand in human keratinocytes. Arch. Dermatol. Res. 286:273-277, 1994
  pubmed

• 8) Kunisada T, Lu SZ, Yoshida H, etal.:Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J. Exp. Med. 187:1565-1573, 1998
  pubmed

• 9) Yamamoto S, etal.:Keratinocyte-derived Modulators of mast cells. In:Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function, ed. by Kitamura Y, Yamamoto S, Galli SJ, et al., Elsevier Science Publishers, USA, 1995, pp. 131-138

• 10) Hiragun T, Morita E, Tanaka T, et al.:A fibrogenic cytokine, platelet-derived growth factor (PDGF), enhances mast cell growth indirectly via a SCF-and fibroblast-dependent pathway. J. Invest. Dermatol. 111:213-217, 1998

• 11) Tanaka T, Morita E, Mihara S, etal.:Identification of leukemia inhibitory factor as a potent mast cell growth-enhancing factor produced by mouse keratinocyte cell line, KCMH-1. Arch. Dermatol. Res. 293:18-25, 2001
  pubmed

• 12) Kameyoshi Y, Morita E, Tanaka T, et al.:Interleukin-1α enhances mast cell growth by a fibroblast-dependent mechanism. Arch. Dermatol. Res. 292:240-247, 2000

• 13) Hiragun T, Morita E, Mihara S, et al.:Leukemia inhibitory factor enhances mast cell growth in a mast cell/fibroblast co-culture system through stat3 signaling pathway of fibroblasts. FEBS Lett. 487:219-223, 2000

P.210 掲載の参考文献

• 1) Grattan CEH, Wallington TB, Warin RP, et al.:Aserological mediator in chronic idiopathic urticaria a clinical, immunological and histological evaluation. Br. J. Dermatol. 114:583-590, 1986

• 2) Grattan CEH, Francis DM, Hide M, et al.:Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin. Exp. Allergy 21:695-704, 1991

• 3) Hide M, Francis DM, Gratten CEH, et al.:Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 328:1599-1604, 1993

• 4) Niimi N, Francis DM, Kermani F, et al.:Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J. Invest. Dermatol. 106:1001-1006, 1996
  pubmed

• 5) Ferrer M, Kinet Jp, Kaplan AP:Comparative studies of functional and binding assays for IgG anti-FcεRIα (α-subunit) in chronic urticaria. J. Allergy. Clin. Immunol. 101:672-676, 1998

• 6) Fiebiger E, Maurer D, Holub H, et al.:Serum IgG autoantibodies directed against the α chain of FcεRI:aselective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J. Clin. Invest. 96:2606-2612, 1995

• 7) Fiebiger E, Hammerschmid F, Stingl G, et al.:Anti-FcεRIα autoantibodies in autoimmunemediated disorders. Identification of a structure-functional relationship. J. Clin. Invest. 101:243-251, 1998

• 8) Kermani F, Niimi N, Francis DM, et al.:Characterization of a novel mast cell-specific histamine releasing activity in chronic idiopathic urticaria (CIU). J. Invest. Dermatol. 105:452 (Abstract), 1995

• 9) Ferrer M, Nakazawa K, Kaplan AP, et al.:Complement dependence of histamine release in chronic urticaria. J. Allergy Clin Immunol. 104:169-172, 1999
  pubmed

• 10) Horn MP, Gerster T, Ochensberger B, et al.:Human anti-FcεRIα autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur. J. Immunol. 29:1139-1148, 1999

• 11) Sabroe RA, Seed PT, Francis DM, et al.:Chronic idiopathic urticaria:comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J. Am. Acad. Dermatol. 40:443-450, 1999

• 12) O'Donnell BF, O'Neill CM, Francis DM, etal.:Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br. J. Dermatol. 140:853-858, 1999
  pubmed

• 13) Sabroe RA, Poon E, Orchard GE, et al.:Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria:comparison of patients with and without anti-FcεRI or anti-IgE autoantibodies. J. Allergy Clin. Immunol. 103:484-493, 1999

• 14) Sabroe RA, Francis DM, Barr RM, etal.:Anti-FcεRI autoantibodies and basophil histamine releasability in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 102:651-658, 1998

• 15) Grattan CEH, Walpole D, Francis DM, et al.:Flow cytometric analysis of basophil numbers in chronic urticaria:basopenia is related to serum histamine releasing activity. Clin. Exp. Allergy. 27:1417-1424, 1997

• 16) Sabroe RA, Grattan CEH, Francis DM, et al.:The autologous serum skin test:ascreening test for autoantibodies in chronic idiopathic urticaria. Br. J. Dermatol. 140:446-4521999

• 17) Fradin MS, Ellis CN, Goldfarb MT, et al.:Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J. Am. Acad. Dermatol. 25:1065-1067, 1991
  pubmed

• 18) Toubi E, Blant A, Kessel A, et al.:Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 52:312-316, 1997
  pubmed

• 19) Grattan CEH, O'Donnell BF, Francis DM, et al.:Randomized double-blind study of cyclosporin in chronic:'diopathic':urticaria. Br. J. Dermotol. 143:365-372, 2000

• 20) Grattan CEH, Francis DM, Slater NGP, et al.:Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 339:1078-1080, 1992

• 21) 新見直正, 秀道広, 山本昇壯:自己免疫性蕁麻疹とアフェレシス. 日本アフェレシス学会雑誌 19:209-215, 2000

• 22) O'Donnell BF, Barr RM, Black AK, et al.:Intravenous immunoglobulin in autoimmune chronic urticaira. Br. J. Dermatol. 138:101-106, 1998
  pubmed

P.216 掲載の参考文献

• 1) Medsger TA Jr:Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis In:Arthritis and Allied Conditions 12th edition, ed. by DJ McCarty, WJ Koopman. Lea & Febiger, Philadelphia, 1993, pp.1118-1665

• 2) LeRoy EC, Black C, Fleischmajer R, et al.:Scleroderma (systemic sclerosis):classification, subsets, and pathogenesis. J. Rheumatol. 15:202-205, 1998

• 3) 菊地かな子:強皮症の病因論 (2) 細胞成長因子よりみた異常. MB Derma. 12:11-14, 1998

• 4) Valent P, Spanblochl E, Sperr WR, et al.:Induction of defferentiation of human mast cells fro bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237-2245, 1992

• 5) Irani AA, Nilsson G, Miettinen U, et al.:Recombinant human stem cell factor stimulates defferentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021, 1992

• 6) Yamamoto T, Katayama I, Nishioka K:Expression of stem cell factor in the lesional skin of systemic sclerosis. J. Dermatology 197:109-114, 1998

• 7) Kihira C, Mizutani H, Asahi K, et al.:Increased cutaneous immunoreactive stem cell factor exression and serum stem cell factor level in systemic scleroderma. J. Dermatol. Sci. 20:72-78, 1998

• 8) Abe M, Kurosawa M, Ishikawa O, et al.:Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collageng production. J. Allergy Clin. Immunol. 106:S78-S84, 2000

• 9) Irani AA, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986
  pubmed

• 10) Irani AA, Bradford TR, Kepley CL, etal.:Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodeis. J. Histochem. Cytochem 37:1509-1515, 1989

• 11) Algermissen B, Bauer F, Schadendorf D, et al.:Analysis of mast cell subpopulations (MCT, MCTc) in cutaneous inflammation using novel enzyme-histochemical staining tecniques. Exp Dermatol. 3:290-297, 1994

• 12) Ruoss SJ, Hartmann T, Caughey GH:Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 88:493-499, 1991
  pubmed

• 13) Cairns JA, Walls AF:Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997
  pubmed

• 14) Lees M, Taylor DJ, Wooley DE:Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of geratinases A and B. Eur. J. Biochem. 223:171-177, 1994

• 15) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human ast cell chymase initiates collagen fibril formation and generates a unique corboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997

• 16) Wypij DM, Nichols JS, Novak PJ, et al.:Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endthelin-1 in the perfused rat lung. Biochem. Pharmacol. 43:845-853, 1992

• 17) Hawkins RA, Claman HN, Clark RA, et al.:Increased dermal mast cell populations in progressive systemic sclerosis:alink in chronic fibrosis? Ann. Intern. Med. 102:182-186, 1985

• 18) Nishioka K, Kobayashi Y, Katayama I, et al.:Mast cell numbers in diffuse scleroderma. Arch. Dermatol. 123:205-208, 1987
  pubmed

• 19) Seibold JR, Giorno RC, Claman HN:Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum. 33:1702-1709, 1990
  pubmed

• 20) Irani AA, Gruber BL, Kaufman LD, etal.:Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum. 35:933-939, 1992

• 21) Akimoto S, Ishikawa O, Igarashi Y, etal.:Dermal mast cells in scleroderma:their skin density, tryptase/chymase phenotyps and degranulation. Br. J . Dermatol. 138:399-406, 1998

• 22) Black C, Dieppe P, Huskisson T, et al.:Regressive systemic sclerosis. Ann. Rheum. Dis. 45:384-388, 1986
  pubmed

• 23) LeRoy EC:Increased collagen synthesis by scleroderma skin fibroblasts in vitro. A possible defect in regulation or activation of the scleroderma fibroblast. J. Clin. Invest. 54:880-889, 1974
  pubmed

• 24) Takeda K, Hatamochi A, Ueki H, et al.:Decreased collagenase expression in cluturedsystemic sclerosis fibroblasts. J. Invest. Dermatol. 103:359-363, 1994
  pubmed

P.221 掲載の参考文献

• 1) 新井克志:ケロイド. 日外会誌 100:529-533, 1999

• 2) Smith CJ, Snith JC, Finn MC:The possible role of mast cells (allergy) in the production of keloi and hypertrophic scarring. J. Burn Care Rehabil. 8:126-131, 1987

• 3) Beer TW, Baldwin H, West L, et al.:Mast cells in pathological and surgical scars. Br. J. Ophthalmol. 82:691-694, 1998
  pubmed

• 4) 神戸直智, 黒沢元博, 神戸美千代ほか:マスト細胞の病理組織学的検討. 臨床検査 43:762-766, 1999

• 5) 大浦武彦, 杉原平樹, 吉田哲憲:ケロイドと肥厚性瘢痕の定義ならびに分類. 形成外科 36:265-274, 1993

• 6) Koda A, Nagai H, Watanabe S, et al.:Inhibition of hypersensitivity reactions by a new drug N (3', 4'-dimethoxycinnamoyl) anthranilic acid (N-5'). J. Allergy Clin. Immunol. 57:396-407, 1976
  pubmed

• 7) 早稲田豊美:ケロイドへのトラニラストの適用. 医薬ジャーナル 21:457-461, 1984

• 8) 難波雄哉, 緒方茂寛, 奈良 卓ほか:ケロイド・肥厚性瘢痕に対するトラニラストの臨床効果の検討. 熱傷 13:213-227, 1987

• 9) Berman B, Duncan MR:Short-term keloid treatment in vivo with human interferon alfa-2b results in selective and persistant normalization of keloid fibroblast collagen, glycosaminoglycan, and collagen production in vitro. J. Am. Acad. Dermatol. 21:694-702, 1989
  pubmed

• 10) 須澤東夫, 菊池伸次, 市川 潔ほか:アレルギー性疾患治療薬Tranilastのケロイド組織に対する作用. 日薬理誌 99:231-239, 1992
  Medical*Online

• 11) Suzawa H, Kikuchi S, Arai N, et al.:The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn. J. Pharmacol. 60:91-96, 1992
  pubmed

• 12) Kleeberger SR, Seiden JE, Levitt RC, et al.:Mast cell modulate acute ozone-induced inflammation of the murine lung. Am. Rev. Respir. Dis. 148:1284-1291, 1993
  pubmed

• 13) Takizawa H, Ohta K, Hirai K, et al.:Mast cells are important in the development of hypersensitivity pneumonitis. A study with mast-cell-deficient mice. J. Immunol. 143:1982-1988, 1989
  pubmed

• 14) Hatamochi A, Fujiwara K, Veki H:Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch. Dermatol. Res. 277:60-64, 1985

• 15) Ruoss SJ, Harrmann T, Caughey GH:Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 88:493-499, 1991

• 16) Guidry C, Grinnel F:Heparin modulates the organization of hydrate collagen gels and inhibits gel contraction by fibroblasts. J. Cell Biol. 104:1097-1103, 1987

• 17) Kanbe N, Kurosawa M, Nagata H, et al.:Cord blood-derived human cultured mast cells produce transforming growth factor β1. Clin. Exp. Allergy 29:105-113, 1999

• 18) Qu Z, Liebler JM, Powers MR, et al.:Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147:564-573, 1995

• 19) Reed JA, Albino AP, McNutt NS:Human cutaneous mast cells express basic fibroblast growth factor. Lab. Invest. 72:215-222, 1995
  pubmed

• 20) Sugihara A, Tsujimura T, Fujita Y, et al.:Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. J. Hepatol. 30:859-867, 1999
  pubmed

• 21) Okazaki T, Hirota S, Xu ZD, et al.:Increase of mast cells in the liver and lung may be associated with but not a cause of fibrosis:demonstration using mast cell-deficient Ws/Ws rats. Lab. Invest. 78:1431-1438, 1998

• 22) Schwartz LB, Bradford TR, Littman BH, et al.:The fibrinogenolytic activity of purified tryptase from human lung mast cells. J. Immunol. 135:2762-2767, 1985
  pubmed

• 23) Gruber BL, Schwartz LB:The mast cell as an effector of connective tissue degradation:a study of matrix susceptibility to human mast cells. Biochem. Biophys. Res. Commn. 171:1272-1278, 1990

• 24) Kanbe N, Tanaka A, Kanbe M, et al.:Human mast cells produce matrix metalloproteinase 9. Eur. J. Immunol. 29:2645-2649, 1999
  pubmed

• 25) Matsuda H, Nakano T, Kiso T, et al.:Normalization of anti-tick response of mast cell-deficient W/Wv mice by intracutaneous injection of cultured mast cells. J. Parasitol. 73:155-160, 1987

• 26) Galli SJ, Wershil BK:The two faces of the mast cell. Nature 81:21-22, 1996

P.231 掲載の参考文献

• 1) Irani AA, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4469, 1986
  pubmed

• 2) 辻浩一郎, 中畑龍俊:肥満細胞の起源と分化増殖. 臨床免疫 27:874-879, 1995

• 3) 大幡勝也, 河野茂勝:ケミカルメディエーター遊離. 肥満細胞-生理と病理-(黒沢元博編), メディカルレビュー社, 大阪, 1990, pp. 330-340

• 4) 本田まりこ, 新村眞人:神経線維腫症/Neurofibromatosis type I, Type II. 実験医学 12:739, 1994

• 5) Greggio H:Les cellules granuleuses (Mastzellen) dans les tissues normaux et dans certaines maladies churgicales. Arch. Med. Exp. 23:323, 1911

• 6) Isaacson P:Mast cells in benign nerve sheath tumours. J. Pathol. 119:193-196, 1976
  pubmed

• 7) 西岡 清:皮膚. 肥満細胞-生理と病理-(黒沢元博編), メディカルレビュー社, 大阪, 1990, pp. 117-123

• 8) Ingram DA, Yang FC, Travers JB, et al.:Genetic and biochemical evidence that haploin-sufficiency of the Nfl tumor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med. 191:181-188, 2000

• 9) 新村眞人, 上出良一:Recklinghausen病の研究-神経線維腫症にみられるマスト細胞について. 厚生省特定疾患神経皮膚症候群調査研究班, 昭和58年度研究報告書, p.127

• 10) Matsuda R, Takahashi T, Nakamura S, et al.:Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am. J. Pathol. 142:339-346, 1993

• 11) Duronio V, Welham MJ, Abrasham S, et al.:p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating Protein. Proc. Natl. Acad. Sci. USA 89:1587-1591, 1992

• 12) Hirota S, Nomura S, Asada H, et al.:Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch. Pathol. Lab. Med. 117:996-999, 1993
  pubmed

• 13) Ryan JJ, Klein KA, Neuberger TJ, et al.:Role for the stem cell factor/kit complex in schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J. Neurosci. Res. 37:415-432, 1994
  pubmed

• 14) Kirkpatrick CJ, Curry A:Interaction between mast cells and perineurial fibroblasts in neurofibroma. Path. Res. Pract. 1183:453-461, 1988

• 15) 斎藤博久, 飯倉洋治:GTP結合蛋白. 肥満細胞-生理と病理-(黒沢元博編), メディカルレビュー社, 大阪, 1990, pp. 198-205

P.237 掲載の参考文献

• 1) 窪田泰夫:ヒト皮膚肥満細胞とその関連疾患 (III). 西日皮膚 59:864-869, 1997

• 2) Metcalfe DD, Baram D, Mekori YA:Mast cells. Physiol. Reviews 77:1033-1079, 1997
  pubmed

• 3) Glowacki J, Mulliken JB:Mast cells in hemangiomas and vascular malformation. Pediatrics 70:48-51, 1982
  pubmed

• 4) Kessler DA, Langer RS, Pless NA, et al.:Mast cells and tumor angiogenesis. Int. J. Cancer 18:703-709, 1976
  pubmed

• 5) Qu Z, Liebler JM, Powers MR, et al.:Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147:564-573, 1995

• 6) Hagiwara K, Khaskhely NM, Uezato H, et al.:Mast cell "densities" in vascular proliferations:a preliminary study of pyogenic granuloma, portwine stain, cavernous hemangioma, cherry angioma, Kaposi's sarcoma and malignant hemangioendothelioma. J. Dermatol. 26:577-586, 1999
  pubmed

• 7) Mikhail GR, Miller-Milinska A:Mast cell population in human skin. J. Invest. Dermatol. 43:249-254, 1964
  pubmed

• 8) Shea CR, Prieto VG:Mast cells in angiolipomas and hemangiomas of human skin:are they important for angiogenesis? J. Cutan. Pathol. 21:247-251, 1994
  pubmed

• 9) Reed JA, Albino AP, McNutt NS:Human cutaneous mast cells express basic fibroblast growth factor. Lab. Invest. 72:215-222, 1995
  pubmed

• 10) Detmar M, Brown LF, Schon MP, et al.:Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111:1-6, 1998
  pubmed

• 11) Ribatti D, Nico B, Vacca A, et al.:Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br. J. Cancer 77:1900-1906, 1998

• 12) Boesiger J, Tsai M, Maurer M, et al.:Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immuroglobulin E-dependent upregulation of Fcε receptor I expres-sion. J. Exp. Med 188:1135-1145, 1998

• 13) Wong KT, Shamsol S:Quantitative study of mast cells in Kimura's disease. J. Cutan. Pathol. 26:13-16, 1999
  pubmed

• 14) Blair RJ, Meng H, Marchese MJ, et al.:Human mast cells stimulate vascular tube for-mation. Tryptase is a novel, potent angiongenic factor. J. Clin. Invest. 99:2691-2700, 1997

P.245 掲載の参考文献

• 1) Valent P, Eschbano L, Pawaresch RM, et al.:Recent advances in mastocytosis research. Int. Arch. Allergy Immunol. 120:1-7, 1999

• 2) Hartmann K, Henz BM:Mastocytosis:recent advances in defining the disease. Br. J. Dermatol. 144:682-695, 2001
  pubmed

• 3) Tsujimura T, Koshimizu U, Katoh H, et al.:Mast cell number in the skin of heterozygotes reflects molecular nature of c-kit mutation. Blood 81:2530-2538, 1993
  pubmed

• 4) Tsujimuta T:Role of c-kit receptor tyrosine kinase for development, survival and neoplastic transformation of mast cells. Pathol. Int. 46:933-938, 1996

• 5) Metcalfe DD:Classification and diagnosis of mastocytosis:Current Status. J. Invest. Dermatol. 96:2S-4S, 1991

• 6) Travis WD, Li CY, Bergstralh EJ, et al.:Systemic mast cell disease:analysis of 58 cases and literature review. Medicine 67:345-368, 1988
  pubmed

• 7) Furitsu T, Tsujimura T, Tono T, et al.:Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J. Clin. Invest. 92:1736-1744, 1993

• 8) Tsujimura T, Furitsu T, Morimoto M, et al.:Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83:2619-2626, 1994

• 9) Tsujimura T, Furitsu T, Morimoto M, et al.:Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol. 106:377-385, 1995

• 10) Moriyama Y, Tsujimura T, Hashimoto K, et al.:Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J. Biol. Chem. 271:3347-3350, 1996
  pubmed

• 11) Tsujimura T, Morimoto M, Hashimoto K, et al.:Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87:273-283, 1996
  pubmed

• 12) Kitayama H, Kanakura Y, Furitsu T, et al.:Constitutive activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85:790-798, 1995
  pubmed

• 13) Hashimoto K, Tsujimura T, Moriyama Y, et al.:Transforming and differentiation-inducing potentials of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am. J. Pathol. 148:189-200, 1996
  pubmed

• 14) Kitayama H, Tsujimura T, Matsumura I, et al.:Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88:995-1004, 1996
  pubmed

• 15) Tsujimura T, Hashimoto K, Kitayama H, et al.:Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 93:1319-1329, 1999

• 16) Nagata H, Worobec AS, Oh CK, et al.:Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-10564, 1995
  pubmed

• 17) Longley BJ, Tyrrell L, Lu SZ, et al.:Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis:establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312-314, 1996

• 18) Worobec AS, Semere T, Nagata H, et al.:Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 83:2120-2129, 1998
  pubmed

• 19) Longley BJ Jr, Metcalfe DD, Tharp M, et al.:Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA 96:1609-1614, 1999
  pubmed

• 20) Heinrich MC, Griffith DJ, Druker BJ, et al.:Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
  pubmed

P.252 掲載の参考文献

• 1) Kerdel FA, Moschella SL:Sarcoidosis:an updated review. J. Am. Acad. Dermatol. 11:1-19, 1984
  pubmed

• 2) Kawanami O, Ferrans VJ, Fulmer JD, et al.:Ultrastucture of pulmonary mast cells in patients with fibrotic lung disorders. Lab. Invest. 40:717-734, 1979

• 3) Flint KC, Leung KBP, Hudspith BN, et al.:Bronchoalveolar mast cells in sarcoidosis:increased numbers and accentuation of mediator release. Thorax 41:94-99, 1986

• 4) Bjermer L, Engstrom-Laurent A, Thunell M, et al.:The mast cell and signs of pulmonary fibroblast activation in sarcoidosis. Int. Arch. Allergy Appl. Immunol. 82:298-301, 1987
  pubmed

• 5) Rottoli P, Rottoli L, Perari MG, et al.:Mast cells in brochoalveolar Iavage in sarcoidosis:correlation with alveolar lymphocytes. Respiration 54 (Suppl. 1):42-48, 1988

• 6) Eklund A, van Hage-Hamsten M, Skold CM, et al.:Elevated levels of tryptase in bronchoalveolar lavage fluid from patients with sarcoidosis. Sarcoidosis 10:12-17, 1993
  pubmed

• 7) Irani AMA, Bradford TR, Kepley CL, et al.:Detection of MCT and MCTc types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J.Histochem. Cytochem. 37:1509-1515, 1989

• 8) Cordell J, Falini B, Erber W, et al.:Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 32:219-229, 1984
  pubmed

• 9) Mana J, Marcoval J, Graells J, et al.:Cutaneous involvement in sarcoidosis. Arch. Dermatol. 133:882-888, 1997
  pubmed

• 10) Celasun B, Crow J, Scheuer PJ:Mast cells in granulomatous liver disease. Pathol. Res. Pract. 188:97-100, 1992
  pubmed

• 11) Sheffield EA, Mitchell DN, Dewar A, et al.:The ultrastructural features of developing Kveim test granulomas. Sarcoidosis 6 (Suppl. 1):6-7, 1989

• 12) Harvima IT, Naukkarinen A, Harvima RJ, et al.:Quantitation of tryptase-and chymase-containing mast cells in cutaneous lichen planus. Acta Derm. Venereol. (Stockh) 71:394-398, 1990

• 13) Harvima IT, Naukkarinen A, Harvima RJ, et al.:Quantitative enzyme-histochemical analysis of tryptase-and chymase-containing mast cells in psoriatic skin. Arch. Dermatol. Res. 282:428-433, 1990
  pubmed

• 14) Irani AMA, Gruber BL, Kaufman LD, etal.:Mast cell changes in scleroderma:presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum. 35:933-939, 1992

• 15) Algermissen B, Bauer F, Schadendorf D, et al.:Analysis of mast cell subpopulations (MCT, MCTc) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp. Dermatol. 3:290-297, 1994
  pubmed

• 16) Wintroub BU, Schechter NB, Lazarus GS, et al.:Angiotensin I conversion by human and rat chymotryptic proteinases. J. Invest Dermatol. 83:336-339, 1984
  pubmed

• 17) Galli SJ, Gordon JR, Wershie BK:Mast cell cytokines in allergy and inflammation. Agents Actions 43 (Suppl.):209-220, 1993

VI / 整形外科疾患

P.263 掲載の参考文献

• 1) Ehrlich P:Beitrage zur kenntnis der granulierten Bindegewebesrellen und der esinophilen Leukocyten. Verh. Physiol. Ges. Berlin Arch. Anat. Physiol. Phys. Abt.:166-169, 1879

• 2) Kitamura Y, et al.:Hematopoietic Stem Cells. Alfred Benson Symposium 18, Munksgaard, 1984, pp. 350

• 3) Gleich GJ, et al.:Mast cell heterogeneity:biological and clinical significance. In:Mast cell Differentiation and Heterogeneity, ed. by Befus AD, Bienenstock J, Denburg JA, Raven Press, New York, 1986, pp. 347-366

• 4) 中畑龍俊, 高木峰生:マスト細胞とサイトカイン. 細胞工学 10:579-586, 1991

• 5) Irani AMA, Schwartz LB:Mast cell heterogeneity. Clin. Exp. Allergy 19:143-155, 1989

• 6) Arizono N, Matsuda S, Hattori T, et al.:Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Lab. Invest. 62:626-634, 1990
  pubmed

• 7) Azizkhon RG, Azizkhon JC, Zetter BR:Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J. Exp. Med. 152:931-944, 1980

• 8) Taylor S, Folkman J:Protarnine is an inhibitor of angiogenesis. Nature 297:307-312, 1982
  pubmed

• 9) Tharp MD:The interaction between mast cells and endothelial cells. J. Invest. Dermato. 93:107S-112S, 1989

• 10) Atkins FM, Friedman MM, Subba Rao PV, et al.:Interactions between mast cells, fibroblast and connective tissue components. Int. Arch. Allergy Appl. Immunol. 77:96-102, 1985
  pubmed

• 11) Severson AR:Mast cells in areas of experimental bone resorption and remodeling. Br. J. Exp. Pathol. 50:17-21, 1969
  pubmed

• 12) Lindholm RV, Lindholm TS:Mast cells in endosteal and periosteal bone repair. I. The periosteal callus n rats. Acta Orthop. Scand. 41:129-133, 1970

• 13) Cruess RL:Healing of bone, tendon, and ligament. In:Fracture in Adults. vol 1 2nd, ed. by Rockwood CAJ, Green DP, JB Lippincott Philadelphia, 1984, pp.147-167

• 14) Goldhaber P:Heparin enhancement of factors stimulating bone resorption in tissue culture. Science 147:407-408, 1965
  pubmed

• 15) Straus AH, Nader BN, Dietrich CP:Absence of heparin or heparin-like compounds in mastcell-free tissues and animals. Biochem. Biophys. Acta 717:478-485, 1982

• 16) Glowaki J:The effects of heparin amd protamine on resorption of bone particles. Life Sci. 33:1019-1024, 1983

• 17) Alm PE:Sodium fluoride evoked histamine release from mast cells. A study of cyclic AMP levels and effects of catecholamines. Agents Actions 13:132-137, 1983
  pubmed

• 18) De Forrest JM, Hollis TM:Shear stress and aortic histamine synthesis. Am. J. Physiol. 234:701-705, 1978

• 19) Hasegawa S, Sato S, Saito S, et al.:Mechanical stretching increases the number of cultured bone ells synthesizing DNA and alters their pattern of protein synthesis. Calcif Tissue Int. 37:431-436, 1985

• 20) 大竹 進, 原田征行, 岡本佳隆ほか:剛体バネモデルによる頸椎周囲の応力解析について. 中部整災誌 30 748-750, 1987

P.268 掲載の参考文献

• 1) Crisp AJ, Chapman CM, Kirkham SE, et al.:Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum. 27:845-851, 1984
  pubmed

• 2) Olsson N, Ulfgren AK, Nilsson G:Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann. Rheum. Dis. 60:187-193, 2001
  pubmed

• 3) 黒沢元博, 神戸直智, 稲村弘明ほか:炎症における肥満細胞の役割. 炎症と免疫 7:150-156, 1999
  Medical*Online

• 4) Bromley M, Woolley DE:Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum. 27:857-863, 1984
  pubmed

• 5) Zvaifler NJ, Firestein GS:Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum. 37:783-789, 1994
  pubmed

• 6) Gotis-Graham I, McNeil HP:Mast cell responses in rheumatoid synovium. Association of the MCTc subset with matrix turnover and clinical Progression. Arthritis Rheum. 40:479-489, 1997
  pubmed

• 7) Gotis-Graham I, Smith MD, Parker A, et al.:Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis. 57:664-671, 1998
  pubmed

• 8) Thomas R, Lipsky PE:Presentation of self peptides by dendritic cells:possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 39:183-189, 1996
  pubmed

• 9) Marone G:Mast cells in rheumatic disorders:mastermind or workhorse? Clin. Exp. Rheumatol. 16:245-249, 1998
  pubmed

• 10) Gruber BL:Mast cells:accessory cells which potentiate fibrosis. Intern. Rev. immunol. 12:259-279, 1995

• 11) 小山内俊久, 山川光徳, 高木理彰ほか:RA関節面パンヌスにおける肥満細胞の分布と形態学的検討. 関節の外科16:37-42, 1989

• 12) Allard SA, Muirden KD, Maini RN:Correlation of histopathological features of pannus with patterns of damage in different joints in rheumatoid arthritis. Ann. Rheum. Dis. 50:278-283, 1991
  pubmed

• 13) Tetlow LC, Woolley DE:Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion:dual immunolocalization studies. Ann. Rheum. Dis. 54:896-903, 1995

• 14) Antoni C, Kalden JR:Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 178:S73-S77, 1999

• 15) Weinblatt ME, Kremer JM, Bankhurst AD, et al.:Atrial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. 340:253-259, 1999

• 16) Steffen M, Abboud M, Potter GK, et al.:Presence of tumor necrosis factor or related factor in human basophil/mast cells. Immunology 66:445-450, 1989
  pubmed

• 17) Kirshenbaum AS, Gaff Jp, Kessler SW, et al.:Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 148:772-777, 1992

• 18) Kiener HP, Hofbauer R, Tohidast-Akrad M, et al.:Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum. 43:164-174, 2000
  pubmed

• 19) Buckley CD, Pilling D, Lord JM, et al.:Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 22:199-204, 2001
  pubmed

• 20) Takayanagi H, Oda H, Yamamoto S, et al.:A new mechanism of bone destruction in rheumatoid arthritis:synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240:279-286, 1997

VII / 耳鼻咽喉科疾患

P.279 掲載の参考文献

• 1) 川堀眞一, 金井直樹:ヒト鼻粘膜のトリプターゼ単独陽性とトリプターゼ, キマーゼ両陽性肥満細胞の分布-フォルマリン感受性及び抵抗性肥満細胞との関係-. アレルギー 42:894-899, 1993
  Medical*Online

• 2) 奥田実:鼻アレルギーの基礎と臨床. 耳鼻 20:297-344, 1974

• 3) Otsuka H, Denburg J, Dolovich J, et al.:Heterogeneity of metachromatic cells in human nose:significance of mucosa mast cells. J. Allergy Clin. 1mmunol. 76:695-702, 1985

• 4) Kawabori S, Okuda M, Unno T:Mast cells in allergic nasal epithelium and lamina propria before and after provocation. An electron microscopic study. Clin. Allergy 13:181-189, 1983
  pubmed

• 5) Naclerio RM, Meier HL, Kagey-Sobotka A, et al.:Mediator release after nasal airway challenge with antigen. Am. Rev. Respir. Dis. 128:597-602, 1983
  pubmed

• 6) Enerback L, Pipkorn U, Granerus G:Intraepithelial migration of nasal mucosal mast cells in hay fever:ultrastructural observations. Int. Arch. Allergy Appl. Immunol. 80:44-51, 1986

• 7) Pipkorn U, Kalsson G, Enerback L, et al.:The cellular response of the human allergic mucosa to natural allergen exposure. J. Allergy Clin Immunol. 82:1046-1054, 1988

• 8) Kawabori S, Okuda M, Unno T, et al.:Dynamics of mast cell degranulation in human allergic nasal epithelium after provocation with allergen. Clin. Allergy 15:509-515, 1985
  pubmed

• 9) Juliusson S, Karlsson G, Bachert C, et al.:Metachromatic, IgE-bearing and tryptase-containing cells in the nasal mucosal surface in provoked allergic rhinitis. APMIS 102:153-160, 1994
  pubmed

• 10) Nilsson G, Hjertson M, Andersson M, et al.:Demonstration of mast-cell chemotactic activity in nasal lavage fluid:characterization of one chemotaxin as c-kit ligand, stem cell factor. Allergy 53:874-879, 1998

• 11) Otsuka H, Kusumi T, Kanai S, et al.:Stem cell factor mRNA expression and production in human nasal epithelial cells:contribution to the accumulation of mast cells in the nasal epithelium of allergy. J. Allergy Clin. Immunol. 102:757-764, 1998

• 12) Kawabori S, Kanai N, Tosho T:Proliferative activity of mast cells in allergic nasal mucosa. Clin. Exp. Allergy 25:173-178, 1995
  pubmed

• 13) Kawabori S, Kanai N, Tosho T, et al.:Existence of c-kit receptor-positive, tryptase-negative, IgE-negative cells in allergic nasal mucosa:a candidate for mast cell progenitor. Int. Arch. Allergy Immunol. 112:36-43, 1997
  pubmed

• 14) Kawabori S, Sakata A, Uehara M, etal.:Changes in nasal symptoms and inflammatory cells over the course of perennial allergic rhinitis. Allergol. International 47:197-204, 1998

• 15) Bradding P, Feather IH, Wilson S, et al.:Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic inflammation. J. Immunol. 151:3853-3865, 1993
  pubmed

• 16) Pawankar R, Ra C:IgE-FcεRI-mast cell axis in the allergic cycle. Clin. Exp. Allergy 28:(Suppl. 3) 6-14, 1998

• 17) Ying S, Durham SR, Jacobson MR, et al.:T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 82:200-206, 1994
  pubmed

• 18) Ying S, Durhan SR, Barkans J, et al.:T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am. J. Respir. Cell Mol. Biol. 9:356-360, 1993

• 19) Kawabori S, Watanabe A, Goto T:Differences in mast cell-bound IgE in the nasal epithelial and lamina propria. Allergol. International 50:99-104, 2001

• 20) Okuda M, Sakaguchi K, Ohtsuka H, et al.:Intranasal beclomethasone:mode of action in nasal allergy. Ann. Allergy 50:116-120, 1983
  pubmed

• 21) Holm AF, Godthelp T, Fokkens WJ, et al.:Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perehnial allergic rhinitis. Clin. Exp. Allergy 29:1356-1366, 1999
  pubmed

• 22) Jacobson MR, Juliusson S, Lowhagen O, et al.:Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis:a comparison of n sal brush and biopsy methods. Clin. Exp. Allergy 29:1347-1355, 1999

• 23) Otsuka H, Mezawa A, Ohnishi M, etal.:Changes in nasal metachromatic cells during allergen immunotherapy. Clin. Exp. Allergy 21:115-119, 1991
  pubmed

P.286 掲載の参考文献

• 1) Konno A, Terada N, Okamoto Y, et al.:The role of chemical mediators and mucosal hyperreactivity in nasal hypersecretion in nasal allergy. J. Allergy Clin. Immunol. 79:620-626, 1987
  pubmed

• 2) 今野昭義:鼻過敏症-その病態と臨床. 第97回日本耳鼻咽喉科学会宿題報告モノグラフ. 1996

• 3) 岡本美孝, 松崎全成:ウイルスと気道アレルギー. 気道アレルギー'96. 牧野荘平, 石川哮編, メディカルレビュー社, 大阪, 1996, pp. 109-115

• 4) Konno A, Terada N, Okamoto Y:Change of adrenergic and cholinergic receptors in nasal mucosa in nasal allergy. ORL 49:103-111, 1987
  pubmed

• 5) Konno A, Terada N, Okamoto Y:Cholinergic muscarinic receptor in the nasal mucosa of guinea pigs with bronchial asthma with and without hypersensitive nasal symptoms. ORL 47:307-313, 1985
  pubmed

• 6) Baraniuk JN:Pathogenesis of allergic rhinitis. J. Allergy Clin. Immunol. 99. S763-S723, 1997
  pubmed

• 7) Bascom R, Pipkorn U, Lichtenstein LM, et al.:The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Am. Rev. Respir. Dis. 138:406-412, 1988
  pubmed

• 8) del Pozo V, de Arruda-Chaves E, de Andres B, et al.:Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J. Immunol. 158:859-864, 1997
  pubmed

• 9) 岡本美孝:鼻粘膜過敏症-好酸球の関与-. アレルギー48:569-571, 1999

• 10) Okuda M:Functional heterogeneity of airway mast cells. Allergy 54:50-62, 1999
  pubmed

• 11) Holgate ST:Genetic and environmental interaction in allergy and asthma. J. Allergy Clin. Immunol. 104:1139-1146, 1999
  pubmed

• 12) Pawankar R, Ra C:IgE-Fc epsilon RI-mast cell axis in allergic cycle. Clin. Exp. Allergy 28 (Suppl. 3):6-14, 1998

• 13) Westin U, Lundberg E, Wihl JA, et al.:The effect of immediate-hypersensitivity reactions on the level of SLPI, granulocyte elastase, al-antitrypsin, and albumin in nasal secretions, by the method of unilateral antigen challenge. Allergy 54:857-864, 1999

• 14) Gaughey GH:The structure and airway biology of mast cell proteinase. Am. J. Respir. Cell Mol. Biol. 4:387-394, 1991

• 15) Gauchat JF, Henchoz S, Mazzei G, et al.:Induction of human IgE synthesis in B cells by mast cells and basophilic metachromatic cells in allergic rhinitis. Nature 365:340-343, 1993

• 16) Pawanker R, Okuda M, Yssel M, et al.:Nasal mast cells in perenial allergic rhinitis exhibitincreased expression of the FcεRI, CD40L, IL-4 and can induce IgE synthesis in B cells. J. Clin. Invest. 99:1492-1499, 1997

• 17) 松崎全成, 岡本美孝:アレルギー性鼻炎における鼻粘膜炎症の成立機序とその臨床的意義-T細胞からみて-. 日鼻誌 39:74-75, 2000

• 18) Wang M, Saxon A, Diaz-Sanchez D:Early IL-4 production driving Th2 differentiation in a human in vivo allergic model is mast cell derived. Clin. Immunol. 90:47-54, 1999

• 19) Okuda M, Ohtsuka H, Kawabori S:Studies of nasal surface basophilic cells. Ann. Allergy 54:69-71, 1985
  pubmed

• 20) Otuka H, Inada M, Fujita T, et al.:Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis. J. Allergy Clin. Immunol. 96:528-536, 1995

P.294 掲載の参考文献

• 1) 野々山勉, 間島雄一, 有馬 忍ほか:当科における内視鏡下鼻内副鼻腔手術症例の検討. 特に鼻茸合併症例を中心に. 目耳鼻 103:1001-1006, 2000

• 2) 間島雄一:鼻茸の成因と治療. 耳展 42:525-530, 1999

• 3) 平出文久, 友松英男, 西澤伸志ほか:最近の鼻茸の病理組織学的検討. 特に好酸球と形質細胞の浸潤状態について. 耳展 28:125-133, 1985

• 4) Hellquist HB:Histopathology. In:Nasal polyps, ed. by Settipaue GA, Lung VJ, Bernstein JM, et al, OceanSide Publications, Providence, 1997, pp.31-39

• 5) 高坂知郎:形態面からみた鼻茸の病態について. 耳喉頭頸 62:1141-1147, 1990

• 6) Tos M:Early stages of polyp formation. In:Nasal polyps, ed. by Settipaue GA, Lung VJ, Bernstein JM, et al, OceanSide Publications, Providence, 1997, pp.65-72

• 7) 荻野 敏, 原田 保, 入船盛弘:アスピリン喘息とその鼻茸. 耳鼻臨床 (補) 41:113-121, 1991

• 8) Hamilos DL, Leung DYM, Wood R, et al.:Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J. Allergy Clin. Immunol. 96:537-544, 1995

• 9) Bernstein JM:The immuno-histopathology and pathophysiology of nasal polyps. In:Nasal Polyps, ed. by Settipaue GA, Lung VJ, Bernstein JM, et al, OceanSide Publications, Providence, 1997, pp. 85-95

• 10) Gauldie J, Cox G, Jordana M, et al.:Growth and colony-stimulating factors mediate eosinophil fibroblast interactions in chronic airway inflammation. Ann. NY Acad. Sci. 725:83-93, 1994
  pubmed

• 11) Ohno I, Lea RG, Finotto S, et al.:Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene expression by eosinophils in nasal polyposis. Am. J. Respir. Cell Mol. Biol. 5:505-510, 1991

• 12) Hamilos DL, Leung DYM, Wood R, et al.:Chronic hyperplastic sinusitis:association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J. Allergy Clin. Immunol. 92:39-48, 1993

• 13) Jordana M, Dolovich J:Eosinophils in nasal polyps. In:Nasal Polyps, ed. by Settipaue GA, Lung VJ, Bernstein JM, et al, OceanSide Publications, Providence, 1997, pp.49-56

• 14) Wright FD, Frenkiel S, AL-Ghamdi K, et al.:Interleukin-4, interleukin-5, and granulocyte-macrophage colony-stimulilating factor receptor expression in chronic sinusitis and response to topical steroids. Otolaryngol. Head Neck Surg. 118:490-495, 1998

• 15) Stierna PLE:Nasal polyps:Relationship to infection and inflammation. In:Nasal Polyps, ed. by Settipaue GA, Lung VJ, Bernstein JM, et al, OceanSide Publications, Providence, 1997, pp.119-126

• 16) Bhandari A, 原田輝彦, 間島雄一:鼻茸の形成段階における粘膜遊走細胞の役割について. (免疫アレルギー掲載予定)

• 17) Nishimoto K, Ukai K, Harada T, et al.:Lymphocyte subsets of maxillary mucosa in chronic inflammation. Acta Otolaryngol. (Stockh.) 106:291-298, 1988
  pubmed

• 18) Church MK, Caulfield JP:Mast cell and basophil functions. In:Allergy, Gower Medical Publishing, London, 1993, pp.5.1-5.12

• 19) Drake-Lee A, Price J:Mast cell ultrastructure in the inferior turbinate and stroma of nasal polyps. J. Laryngol. Otol. 111:340-345, 1997
  pubmed

• 20) Williams CM, Galli SJ:The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 105:847-859, 2000

• 21) 原田輝彦:耳鼻咽喉科疾患と細胞外マトリックス. 細胞外マトリックス, 羊土社, 東京, 1995, pp.130-141

• 22) 原田輝彦:鼻茸の発症メカニズムと細胞外マトリックス. アレルギー科 10:118, 2000

• 23) Cairns JA, Walls AF:Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997
  pubmed

• 24) Berton A, Levi-Schaffer F, Emonard H, et al.:Activation of fibroblasts in collagen lattices by mast cell extract:a model of fibrosis. Clin. Exp. Allergy 30:485-492, 2000

• 25) Bond M, Fabunmi RP, Baker AH, et al.:Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines:an absolute requirement for transcription factor NF-κB. FEBS Lett. 435:29-34, 1998

VIII / 眼科疾患

P.303 掲載の参考文献

• 1) Irani AM, Butrus SI, Tabbara KF, et al.:Human conjunctival mast cells:distribution of MCT an MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 86:34-39, 1990
  pubmed

• 2) Morgan SJ, Williams JH, Walls AF, et al.:Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva. J. Allergy Clin. Immunol. 87:111-116, 1991
  pubmed

• 3) Allansmith MR, Baird RS, Greiner JV:Vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis compared and contrasted. Am. J. Ophthalmol. 87:544-555, 1979
  pubmed

• 4) Anderson DF, Zhang S, Bradding P, et al.:The relative contribution of mast cell subsets to conjunctival Th2-like cytokines. Invest. Ophthalmol. Vis. Sci. 42:995-1001, 2001
  pubmed

• 5) Morgan SJ, Willams JH, Walls AF, et al.:Mast cell hyperplasia in atopic keratoconjunctivitis. Eye 5:729-735, 1991

• 6) Heriquez AS, Kenyon KR, Allansnith MR, et al.:Mast cell ultrastructure. Arch. Ophthalmol. 99:1266-1272, 1981

• 7) Allansmith MR, Baird RS:Percentage of de-granulated mast cells in vernal conjunctivitis and giant papillary conjunctivitis associated with contact lens wear. Am. J. Ophthalmol. 91:71-75, 1981

• 8) Toru H, Eguchi M, Matsumoto R, et al.:Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998
  pubmed

• 9) Ahn K, Takai S, Pawankar R, et al.:Regulation of chymase production in human mast cell progenitors. J. Allergy Clin. Immunol 106:321-328, 2000
  pubmed

• 10) Zhang S, Anderson DF, Bradding P, et al.:Human mast cells express stem cell factor. J. Pathol. 186:59-66, 1998
  pubmed

• 11) Paulis AD, Minopoli G, Arbustini E, et al.:Stem cell factor is localized in, released from, and cleaved by human mast cells. J. Immunol. 163:2799-2808, 1999

• 12) Longley BJ, Tyrrell L, Ma Y, et al.:Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl. Acad. Sci. USA 94:9017-9021, 1997
  pubmed

• 13) Miyazaki K, Williams DA, Gotoh A, et al.:Membrane-bound steel factor induces more persistent tryrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85:641-649, 1995

• 14) Broudy VC:Stem cell factor and hematopoiesis. Blood 90:1345-1364, 1997
  pubmed

• 15) Butrus SI, Ochsner KI, Abelson MB, et al.:The level of tryptase in human tears. Ophthalmology 97:1678-1683, 1990
  pubmed

• 16) Magrini L, Bonini S, Centofanti M, et al.:Tear tryptase levels and allergic conjunctivitis. Allergy 51:577-581, 1996
  pubmed

• 17) Tabbara KF:Tear tryptase in vernal keratoconjunctivitis. Arch. Ophthalmol. 119:338-342, 2001
  pubmed

• 18) Hara M, Matsumori A, Ono K, et al.:Mast cell cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443-1449, 1999
  pubmed

• 19) Leskinen M, Wang Y, Leszczynski D, et al.:Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:516-522, 2001
  pubmed

• 20) Frisch SM, Francis H:Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell. Biol. 124:619-626, 1994
  pubmed

• 21) Vartio T, Seppa H, Vaheri A:Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J. Biol. Chem. 256:471-477, 1981
  pubmed

• 22) Trocme SD, Gleich GJ, Kephart GM, et al.:Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest. Opthalmol. Vis. Sci. 35:3051-3056, 1994

• 23) Trocme SD, Hallberg CK, Gill KS, et al.:Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology. Invest. Opthalmol. Vis. Sci. 38:593-599, 1997

• 24) Nakajima T, Matsumoto K, Suto H, et al.:Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays:abundant expression of major basic protein in mast cells. Blood 98:1127-1134, 2001
  pubmed

• 25) Leckie MJ, Brinke A, Lordan J, et al.:SB24053, a humanized anti-IL-5 monoclonal antibody, initial single dose safety and activity in patients with athema. Am. J. Respir. Crit. Care Med. 159:A624 (abstract), 2000

P.311 掲載の参考文献

• 1) Coroneo MT:Pterygium as an early indicator of ultraviolet insolation:a hypothesis. Br. J. Ophthalmol. 77:734-739, 1993
  pubmed

• 2) Gardner BP, Townsend WM:Pterygium. In:The Cornea, ed. by Kaufman HE, Barron BA, McDonald MB, Butterworth-Heinemann, Massachusetts, 1998, pp.497-523

• 3) 沖坂重邦, 工藤正人, 舩橋正員ほか:翼状片の発生機転. 眼科 27:633-642, 1985

• 4) Levi-Schaffer F:Mast cell/fibroblast interactions in health and disease. Chem. Immunol. 61:161-185, 1995
  pubmed

• 5) 中神哲司, 村上 晶, 沖坂重邦ほか:翼状片と肥満細胞-肥満細胞数, 表現型, stem cell factor 局在の検討-. 日眼会誌 101:662-668, 1997

• 6) Bradding P, Okayama Y, Howarth PH, et al.:Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155:297-307, 1995

• 7) 中神哲司, 村上 晶, 沖坂重邦:翼状片と肥満細胞-翼状片の肥満細胞では塩基性線維芽細胞増殖因子の発現が亢進している-. 日眼会誌 102:300-306, 1998

• 8) Galli SJ:New insights into "the riddle of the mast cells":microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab. Invest. 62:5-33, 1990
  pubmed

• 9) Church MK, Levi-Schaffer F:The human mast cell. J. Allergy Clin. Immunol. 99:155-160, 1997
  pubmed

• 10) Irani AM, Butrus SI, Tabbare KF, et al.:Human conjunctival mast cells:distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 86:34-40, 1990

• 11) Baddeley SM, Bacon AS, McGill JI, et al.:Mast cell distribution and neutral protease expression in acute and chronic allergic conjunctivitis. Clin. Exp. Allergy 25:41-50, 1995
  pubmed

• 12) Valent P:The riddle of the mast cells:kit (CD117)-ligand as the missing link? Immunol. Today 15:111-114, 1994
  pubmed

• 13) Bankl HC, Radaszkiewicz T, Klappacher GW, et al.:Increase and redistribution of cardiac mast cells in auricular thrombosis. Circulation 91:275-283, 1995
  pubmed

• 14) Galli SJ, Tsai M, Wershil BK:The c-kit receptor, stem cell factor, and mast cells. Am. J. Pathol. 142:965-974, 1993

• 15) Nakagami T, Watanabe I, Murakami A, et al.:Expression of stem cell factor in pterygium. Jpn. J. Ophthalmol. 44:193-197, 2000
  pubmed

• 16) Dushku N, Reid TW:P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr. Eye Res. 16:1179-1192, 1997
  pubmed

IX / 麻酔

P.320 掲載の参考文献

• 1) Withington DE:Allergy, anaphylaxis and anaesthesia. Can. J. Anaesth. 41:1133-1139, 1994
  pubmed

• 2) 森脇克行, 弓削孟文:ヒスタミンと肥満細胞, 麻酔管理における重要性. 麻酔と蘇生 30:323-328, 1994

• 3) McKinnon RP, Wildsmith AW:Histaminoid reactions in anaesthesia. Br. J. Anaesth. 74:217-228, 1995

• 4) 森脇克行:アレルギーと麻酔. 麻酔 48:S143-S153, 1999

• 5) Beard K, Jick H:Cardiac arrest and anaphylaxis with anaesthetic agents. JAMA 254:2741-2742, 1985

• 6) SanchezFernandez C, Quirce S, Sanchez-Cano M:Preoperative screening for general anesthesia. Allergy 53:542-543, 1998
  pubmed

• 7) 黒沢元博, 小林裕幸:歴史, 肥満細胞-生理と病理, 黒沢元博編, メディカルレビュー社, 大阪, 1990, pp.24-29

• 8) Galli SJ:New concepts about the mast cell. N. Engl. J. Med. 328:257-265, 1993
  pubmed

• 9) 森脇克行, 檜垣昭光, 佐々木宏ほか:脊椎麻酔薬, テトカインによるアナフィラキシーショックの1例. 麻酔 35:1279-1284, 1986

• 10) Sim TC:Anaphylaxis-How to manage and prevent this medical emergency. Postgrad. Med. 92:277-296, 1992
  pubmed

• 11) Beupre PN, Roizen MF, Cahalan MK, et al.:Hemodynamic and two-dimentional transesophageal echocardiographic analysis of an anaphylactic reaction in man. Anesthesiology 60:482-484, 1984

• 12) Kotani N, Kushiikawa T, Matsukawa T, et al.:A rapid increase in foot tissue temperature predicts cardiovascular collapse during anaphylactic and anaphylactoid reactions. Anesthesiology 87:559-568, 1997

• 13) Fisher MM:Anaphylactoid reactions during anaesthesia. In:International Practice of Anaesthesia. Successor to General Anaesthesia. ed. by Prys-Roberts C, Brown Jr BR, London, Butterworth Heinemann, 1/85/1-13, 1996

• 14) 光畑裕正, 松本 茂, 長谷川淳一:麻酔科領域におけるアナフィラキシー・アナフィラキシー様反応の統計学的検討. 麻酔 41:1664-1669, 1992

• 15) Pollard RJ, Layon AJ:Latex allergy in the operating room:case report and a brief review of the literature. (comments by Setzer N) J. Clin. Anesth. 8:161-167, 1996

• 16) LebenbomMansour MH, Oesterle JR, Ownby DR, et al.:The incidence of latex sensitivity in ambulatory surgical patients:a correlation of historical factors with positive serum immunoglobulin E levels. Anesth. Analg. 85:44-49, 1997
  pubmed

• 17) 上野川修一:からだと免疫のしくみ. 入門ビジュアルサイエンス. 日本実業出版社, 東京, 1996, pp.1-173

• 18) 奥村 康:免疫生体防御のメカニズム. 講談社選書メチエ. 講談社, 東京, 1996, pp.7-220

• 19) Oettgen HC:Regulation of the IgE isotype switch:new insights on cytokine signals and the functions of epsilon germline transcripts. Curr. Opin. Immunol. 12:618-623, 2000
  pubmed

• 20) Serafin WE:Drugs used in the treatment of asthma. In:Goodman & Gilman's the pharmacological basis of therapeutics. ed. by Hardman JG, Limbird LE, Molinoff PB, et al. New York McGrawHill, 1995, pp. 659-682

• 21) Patterson L, Milne B:Latex anaphylaxis causing heart block:role of ranitidine. Can. J. Anesth. 46:776-778, 1999
  pubmed

• 22) 森脇克行, 弓削孟文:麻酔導入直後と開腹手術開始後に生じた低血圧と頻脈. 症例検討アナフィラキシー. LiSA 3:668-674, 1996

• 23) 弓削孟文, 河本昌志, 森脇克行:急性薬物過敏症. 第24回日本医学会総会会誌 11:318-319, 1995

• 24) Levy JH:Allergic reactions during anesthesia. J. Clin. Anesth. 1:39-46, 1988
  pubmed

• 25) 光畑祐正:アナフィラキシー, アナフィラキシー様反応への対処法. LiSA 3:676-686, 1996

• 26) Fisher MM:Treating anaphylaxis with sympathomimetic drugs. BMJ 305:1107-1108, 1992

• 27) Vaughan STA, Jones GN:Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53:804-809, 1998

• 28) Stellato C, Marone G:Mast cells and basophils in adverse reactions to drugs used during general anesthesia. In:Human basophils and mast cells:Clinical aspects. Chem. Immunol. 62, ed. by Morone G, Basel, Karger, pp.108-131, 1995

• 29) Sueyasu M, Komasu C, Hara T, et al.:Enhancement by morphine of radiographic contrast media-induced histamine release in rat peritoneal mast cells. Jpn. J. Pharmacol. 74:217-220, 1997
  pubmed

• 30) Seltzer JL, Goldberg ME, Larijani GE, et al.:Prostacyclin mediation of vasodilation following mesenteric traction. Anesthesiology 68:514-518, 1988
  pubmed

• 31) 森脇克行, 弓削孟文:手術侵襲とマスト細胞活性化. 日本臨床麻酔学会誌 17:517-520, 1997

• 32) Hayashi R, Kawamoto M, Moriwaki K, et al.:Cardiac arrest after mesenteric manipulation in a patient undergoing abdominal surgery. Anesth. Analg. 84:1382-1383, 1997

• 33) 野中雅子, 坂梨祐司, 須加原一博ほか:喘息の既往を有する患者の麻酔中発作発生頻度. 麻酔48:759-762, 1999

• 34) Forman MB, Oates JA, Robertson D, et al.:Increased adventitial mast cells in a patient with coronary spasm. N. Engl. J. Med. 313:1138-1141, 1985

• 35) 森脇克行:手術侵襲と生体の反応 反応の実際, 止血機能. 小川龍, 弓削孟文, 細川豊史編. 手術侵襲とその防御21世紀の指 . 真興交易医書出版部. 東京, 2001, pp.119-143

P.329 掲載の参考文献

• 1) Mikawa K, Maekawa N, Ikegaki J, et al.:Anesthetic management of an infant with a solitary mastocytoma. J. Anesth. 4:167-171, 1990
  pubmed

• 2) Greenblatt EP, Chen L:Urticaria pigmentosa:an anesthetic challenge. J. Clin. Anesth. 2:108-115, 1990
  pubmed

• 3) Golkar L, Bernhard JD:Mastocytosis. Lancet 349:1379-1385, 1997
  pubmed

• 4) Coleman MA, Liberthson RR, Crone RK, et al.:General anesthesia in a child with urticaria pigmentosa. Anesth. Analg. 59:704-706, 1980

• 5) Korenblat PE, Wedner HJ, Whyte MP, et al.:Systemic mastocytosis. Arch. Intern. Med. 144:2249-2253, 1984
  pubmed

• 6) Hosking MP, Warner MA:Sudden intraoperative hypotension in a patient with a symptomatic urticaria pigmentosa. Anesth. Analg. 66:344-346, 1987

• 7) 小板橋俊哉, 滝野善夫:色素性蕁麻疹患者の麻酔経験. 麻酔 44:279-281, 1995
  Medical*Online

• 8) James PD, Krafchik BR, Johnston AE:Cutaneous mastocytosis in children:anaesthetic considerations. Can. J. Anaesth. 34:522-524, 1987
  pubmed

• 9) 落合亮一 監訳:麻酔薬ハンドブック. 医学書院 MYW, 東京, 1996

P.337 掲載の参考文献

• 1) 三原基之:色素性蕁麻疹, 皮膚科MOOK No.12 蕁麻疹, 今村貞夫・小川秀興編, 金原出版, 東京, 1988, pp.178-189

• 2) Smith MF:Skin and connective tissue disease. In:Anesthesia and Uncommon Pediatric Disease. ed by Katz J, Steward DJ, WB Saunders, Philadelphia, 1987, pp.378-428

• 3) Tharp MD:The spectrum of mastocytosis. Am. J. Med. Sci. 289:119-132, 1985
  pubmed

• 4) 神畠 茂:肥満細胞症 (色素性蕁麻疹). 現代皮膚科学大系10間葉系腫瘍・神経腫瘍, 山村雄一 他編, 中山書店, 東京, 1980, pp.193-223

• 5) 義澤 泉, 伊東文行, 江川ゆりほか:単発性肥満細胞腫の1例と本邦報告例の統計的考察, 皮膚臨床35:589-593, 1993

• 6) Kacker A, Huo J, Huang R, et al.:Solitary mastocytoma in an infant-case report with review of literature. Int. J. Pediatr. Otorhinolaryngol. 52:93-95, 2000

• 7) 中田弓子, 後明郁男, 河野朗久:全身性肥満細胞症の麻酔経験. 日本臨床麻酔学会誌11:97-100, 1991

• 8) 代田裕子, 白土辰子, 桜井裕ほか:Mastocytosis患者における全身麻酔の経験, 臨床麻酔 6:275-278, 1982

• 9) 堀口哲男, 杉原玄久, 永納和子ほか:肥満細胞症の麻酔経験, 臨床麻酔 25:697-698, 2001

• 10) Mikawa K, Maekawa N, Ikegaki J, et al.:Anesthetic management of an infant with a solitary mastocytoma. J. Anesth. 4:167-171, 1990
  pubmed

• 11) Levy JH:The allergic response. In:Clinical Anesthesia 3rd ed. by Barash PG, Cullen BF, Stoelting RK, Lippincott-Raven, 1997, pp.1205-1217

P.341 掲載の参考文献

• 1) Lerno G, Slaats G, Coenen E, et al.:Anaesthetic management of systemic mastocytosis. Br. J. Anaesth. 65:254-257, 1990
  pubmed

• 2) Levy JH:The allergic response. In:Clinical Anesthesia, ed. by Barash PG, Lippincott-Raven Publishers Philadelphia, 1996, pp.1205-1217

• 3) Parris WCV, Scotto HW, Smith BE:Anesthetic management of systemic mastocytosis:experience with 42 cases. Anesth. Analg. 65:S117, 1986

• 4) Vaughan STA, Jones GN:Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 53:804-809, 1998

• 5) Roizen MF:Anesthetic Implications of Concurrent Diseases. In:Anesthesia, ed. by Miller RD. Philadelphia, Churchill Livingstone, 2000, pp.967-968

• 6) Tashiro Y, Shiratsuichi T, Sakurai Y, et al.:Anesthetic management of systemic mastocytosis. Rinshou Masui 6:275-278, 1982

• 7) Rosenbaum KJ, Strobel GE:Anesthetic considerations in mastocytosis. Anesthesiology 38:398-401, 1973
  pubmed

• 8) James PD, Krafchik BR, Johnston AE:Cutaneous mastocytosis in children:anaesthetic considerations. Can. Anaesth. 34:522-524, 1987
  pubmed

• 9) Roberts LJ, Sweetman BJ, Lewis RA, et al.:Increased production of prostaglandin D2 in patients with systemic Mastocytosis. N. Engl. J. Med. 303:1400-1404, 1980
  pubmed

• 10) Scott HW, Parris WCV, Sandidge PC, et al.:Hazards in operative management of patients with systemic mastocytosis. Ann. Surg. 197:507-514, 1983

• 11) Desborough JP, Taylor A, Hattersley A, et al.:Massive histamine release in a patient with systemic mastocytosis. Br. J. Anaesth. 65:833-836, 1990

• 12) Levy JH, Brister NW, Shearin A, et al.:Wheal and flare response to opioids in humans. Anesthesiology 70:756-760, 1989
  pubmed

• 13) Bongreat A, Ruetsch YA:Anesthesia in a patient with maligant system mastocytosis using a total intravenous anessthetic tecnique. Anesth. Analg. 86:442-444, 1998

• 14) Koitabashi T, Takino Y:Anesthetic management of patient with urticaria pigmentosa. Masui 44:279-281, 1995
  pubmed

• 15) Gerecke WB, Imasato Y, Keats AS:Histamine release by drugs used in association with anethesia in a man. Abstracts of Scientific Papers, Annual Meeting of the America Society of Anesthesiologists, pp.127-128, 1969

• 16) Babe KS Jr, Serafin WE:Histamine, bradykinin, and their anatagonists. In:Goodman & Gilman's The Pharmacological Basis of Therapeutics. ed. by Hardman JG, Limbird LE, McGaw-Hill, Nes York, 2000, pp.581-600

• 17) Fisher M:Blood volume replacement in acute anaphylactic cardiovascular collapse related to anaesthesia. Br. J Anaesth. 49:1023-1026, 1977
  pubmed

• 18) Stark BJ,Sullivan TJ:Biphasic and protracted anaphylaxis. J Allergy Clin. Immunol. 78:76-83, 1986
  pubmed

X / 癌

P.347 掲載の参考文献

• 1) Galli SJ:New concepts about the mast cell. N. Engl. J. Med. 328:257-265, 1993
  pubmed

• 2) Weidner N, Austen KF:Evidence for morphological diversity of human mast cells. An ultrastructural study of mast cells from multiple sites. Lab. Invest. 63:63-72, 1990
  pubmed

• 3) 赤須東樹, 川並汪一・:ヒト甲状腺マスト細胞の形態学的ならびに機能的特徴ラット甲状腺マスト細胞との比較. 日医大誌61:129-136, 1994

• 4) Santos AAS, Machado CRS:Histochemical and ultrastructural studies of mast cells in the intestinal mucosa and skin of the opossum Didelphis albiventris. Histochem. J. 26:233-238, 1994

• 5) Whitaker-Menezes D, Schechter NM, Murphy FM:Serine proteinase regionally segregated within mast cell granules. Lab. Invest. 72:34-41, 1995

• 6) Craig SS, Schechter NM, Schwartz LB:Ultrastructural analysis of human T and TC mast cells identified by immunoelectron microscopy. Lab. Invest. 58:682-678, 1986

• 7) Dvorak AM, Schleimer RP, Sculman ES, et al.:Human mast cell use conservation and condensation mechanisms during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Lab. Invest. 54:663-678, 1986

• 8) Caulfield Jp, el-Lati S, Thomas G, et al.:Dissociated human foreskin mast cells degranulate in response to anti-IgE and substance P. Lab. Invest. 63:502-510, 1990
  pubmed

• 9) Caulfield JP, Lewis RA, Hein A, et al.:Secretion in dissociated human pulmonary mast cells. Evidence for solubilization of granule contents before discharge. J. Cell. Biol. 85:299-312, 1980
  pubmed

• 10) Drake-Lee A, Price J, Varley R:Mast cell ultrastructure in the adenoide of children with and without secretory otitis media. J. Laryngol. Otol. 108:1058-1063, 1994

• 11) Dvorak AM, Hammel I, Schulman ES, et al.:Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J. Cell. Biol. 99:1678-1687, 1984
  pubmed

• 12) Dvorak AM, Morgan ES, Schleimer RP, et al.:Diamine oxidase-gold labels histamine in human mast-cell granules:a new enzyme-affinity ultrastructural method. J. Histochem. Cytochem. 41:787-800, 1993

• 13) Drake-Lee AB, Price J:Ultrastructure of nasal mast cells in normal subjects and patients with perennial allergic rhinitis. J. Laryngol. Otol. 105:1006-1013, 1991
  pubmed

• 14) Kawanami O, Ferrans VJ, Fulmer JD, et al.:Ultrastructure of pulmonary mast cells inpatients with lung fibrotic disorders. Lab. In vest. 40:717-734, 1979

• 15) Theoharides CT, Spanos C, Pang X, et al.:Stress-induced intracranial mast cell degranuation:a corticotropin-releasing hormone-mediated effect. Endocrinology 136:5745-5750, 1995

• 16) 松田健, 川並汪一, 宮下正夫ほか:気管支喘息患者生検肺にみられた肥満細胞の超微形態学的脱顆粒現象. 日胸疾会誌 25:106-111, 1987

• 17) Demitsu T, Murata S, Kiyosawa T, et al.:Malignant schwannoma arising in patients with von Recklinghausens disease:report of two cases and the comparison of mast cells between benign and malignant portions. J. Dermatol. 22:747-754, 1995
  pubmed

• 18) Beil WJ, Schulz M, Wefelmeyer U:Mast cell granule composition and tissue location-a close correlation. Histol. Histopathol. 15:937-946, 2000
  pubmed

P.353 掲載の参考文献

• 1) Ehrlich Beitrality zur Kenntnis der granulierten Bindegewebezellen und der eosinophilen Leukocyten. Arch. Anat. Physiol. 3:166-169, 1879

• 2) Cawley EF, Hoch-Ligeti C:Association of tissue mast cells and skin tumors. Arch. Dermatol. 83:92-96, 1961

• 3) Baroni C:On the relationship of mast cells to various soft tissue tumors. Br. J. Cancer 18:686-691, 1964
  pubmed

• 4) Glowackiulliken JB:Mast cells in hemangiomas and vascular malformations. Pediatrics 70:48-51, 1982

• 5) Ho KL:Ultrastructure of cerebellar capillary hemangioblastoma. Acta Nezaropathol. 64:308-318, 1984
  pubmed

• 6) Flynn EA, Schwartz JL, Shklar G:Sequential mast cell infiltration and degranulation during experimental carcinogenesis. J. Cancer Res. Clin. Oncol. 117:115-122, 1991
  pubmed

• 7) Yano H, Kinuta M, Maruyama H, et al.:Clinicopathological evaluation of mast cell infiltrations around gastric cancer cells. Recent Adv. In:Gastroenterol. Carcinogenesis I. ed. by Monduzzi editore, pp. 887-891, 1996

• 8) Yano H, Kinuta M, Tateishi H, et al.:Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric. Cancer 2:26-32, 1999
  pubmed

• 9) Marks RM, Roche WR, Czerniecki M, etal.:Mast cell granules cause proliferation of human microvascular endothelial cells. Lab. Invest. 55:289-294, 1986
  pubmed

• 10) Azizkhan RG, Azizkhan JC, Zetter BR, et al.:Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J. Exp . Med. 152:931-944, 1980
  pubmed

• 11) Starkey JR, Crowle PK, Taubenberger S:Mast cell-deficient w/wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer 42:48-52, 1988
  pubmed

• 12) Yano H, Zetter BR:Purification and characterization of a tumor-derived mast cell motility factor that possesses autocrine motility activity. Mol. Biol. Cell 3:360A, 1992

• 13) Liotta LA, Mandler R, Murano G, et al.:Tumor cell autocrine motility factor. Proc. Natl. Acad. Sci. USA 83:3302-3306, 1986
  pubmed

• 14) Poole TJ, Zetter BR:Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res 43:5857-5861, 1983
  pubmed

• 15) Matsuura N, Zetter BR:Stimulation of mast cell chemotaxis by interleukin 3. J. Exp. Med. 170:1421-1426, 1989
  pubmed

• 16) Thompson HL, Burbelo PD, Yamada Y, et al.:Mast cells chemotax to laminin with enhancement after IgE-mediated activation. J. Immunol. 143:4188-4192, 1989
  pubmed

• 17) Meininger CJ, Yano H, Rottapel R, etal.:The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79:958-963, 1992

P.360 掲載の参考文献

• 1) Duarte IG, Bufkin BL, Pennington MF, et al.:Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 115:652-658, 1998

• 2) Shibusa T, Shijubo N, Abe S:Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin. Cancer Res 4:1483-1487, 1998

• 3) Shijubo N, Uede T, Kon S, etal.:Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160:1269-1273, 1999

• 4) Imada A, Shijubo N, Kojima H, et al.:Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur. Respir. J. 15:1087-1093, 2000

• 5) Takanami I, Takeuchi K, Naruke M:Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692, 2000
  pubmed

• 6) Tomita M, Matsuzaki Y, Onitsuka T:Effect of mast cells on tumor angiogenesis in lung cancer. Ann. Thorac. Surg. 69:1686-1690, 2000
  pubmed

• 7) Dimitiradou V, Koutsilieris M:Mast cell-tumor interactions:for or against tumour growth and metastasis. Anticancer Res. 17:1541-1549, 1997
  pubmed

• 8) Gooch JL, Lee AV, Yee D:Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 58:4199-4205, 1998
  pubmed

• 9) Metcalfe DD, Baram D, Mekori YA:Mast cells. Physiol. Rev. 77:1033-1079, 1997
  pubmed

• 10) Blair RJ, Meng H, Marchese MJ, et al.:Human mast cells stimulate vascular tube formation:tryptase is a novel, potent angiogenic factor. J. Clin. Invest. 99:2691-2700, 1997
  pubmed

• 11) Grutzkau A, Kruger-Krasagakes S, Baumeister H, et al.:Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells:implications for the biological significance of VEGF206. Mol. Biol. Cell 9:875-884, 1998
  pubmed

• 12) Boesiger J, Tsai M, Maurer M, et al.:Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J. Exp. Med. 188:1135-1145, 1998
  pubmed

• 13) Fang KC, Wolters PJ, Steinhoff M, et al.:Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-β. J. Immunol. 162:5528-5535, 1999

• 14) Starkey JR, Crowle PK, Taubenberger S:Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer 42:48-52, 1988
  pubmed

• 15) Gruber BL, Marchese MJ, Kew R:Angiogenic factors stimulate mast-cell migration. Blood 86:2488-2493, 1995
  pubmed

• 16) Detmar M, Brown LF, Schon MP, et al.:Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J.Invest. Dermalol. 111:1-6, 1998
  pubmed

XI / その他の疾患

P.371 掲載の参考文献

• 1) Kirshenbaum AS, Kessler SW, Goff JP, et al.:Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J. Immmunol. 146:1410-1415, 1991
  pubmed

• 2) Enerback L:Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol. Microbiol. Scand. 66:289-302, 1966
  pubmed

• 3) Enerback L:Mast cells in rat gastrointestinal mucosa. II. Dye binding and metachromatic properties. Acta Pathol. Microbiol. Scand. 66:303-312, 1966

• 4) Irani AA, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986
  pubmed

• 5) Irani AM, Schwartz LB:Mast cell heterogeneity. Clin. Exp. Allergy 19:143-155, 1989

• 6) Mori A, Zhai YL, Toki T, et al.:Distribution and heterogeneity of mast cells in the human uterus. Hum. Reprod. 12:368-372, 1997
  pubmed

• 7) Jeziorska M, Salamonsen LA, Woolley DE:Mast cell and eosinophil distribution and activation in human endometrium throughout the menstrual cycle. Biol. Reprod. 53:312-320, 1995
  pubmed

• 8) Guo CB, Kagey-Sobotka A, Lichtenstein LM, et al.:Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 79:708-712, 1992
  pubmed

• 9) Wimazal F, Ghannadan M, Muller MR, et al.:Expression of homing receptors and related molecules on human mast cells and basophils:a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques. Tissue Antigens 54:499-507, 1999
  pubmed

• 10) Tainsh KR, Lau HY, Liu WL, et al.:The human skin mast cell:a comparison with the human lung cell and a novel mast cell type, the uterine mast cell. Agents Actions 33:16-19, 1991

• 11) Cocchiara R, Albeggiani G, Azzolina A, et al.:Effect of substance P on uterine mast cell cytokine release during the reproductive cycle. J. Neuroimmunol 60:107-115, 1995
  pubmed

• 12) Fureder W, Agis H, Willheim M, et al.:Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J. Immunol. 155:3152-3160, 1995
  pubmed

• 13) Massey WA, Guo CB, Dvorak AM, et al.:Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. J. Immunol. 147:1621-1627, 1991
  pubmed

• 14) Mathur VS, Chaudhury RR:The effect of an intra-uterine plastic device on the mast cell count in the rat uterus. J. Reprod. Fertil. 15:135-138, 1968
  pubmed

• 15) Maraspin LE, Bo WJ:Effects of hormones, pregnancy and pseudopregnancy on the mast cell count in the rat uterus. Life Sci. 10:111-120, 1971
  pubmed

• 16) Padilla L, Reinicke K, Montesino H, et al.:Histamine content and mast cells distribution in mouse uterus:the effect of sexual hormones, gestation and labor. Cell. Mol. Biol. 36:93-100, 1990
  pubmed

• 17) Roby KF, Hunt JS:Myometrial tumor necrosis factor α:cellular localization and regulation by etradiol and progesterone in the mouse. Biol. Reprod. 52:509-515, 1995

• 18) Vliagoftis H, Dimitriadou V, Boucher W, et al.:Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int. Arch. Allergy Immunol. 98:398-409, 1992
  pubmed

• 19) Vliagoftis H, Dimitriadou V, Theoharides TC:Progesterone triggers selective mast cell secretion of 5-hydroxytryptamine. Int Arch. Allergy Appl. J. Immunol. 93:113-119, 1990

• 20) Gunin AG, Sharov AA:Role of mast cells in oestradiol effects on the uterus of ovariectomized rats. J Reprod. Fertil. 113:61-68, 1998
  pubmed

• 21) Dupont S, Krust A, Gansmuller A, et al.:Effect of single and compound knockouts of estrogen receptors α (ER α) and β (ER β) on mouse reproductive phenotypes. Development 127:4277-4291, 2000

• 22) Hourihall HM, Sheppard BL, Belsey EM, et al.:Endometrial vascular features prior to and following exposure to levonorgestrel. Contraception 43:375-385, 1991

• 23) Drudy L, Sheppard B, Bonnar J:Mast cells in the normal uterus and in dysfunctional uterine bleeding. Eur. J. Obstet. Gynecol. Reprod. Biol. 39:193-201, 1991
  pubmed

• 24) Zhang J, Nie G, Jian W, et al.:Mast cell regulation of human endometrial matrix metalloproteinases:A mechanism underlying menstruation. Biol. Reprod. 59:693-703, 1998
  pubmed

• 25) Kielty CM, Lees M, Shuttleworth CA, et al.:Catabolism of intact type VI collagen microfibrils:susceptibility to degradation by serine proteinases. Biochem. Biophys. Res. Commun. 191:1230-1236, 1993
  pubmed

• 26) Grutzkau A, Kruger-Krasagakes S, Baumeister H, etal.:Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells:implications for the biological significance of VEGF206. Mol. Biol. Cell 9:875-884, 1998
  pubmed

• 27) Crow J, Wilkins M, Howe S, et al.:Mast cells in the female genital tract. Int. Gynecol. Pathol. 10:230-237, 1991
  pubmed

• 28) Zsebo KM, Wypych J, McNiece IK, et al.:Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63:195-201, 1990
  pubmed

• 29) Mori A, Nakayama K, Suzuki J, et al.:Analysis of stem cell factor for mast cell proliferation in the human myometrium. Mol. Hum. Reprod. 3:411-418, 1997
  pubmed

• 30) Zhang Z, Anthony RV:Porcine stem cell factor/c-kit ligand:its molecular cloning and localization within the uterus. Biol. Reprod. 50:95-102, 1994
  pubmed

• 31) Wang Y, Kovanen PT:Heparin proteoglycans released from rat serosal mast cells inhibit proliferation of rat aortic smooth muscle cells in culture. Circ. Res. 84:74-83, 1999
  pubmed

• 32) Horiuchi A, Nikaido T, Zhai YL, et al.:Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of α-smooth muscle actin, calponin h1 and p27. Mol. Hum. Reprod. 5:139-145, 1999

• 33) Desmouliere A, Rubbia-Brandt L, Grau G, et al.:Heparin induces α-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab. Invest. 67:716-726, 1992

• 34) Hore A, Mehrotra PN:Presence of a blastocyst and mast cell depletion of the mouse uterus. Acta Anat. Basel 132:6-8, 1988
  pubmed

• 35) Salamonsen LA, Jeziorska M, Newlands GF, et al.:Evidence against a significant role for mast cells in blastocyst implantation in the rat and mouse. Reprod. Fertil. Dev. 8:1157-1164, 1996
  pubmed

• 36) Matsumoto Y, Handa S, Taki T:gp49B1, an inhibitory signaling receptor gene of hematopoietic cells, is induced by leukemia inhibitory factor in the uterine endometrium just before implantation. Dev. Growth Differ. 39:591-597, 1997
  pubmed

• 37) Mylona P, Kielty CM, Hoyland JA, et al.:Expression of type VI collagen mRNAs in human endometrium during the menstrual cycle and first trimester of pregnancy. J. Reprod. Fertil. 103:1591-1567, 1995

• 38) Kielty CM, Lees M, Shuttleworth CA, et al.:Catabolism of intact type VI collagen microfibrils:susceptibility to degradation by serine proteinases. Biochem. Biophys. Res. Commun. 191:1230-1236, 1993
  pubmed

• 39) Cocchiara R, Albeggiani G, Di Trapani G, et al.:Dispersal of rat uterine mast cells and their functional response to an embryo-derived histamine releasing factor:a possible model for embryo implantation. J. Reprod. Immunol. 14:191-201, 1988

• 40) Cocchiara R, Lampiasi N, Albeggiani G, et al.:A factor secreted by human embryo stimulates cytokine release by uterine mast cell. Mol. Hum. Reprod. 2:781-791, 1996
  pubmed

• 41) Szukiewicz D, Maslinska D, Stelmachow J, et al.:Biogenetic amines in placental tissue. Relation to the contractile activity of the human uterus. Preliminary communication. Clin. Exp. Obstet. Gγnecol. 22:66-70, 1995

• 42) Shimizu K, Hokano M:Collagen concentration and mast cell in perinatal murine uterus. Acta Anat. Basel 129:262-264, 1987
  pubmed

• 43) Adamson S, Edwin SS, LaMarche S, et la.:Actions of interleukin-4 on prostaglandin biosynthesis by human amnion cells. Prostaglandins Leukot. Essent. Fatty Acids 50:133-135, 1994

• 44) Rudolph MI, Oviedo C, Vega E, et al.:Oxytocin inhibits the uptake of serotonin into uterine mast cells. J. Pharmacol. Exp. Ther. 287:389-394, 1998
  pubmed

• 45) Rudolph MI, Reinicke K, Cruz MA, et al.:Distribution of mast cells and the effect of their mediators on contractility in human myometrium. Br. J. Obstet. Gynaecol. 100:1125-1130, 1993
  pubmed

• 46) Schrey MP, Hare AL, Ilson SL, et al.:Decidual histamine release and amplification of prostaglandin F2 α production by histamine in interleukin-1 β-primed decidual cells:potential interactive role for inflammatory mediators in uterine function at term. J. Clin. Endocrinol. Metab. 80:648-653, 1995

• 47) Garfield RE, Bytautiene E, Vedernikov YP, et al.:Modulation of rat uterine contractility by mast cells and their mediators. Am. J. Obstet. Gynecol. 183:118-125, 2000
  pubmed

• 48) D'Souza OA, Rameshkumar K, Nirmala V:Mast cells and macrophages in endometrial lesions. Indian. J. Pathol. Microbiol. 37:367-373, 1994
  pubmed

• 49) Jain PC, Singh SN, Pratap VK, et al.:Connective tissue changes and mast cell variations in benign and malignant lesions of the uterine cervix. Int. Surg. 62:358-360, 1977
  pubmed

• 50) Orii A, Mori A, Zhai YL, et al.:Mast cells in smooth muscle tumors of the uterus. Int. J. Gynecol. Pathol. 17:336-342, 1998
  pubmed

• 51) Ueda T, Aozasa K, Tsujimoto M, et al.:Prognostic significance of mast cells in soft tissue sarcoma. Cancer 62:2416-2419, 1988
  pubmed

P.379 掲載の参考文献

• 1) Hopkin JM:Mechanism of enhanced prevalence of asthma and atopy in developed countries. Curr. Opin. Immunol 9:788-792, 1997
  pubmed

• 2) Kira J, Yamasaki K, Kawana Y, et al.:Acute myelitis associated with hyperIgEemia and atopic dermatitis. J . Neurol. Sci. 148:199-203, 1997

• 3) Kira J, Kawano Y, Yamasaki K, et al.:Acute myelitis with hyperIgEaemia and mite antigen specific IgE:atopic myelitis. J. Neurol. Neurosurg. Psychiatry 64:676-679, 1998
  pubmed

• 4) Kira J, Kawano Y, Horiuchi I, et al.:Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis). J. Neurol. Sci. 162:56-61, 1999
  pubmed

• 5) 小副川学, 越智博文, 菊池仁志ほか:好酸球性脊髄炎の免疫学的・病理学的検討. 神経免疫学 9:156-157, 2001

• 6) Kikuchi H, Osoegawa M, Ochi H, et al.:Spinal cord lesions of myelitis with hyperlgEemia and mite antigen specific IgE (atopic myelitis) manifest eosinophilic inflammation. J.Neurol. Sci. 183:73-78, 2001
  pubmed

• 7) Horiuchi I, Kawano Y, Yamasaki K, et al.:Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in myelitis with mite antigen specific IgE. J. Neurol. Sci. 172:17-24, 2000

• 8) 呉 暁牧, 越智博文, 小副川学ほか:炎症性中枢神経疾患におけるIL-5, IL-13の検討. 神経免疫学 9:54-55, 2001

• 9) Silver R, Silverman AJ, Vitkovic L, et al.:Mast cell I the brain:evidence and functional significance. Trends Neurosci. 19:25-31, 1996

P.386 掲載の参考文献

• 1) Massie BM, Kramer BL, Topic N, et al.:Long term captopril therapy for chronic congestive heart failure. Am. J. Cardiol. 53:1316-1320, 1984
  pubmed

• 2) 田村拓久, 渋谷統寿:Duchenne型筋ジストロフィーの慢性心不全の治療にcaptoprilは有効である. 神経内科42:22-26, 1995

• 3) Fenichel GM, Florence JM, Pestron KA, et al.:Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41:1874-1877, 1991

• 4) Griggs RC, Moxley RT 3rd, Medell JR, et al.:Duchenne dystrophy:randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43:520-527, 1993

• 5) Enerback L, Norrby K:The mast cells. Curr. Top . Pathol. 79:169-204, 1989
  pubmed

• 6) Urata H, Strobel F, Ganten D:Widespread tissue distribution of human chymase. J. Hypertens. 12 (Suppl. 9):517-522, 1994

• 7) Marone G, De Crescenzo G, Patella V, et al.:Human heart mast cells:Immunological characterization in situ and in vitro. In:Mast Cells and Basophils. ed. by Marone G, Lichtenstein L, Galli SJ, Acad. Press, San Diego, 2000, pp. 455-477

• 8) 奥西秀樹, 塩田直孝:動脈硬化と肥満細胞. 免疫薬理13:29-34, 1995

• 9) Reilly CF, Tewksbury DA, Soechter NM, et al.:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J. Biol. Chem. 257:8619-8622, 1982

• 10) 宮崎瑞夫, 守口知則:アンジオテンシン II の産生酵素-ACEとキマーゼ. アンジオテンシン II 受容体拮抗薬. 日和田邦男, 猿田享男, (編著) 大阪, 医薬ジャーナル社, 1996, pp. 11-21

• 11) Denburg JA:Vasophil and mast cell lineages in vitro and in vivo. Blood 79:846-860, 1992
  pubmed

• 12) Galli SJ, Tsai M, Wershil BK, et al.:Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int. Arch. Allergy Immunol. 107:51-53, 1995

• 13) Galli SJ, Gordon JR, Wershil BK:Cytokine production by mast cells and basophils. Curr. Opin. Immunol. 3:865-873, 1993

• 14) Schelling P, Fisoher H, Gonten D, et al.:Angiotensin and cell growth:a link to cardiovascular hypertrophy? J. Hypertens. 9:3-15, 1991

• 15) Caughey GH, Sohaumbog TH, Zerneck EH, et al.:The human mast cell chymase gene (CMA1):mapping to the catepsin G/granzyme gene cluster and lineage-restricted expression. Genomics 15:614-620, 1993

• 16) Woodard SL, Jackson DS, Abuelyaman AS, et al.:Chymase-directed serine protease inhibitor that reactes with a single 30-kDa granzyme and blocks NK-mediated cytotoxicity. J. Immunol. 153:5016-5025, 1995

• 17) Jenne DE, Tschopp J:Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem. J. 276:567-568, 1991
  pubmed

• 18) Urata H, Boehn KO, Philip A, et al.:Cellular localization and regional distribution of an angiotens n II-forming chymase in the heart. J. Clin. Invest. 91:1269-1281, 1993

• 19) Gorospe JR, Tharp MD, Hinckley J, et al.:A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J. Neurol. Sci. 122:44-56, 1994

• 20) Sahashi K, Tanaka M, Tashiro M, et al.:Increased mitochondrial DNA deletions in skeletal muscle of myotonic dystrophy. Gerontology 38:18-29, 1992
  pubmed

• 21) Stellato C, de Paulis A, Clccarelli A, et al.:Anti-inflammatory effect of cyclosporin A on human skin mast cells. J. Invest. Dermartol. 98:800-804, 1992
  pubmed

• 22) Sharma KR, Mynhier MA, Miller RG:Cyclosporin increases muscular force generation in Duchenne muscular dystrophy. Neurology 43:527-532, 1993
  pubmed

• 23) Kissel JT, Lynn DJ, Rammohan KW, et al.:Mononuclear cell analysis of muscle biopsies in prednisone-and azathioprine-treated Duchenne muscular dystrophy. Neurology 43:532-536, 1993
  pubmed

P.392 掲載の参考文献

• 1) Friedle HP, Till GO, Trentz O, et al.:Role of histamine, commplement and xanthine oxidase in thermal injury of skin. Am. J. Pathol. 135:203-217, 1989

• 2) Till GO, Mulligan MS, Smith CW, et al.:Role of CD-18 in lung and skin injur following thermal skin. Proc. Am. Burn Assoc. 24:79, 1992

• 3) Thomson PD, Till GO, Woolloscroft JO, et al.:Superoxide dismutase prevents lipid peroxidation in burned patients. Burns 16:406-413, 1990

• 4) Shimazaki E, Tanaka H, Ohta S, el al.:Effects of antiprotease ulinastatin on mortality and oxidant injury in scalded rats. Acrh. Surg. 130:994-997, 1995

• 5) Takeda T, Yamashita Y, Shimazaki S, et al.:Histamine decreases the permeability of an endothelial cell monolayer by stimulating cyclic AMP production through the H2-receptor. J. Cell Sci. 101:745-750, 1992
  pubmed

• 6) Sevit S:The failure of anti-histamine drug to influence the local vascular changes in experimental burns. Br. J.Pathol. 30:540, 1949

• 7) Spector WG:Experimental suppression of the acute inflammatory changes of thermal injury. J. Pathol. Bacteriol. 78:121, 1959
  pubmed

• 8) Boykin JV, Manson NH:Mechanisms of cimetidine protection following thermal injury. Am. J. Med. 83 (Suppl. 6):A76-A81, 1987

• 9) Tanaka H, Takako W, Shimazaki S, et al.:Effects of cimetidine on fluid requirement during resuscitation of third degree burn. J. Burn Care Rehabil. 12:425-429, 1991

• 10) Boykin JV, Crute SL, Haynes BW:Cimetidine therapy for burn schock. A quantitative assessment. J. Truma 25:864-870, 1985

• 11) Yosioka T, Monaho WW, Ayvazian VH, et al.:Cimetidine inhibits burn edema formation. Am. J. Surg. 136:681-685, 1978

P.397 掲載の参考文献

• 1) Prokocimer M, Polliack A:Increased bone marrow mast cells in preleukemic syndromes, acute myeloid leukemias and lymphoproliferative disorders. Am. J. Clin. Pathol. 75:34-38, 1981

• 2) Travis WD, Li CY, Yam LT, et al.:Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62:965-972, 1988
  pubmed

• 3) Horny HP, Ruck M, Wehrmann M, et al.:Blood findings in generalized mastocytosis:evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 76:186-193, 1990
  pubmed

• 4) Petit A, Pulik M, Gaulier A, et al.:Systemic mastocytosis associated with chronic myelomonocytic leukemia:clinical features and response to interfer on alpha therapy. J. Am. Acad. Dermatol. 32:850-853, 1995

• 5) Valent P:Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochensch 108:385-397, 1996

• 6) Parwaresch MR, Horney HP, Lennert K, et al.:Tissue mast cells in health and disease. Pathol. Res. Pract. 179:439-461, 1985

• 7) Valent P, Spanblochl E, Bankl HC, et al.:Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemia blast crisis. Blood 84:4322-4332, 1994
  pubmed

• 8) Travis WD, Li CY, Bergstalh EJ, et al.:Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345-368, 1988

• 9) Brunning RD, Mckenna RW, Rosai J, et al.:Systemic mastocytosis:extracutaneous manifestations. Am. J. Surg. Pathol. 7:425-438, 1983
  pubmed

• 10) Horny HP, Parwaresch MR, Lennert K, et al.:Bone marrow findings in systematic mastocytosis. Hum. Pathol. 16:808-814, 1985

• 11) Metcalfe DD:The treatment of mastocytosis. J. Invest. Dermatol. 96:55s-56s, 1991

• 12) Kluin-Nelemans HC, Jansen JH, Breukelman H, et al.:Response to interferon α-2b in a patient with systemic mastocytosis. N. Engl. Med. 326:619-623, 1992

• 13) Travis WD, Li CY, Hoagland HC, et al.:Mast cell leukemia:report of a case and review of the literature. Mayo Clin. Proc. 61:957-966, 1986
  pubmed

• 14) Cervero C, Escribano L, San Miguel JF, et al.:Expression of Bc1-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am. J. Hematol. 60:191-195, 1999

• 15) 坂東伸泰, 伊勢正夫, 秋田裕司ほか:色素性蕁麻疹を伴った全身性肥満細胞症に合併したフィラデルフィア染色体陰性慢性骨髄性白血病の1歳男児例. 小児科臨床 51:2122-2126, 1998

• 16) 杉田記代子, 金子 隆, 関根百合子ほか:Mast cell leukemiaへ進展したRAEB-t (5q-症候群) の12歳女児例. 臨床血液 37:430-436, 1996

• 17) 中澤正樹:肥満細胞株. 血液・腫瘍科 24:353-360, 1992

• 18) Valent P, Bettelheim P:Cell surface structures on human basophils and mast cells:biochemical and functional characterization. Adv. Immunol. 52:333-421, 1992
  pubmed

• 19) Valent P, Ashman LK, Hinterberger W, et al.:Mast cell typing:demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73:1778-1785, 1989

• 20) Baghestanian M, Bankl Hc, Sillaber C, et al.:A case of malignant mastocytosis with circulating mast cell precursors:biologic and phenotypic characterization of the malignant clone. Leukemia 10:159-166, 1996
  pubmed

P.407 掲載の参考文献

• 1) Nettleship E, Tay W:Rare forms of urticaria. Br. Med. J. ii:323-324, 1869

• 2) Ehrich P:Beitrage zur kenntnis der Anilinfarbungen und ihrer Verwendung in der mikroskopischen Technik. Arch. Mikros. Anat . 13:263-277, 1877

• 3) Sangster A:An anomalous mottled rash, accompanied by pruritus factitious urticaria and pigmentation, 'urticaria pigmentosa(?)'. Trans. Clin. Soc. London 11:161-163. 1878

• 4) Unna PG:Beitrage zur anatomie und pathogenese der urticaria simplex und pigmentosa. Monatschr. Prakt. Dermatol. 3 (Suppl Dermatol Stud):9, 1887

• 5) Sezary A, Levy-Coblentz G, Chauvillon P:Dermographisme et mastocytose. Bull. Soc. Fr. Dermatol. Syphilingr. 43:359-361, 1936

• 6) Ellis JM:Urticaria Pigmentosa:A report of a case with autopsy. Arch. Pathol. 48:426-435.1949
  pubmed

• 7) Metcalfe DD:Classification and diagnosis of mastocytosis:current status. J. Invest. Dermatol. 96:2S-4S, 1991

• 8) Lennert K, Parwaresch MR:Mast cells and mast cell neoplasia:a review. Histopathology 3:349-365, 1979
  pubmed

• 9) Greaves MW:Mastocytoses. In:textbook of Dermatology. Blackwell, Oxford, pp. 2065-2072, 1986

• 10) Travis WD, LiC-Y, Bergstralh EJ, et al.:Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 67:345-368, 1988

• 11) Caplan RM:The natural course of urticaria pigmentosa:analysis and follow-up of 112 cases. Arch. Dermatol. 87:146-157, 1963
  pubmed

• 12) Longley BR Jr, Morganroth GS, Tyrrel L, et al.:Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N. Engl. J. Med. 328:1302-1307, 1993

• 13) Nagata H, Worobec AS, Oh CK, et al.:Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-10564, 1995
  pubmed

• 14) Longley BI, Tyrrell L, Lu S-Z, et al.:Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis:establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312-314, 1996

• 15) Kurosawa M, Inamura H, Amuno H, et al.:Nerve growth factor release with mast-cell derived mediators in a patient with systemic mastocytosis after middle-wave ultraviolet irradiation. Allergy 54:994-998, 1999

• 16) Rafii M, Firooznia H, Golimbu C, et al.:Pathologic fracture in systemic mastocytosis. Radiographic spectrum and review of the literature. Clin. Orthoped. Rel. Res. 180:260-267, 1983

• 17) Irani AA, Bradford TR, Kepley CL, et al.:Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J. Histochme. Cytochem. 37:1509-1515, 1989

• 18) Kurosawa M, Amano H, Kanbe N, et al.:Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. J. Allergy Clin. Immunol. 100:S25-S32, 1997
  pubmed

• 19) Kurosawa M, Amano H, Kanbe N, et al.:Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J. Allergy Clin. Immunol. 103:S412-S420, 1999
  pubmed

• 20) Demis DJ:The mastocytosis syndrome:clinical and biological studies. Ann. Intern. Med. 59:194-206, 1963
  pubmed

• 21) Yam LT, Chan CH, Li C-Y:Hepatic involvement in systemic mast cell disease. Am. J. Med. 80:819-826, 1986
  pubmed

• 22) Kluin-Nelemans HC, Jansen JH, Breukelman H, et al.:Response to interferon α-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326:619-623, 1992

• 23) Longley J, Duffy TP, Kohn S:The mast cell and mast cell disease. J. Am. Acad. Dermatol. 32:545-561, 1995
  pubmed

• 24) 神戸直智, 黒沢元博, 五十嵐康ほか:肥満細胞からのヒスタミン遊離に及ぼすアレルギー制御薬の効果-臍帯血由来ヒト培養肥満細胞を用いた検討. 炎症 19:93-98, 1999

XII / 動物疾患モデル

P.414 掲載の参考文献

• 1) Matsumori A:Molecular and immune mechanisms in the pathogenesis of cardiomyopathy role of viruses, cytokines, and nitric oxide. Jpn. Circ. J. 61:275-291, 1997
  pubmed

• 2) Dvorak AM:Mast-cell degranulation in human hearts [letter]. N. Engl. J. Med. 315:969-970, 1986
  pubmed

• 3) Engels W, Reiters PH, Daemen MJ, et al.:Transmural changes in mast cell density in rat heart after infarct induction in vio. J. Pathol. 177:423-429, 1995

• 4) Panizo A, Mindan FJ, Galindo MF, et al.:Are mast cells involved in hypertensive heart disease? J. Hypertens 13:1201-1208, 1995
  pubmed

• 5) Patella V, Marino I, Arbustini E, et al.:Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97:971-978, 1998
  pubmed

• 6) Hara M, Matsumori A, Ono K, et al.:Mast cells cause apoptosis of cadiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443-1449, 1999

P.420 掲載の参考文献

• 1) Atkinson JB, Harlen CW, Harlen GC, et al.:The association of mast cells and atherosclerosis:a morphologic study of early atherosclerotic lesions in young people. Hum. Pathol. 25:154-159, 1994

• 2) Stary HC:The sequence of mast cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur. Heart J. 11 (Suppl. E):3-19, 1990

• 3) Shiota N, Okunishi H, Takai S, et al.:Tranilast suppresses vascular chymase expression and neointima formation in balloon injured dog carotid artery. Circulation 99:1084-1090, 1999
  pubmed

• 4) Laine P, Kaartinen M, Penttila A, et al.:Association between myocardial infarction and the mast cells in the adventitia of the infarct related coronary artery. Circulation 99:361-369, 1999
  pubmed

• 5) Shiota N, Okunishi H, Fukamizu A, et al.:Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 323:239-242, 1993
  pubmed

• 6) Suzawa H, Kikuchi S, Arai N, et al.:The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn. J. Pharmacol. 60:91-96, 1992
  pubmed

• 7) Miyazawa K, Kikuchi S, Fukuyama J, et al.:Inhibition of PDGF-and TGF-β1-induced colagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 118:213-221, 1995

• 8) Tanaka K, Honda M, Kuramochi T, et al.:Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 107:179-185, 1994
  pubmed

• 9) Katoh N, Hirano S, Yasuno H:Solitary mastocytoma treated with tranilast. J. Dermatol. 23:335-339, 1996
  pubmed

• 10) Pennington DW, Lopez AR, Thomas PS, et al.:Dog mastocytoma cells produce transforming growth factor beta 1. J. Clin. Invest 90:35-41, 1992
  pubmed

• 11) Qu Z, Liebler JM, Powers MR, et al.:Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147:564-573, 1995

• 12) Gordon JR, Galli SJ:Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346:274-276, 1990
  pubmed

• 13) Reilly CF, Tewksbury DA, Schechter NM, et al.:Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteases. J. Biol. Chem. 257:8619-8622, 1982
  pubmed

• 14) Powell JS, Clozel JP, Muller RK, et al.:Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186-188, 1989
  pubmed

• 15) Peters S, Gotting B, Trummel M, et al.:Valsartan for prevention of restenosis after stenting of type B2/C lesions:the VAL-PREST trial. J. Invasive. Cardiol. 13:93-97, 2001

• 16) Okunishi H, Miyazaki M, Toda N:Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J. Hypertens. 2:277-284, 1984

• 17) Okunishi H, Miyazaki M, Okamura T, et al.:Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem. Biophys. Res. Commun. 149:1186-1192, 1987
  pubmed

• 18) Okunishi H, Oka Y, Shiota N, et al.:Marked species-difference in the vascular angiotensin II-forming pathways:humans versus rodents. Jpn. J. Pharmacol. 62:207-210, 1993
  pubmed

• 19) Kokkonen JO, Kovanen PT:Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro. J. Biol. Chem. 264:10749-10755, 1989
  pubmed

• 20) Lee M, Uboldi P, Giudice D, et al.:Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase. Implications for HDL function. J. Lipid Res. 41:975-984, 2000
  pubmed

• 21) Taipale J, Lohi J, Saarinen J, et al.:Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270:4689-4696, 1995
  pubmed

• 22) Lindstedt KA, Wang Y, Shiota N, et al.:Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells:a novel function for chymase. FASEB J. 15:1377-1388, 200

• 23) Hara M, Matsumori A, Ono K, et al.:Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells vitro. Circulation 100:11443-1449, 1999

• 24) Leskinen M, Wang Y, Leszczynski D, et al.:Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:516-522, 2001
  pubmed

• 25) Webster WS, Bishop SP, Geer JC:Experimental aortic intimal thickening. I. Morphology and source of intimal cells. Am. J. Pathol. 76:245-264, 1974
  pubmed

• 26) Shi Y, O'Brien JE, Fard A, et al.:Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94:1655-1664, 1996
  pubmed

• 27) Edelman ER, Nugent MA, Smith LT, et al.:Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89:465-73, 1992
  pubmed

P.427 掲載の参考文献

• 1) Llloyd G, Green FHY, Fox H, et al.:Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 16:861-866,1975

• 2) Mani V, Lloyd G, Green FHY, et al.:Treatment of ulcerative colitis with oral disodium cromoglycate. A double-blind controlled trial. Lancet I:439-441, 1976

• 3) 土屋雅春, 宗像良雄, 日比紀文ほか:潰瘍性大腸炎における即時型アレルギーの関与と副腎皮質ステロイド剤の効果. 日消誌 76:2400-2409, 1979

• 4) 米井嘉一:潰瘍性大腸炎の再燃機序-自律神経異常と肥満細胞脱顆粒現象の観点から-. 日消誌 84:1045-1056, 1987

• 5) 千住雅博:潰瘍性大腸炎における即時型アレルギーの関与. 日消誌 85:2168-2177, 1988

• 6) Koda A, Nagai H, Watanabe S, et al.:Inhibition of hypersensitivity reactions by a new drug, N-(3', 4'-dimethoxycinnamoyl) anthranilic acid (N-5'). J. Allergy Clin. Immunol. 57:396-407,1976
  pubmed

• 7) 五十嵐隆夫, 小幡純一, 加納芳郎ほか:小児潰瘍性大腸炎にN-5'を使用した1症例. 小児科診療 42:600-604, 1979

• 8) 黒沢元博, 根本俊和, 田中哲治ほか:N-(3', 4'-Dimethoxycinnamoyl) Anthranilic Acid (N-5') が著効を呈した潰瘍性大腸炎の1例. アレルギー 30:8-15, 1981
  Medical*Online

• 9) 米井嘉一, 織田正也, 赤岩康文ほか:潰瘍性大腸炎におけるmast cell stabilizer (リザベン) の臨床効果. 診療と新薬 22:1755-1761, 1985

• 10) 米井嘉一, 織田正也, 中村正彦ほか:大腸粘膜微小循環動態におよぼす肥満細胞脱顆粒の影響とmast cell stabilizer (tranilast)の効果-基礎的研究-. 日消誌 83:56-65, 1986

• 11) Morris GP, Beck PL, Herridge MS, et al.:Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989
  pubmed

• 12) 岩井淳浩:DSS大腸炎モデルおける肥満細胞動態に関する研究. Gastroenterol. Endosc. 37:255-269, 1995

• 13) 岩井淳浩, 宮原 透, 小山 洋ほか:DSS 大腸炎モデルおけるヒスタミンの影響. Ther. Res. 16 (Suppl. 1):S244-S249, 1995

• 14) 岩井淳浩, 宮原 透:大腸炎におけるマスト細胞の役割-DSS 大腸炎モデルによる検討を中心として. 医学のあゆみ 178:691-694, 1996
  Medical*Online

• 15) 岩井淳浩, 宮原 透, 岩下悦郎ほか:DSS (dextran sulfate sodium) 大腸炎におけるヒスタミン受容体とNO (nitric oxide) の検討. Ther. Res. 17 (Suppl. 1):S152-S157, 1996

• 16) 岩井淳浩, 宮原 透, 岩下悦郎ほか:DSS (Dextran Sulfate Sodium) 大腸炎におけるヒスタミン受容体とNO (Nitric Oxide) の役割-肥満細胞脱顆粒抑制薬の影響-. Ther. Res. 18 (Suppl. 1):S115-S119, 1997

• 17) Araki Y, Andoh A, Fujiyama Y, et al.:Development of dextran sulphate sodium induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats. Clin. Exp. Immunol. 119:264-269, 2000
  pubmed

• 18) Murphey SM, Brown S, Miklos N, et al.:Reagin synthesis in inbred strains of rats. Immunology 27:245-253, 1974
  pubmed

• 19) Sorden SD, Castleman WL:Brown Norway rats are high responders to bronchiolitis, pneumonia, and bronchiolar mastocytosis induced by parainfluenza virus. Exp. Lung. Res. 17:1025-1045, 1991
  pubmed

• 20) Takahashi N, Aramaki Y, Tsuchiya S:Allergic rhinitis model with Brown Norway rat and evaluation of antiallergic drugs. J. Pharmacobiodyn. 13:414-420, 1990
  pubmed

• 21) 杉本幸雄, 片山裕美子, 亀井千晃:Brown-Nor-way 系ラットにおける消化管ヒスタミン含量の特徴. Ther. Res. 19 (Suppl. 1):S170-S175, 1998

• 22) 千住雅博, 牧山和也, 船津史朗ほか:ヒト正常大腸各部位の粘膜における肥満細胞とIgE含有細胞および組織中のヒスタミン含量. 日消誌 84:216-220, 1987

• 23) 杉本幸雄, 亀井千晃:Brown-Norway 系ラットにおける消化管ヒスタミン含量の特徴-能動感作による影響-. Ther. Res. 20 (Suppl. 1):S29-S34, 1999

• 24) 杉本幸雄, 亀井千晃:Brown-Norway 系ラットを用いた潰瘍性大腸炎モデルの作製. Ther. Res. 21 (Suppl. 1):S217-S222, 2000

• 25) Karlsson T, Ellerson JR, Dahlbom I, et al.:Analysis of the serum IgE levels in nonimmunized rats of various strains by a radioimmunoassay. Scand. J. Immunol. 9:217-228, 1979
  pubmed

• 26) Sugimoto Y, Ohishi H, T et al.:Strain differences in histamine release from peritoneal mast cells in rats. Gen. Pharmacol. 31:613-616,1998

• 27) 杉本幸雄, 亀井千晃:ラット潰瘍性大腸炎モデルにおける肥満細胞の関与. Ther. Res. 22 (Suppl. 1):S144-S150, 2001

• 28) Bissonnette EY, Enciso JA, Befus AD:Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-α production by mast cells. J. Immunol. 156:218-223, 1996

P.434 掲載の参考文献

• 1) 滝沢 始:過敏性肺炎. 治療薬 5:90-93, 2000
  Medical*Online

• 2) 安藤正幸:過敏性肺臓炎. 日本内科学会雑誌 83:761-767, 1994

• 3) Ando M, Akira K, Yoneda R, et al.:Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am. Rev. Respir. Dis. 144:765-769, 1991

• 4) Ando M, Konishi K, Yoneda R, et al.:Difference in the phenotypes of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, and bird fancier's lung:report of a nation wide epidemiologic study in Japan. J. Allergy Clin. Immunol. 87:1002-1009, 1991

• 5) 牧野荘平, 小林節雄, 宮本昭正ほか:気管支喘息および過敏性肺臓炎における吸入試験の標準法. アレルギー 31:1074-1076, 1982
  Medical*Online

• 6) Denis M:Proinflammatory cytokines in hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 151:164-169, 1995
  pubmed

• 7) Takizawa H, Suko M, Kobayashi N, et al.:Experimental hypersensitivity pneumonitis in the mouse:histologic and immunologic features and their modulation with cyclosporin A. J. Allergy Clin. Immunol. 81:391-400, 1988
  pubmed

• 8) 滝沢 始, 須甲松信, 小林信之ほか:純系マウスを用いた過敏性肺炎モデル作成に関する基礎的研究. 日胸疾会誌 25:1302-1308, 1987

• 9) Takizawa H, Ohta K, Horiuchi T, et al.:Hypersensitivity pneumontis in the athymic nude mice. Additional evidence of T-cell dependency. Am. Rev. Rev. Respir. Dis 146:479-484, 1992

• 10) Haslam PL, Dewar A, Butchers P, et al.:Mast cells, a typical lymphocytes and neutrophils in bronchoalveolar lavage in extrinsic allergic alveolitis. Comparison with other interstitial lung disease. Am. Rev. Respir. Dis. 135:35-47, 1987

• 11) Miadonna A, Pesci A, Tedeschi A, et al.:Mast cell and histamine involvement in farmer's lung disease. Chest 105:1184-1189, 1994
  pubmed

• 12) Kitamura Y, Go S, Hatanaka K:Decrease of mast cells in W/W mice and their increase by bone marrow transplantation. Blood 52:447-452, 1978

• 13) Takizawa H, Ohta K, Hirai, K, et al.:Mast cells are important in the development of hypersensitivity pneumonitis. A study with mast-cell-deficient mice. J. Immunol. 143:1982-1988, 1989
  pubmed

• 14) Schuyler M, Gott K, Cherne A:Mediators of hypersensitivity pneumonitis. J. Lab. Clin. Med. 136:29-38, 2000
  pubmed

• 15) Denis M, Cormier Y, Fournier M, et al.:Tumor necrosis factor plays an essential role in determining hypersensitivity pneumonitis in a mouse model. Am. J. Respir. Cell Mol. Biol. 5:477-483, 1991

• 16) Denis M, Ghadirian E:Murine hypersensitivity pneumonitis:bidirectional role of interferon-gamma. Clin. Exp. Allergy 22:783-792, 1992
  pubmed

• 17) Denis M, Interleukin-6 in mouse hypersensitivity pneumonitis:changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J. Leukoc. Biol. 52:197-201, 1992
  pubmed

• 18) Ghadirian E, Denis M:Murine hypersensitivity pneumonitis:interleukin-4 administration partially abrogates the disease process. Microb. Pathog. 12:377-382, 1992
  pubmed

• 19) Gudmundsson G, Bosch A, Davidson BL, et al.:Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am. J. Respir. Cell Mol. Biol. 19:812-818, 1998

• 20) Takisawa H, Ohtoshi T, Kikutani T, et al.:Histamine activates bronchial epithelial cells to release inflammatory cytokines in vitro. Int. Arch. Allergy Immunol. 108:260-268, 1995

• 21) 田知本 寛,海老澤元宏,斉藤博久:肥満細胞・好塩基球・好酸球とサイトカイン.現代医療 30:783-792, 1998

• 22) Suzuki N, Horiuchi T, Ohta K:Mast cells are essential for the full development of silica-induced pulmonary inflammation. A study with mast-cell deficient mice. Am. J. Respir. Cell Mol. Biol. 9:475-483, 1993
  pubmed

• 23) Suzuki N, Ohta K, Horiuchi T, et al.:Histamine augments the silica-induced pulmonary inflammation in mast-cell deficient mice. Allergy Clin. Immunol. News Suppl. 1:374, 1991

P.441 掲載の参考文献

• 1) Shiota N, Fukamizu A, Okunishi H, et al.:Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts. Biochem. J. 333:417-424, 1998
  pubmed

• 2) Shiota N, Okunishi H, Takai S, et al.:Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 99:1084-1090, 1999
  pubmed

• 3) 奥西秀樹, 高井真司, 柿添栄一:肥満細胞プロテアーゼ (キマーゼ). 細胞工学別冊 医学実験マニュアルシリーズ 動脈硬化+高脂血症研究ストラテジー, 山田信博他監修, 秀潤社, 東京, 1996, pp.174-180

• 4) Nishikori Y, Kakizoe E, Kobayashi Y, et al.:Skin mast cell promotion of matrix remodeling in burn wound healing in mice:relevance of chymase. Arch. Dermatol. Res. 290:553-560, 1998
  pubmed

• 5) Kakizoe E, Li SH, Kobayashi Y, et al.:Increases in mast cells and chymase in fibro-proliferative paws of collagen-induced arthritic mice. Inflamm. Res. 48:318-324, 1999

• 6) Gilliland BC:Systemic sclerosis (Screloderma). In:Harrison's Principles of Internal Medicine 14th edn, ed. by Braunwald E, et al, McGraw-Hill, New York, 1998, pp. 1888-1896

• 7) Nishioka Y, Kobayashi Y, Katayama I, et al.:Mast cell numbers in diffuse scleroderma. Arch. Dermatol. 123:205-208, 1987

• 8) Kasturi KN, Shibata S, Muryoi T, et al.:Tight-skin mouse an experimental model for scleroderma. Int. Rev. Immunol. 11:253-271, 1994
  pubmed

• 9) Springman EB, Serafin WE:Secretory endo- and exopeptidases of mouse mast cells:structure, genetics, and regulation of expression. In:Mast Cell Proteases in Immunology and Biology. Clinical Allergy and Immunology Vol. 6. ed. by Caughey GH, Marcel Dekker, New York, 1995, pp. 169-201

• 10) Kakizoe E Shiota N Tanabe Y et al.:Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J. Invest. Dermatol. 116:118-123, 2001
  pubmed

• 11) Vartio T, Seppa H, Vaheri A, et al.:Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J. Biol. Chem. 256:471-477, 1981
  pubmed

• 12) Kofford MW, Schwartz LB, Schechter NM, et al.:Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997
  pubmed

• 13) Taipale J, Lohi J, Saarinen J, et al.:Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270:4689-4696, 1995

• 14) Mizutani H, Schechter N, Lazarus G, et al.:Rapid and specific conversion of precursor interleukin l beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174:821-825, 1991

• 15) Wypij DM, Nichols JS, Novak PJ, et al.:Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem. Pharmacol. 43:845-853, 1992
  pubmed

• 16) Lindstedt KA, Wang Y, Shiota N, et al.:Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells:anovel function for chymase. FASEB/ 15:1377-1388, 2001

• 17) Levi-Schaffer F:Mast cell/fibroblast interactions in health and disease. In:Human Baso-Phils and Mast Cell:Biological Aspects. Chemical Immunology Vol. 61. ed. by Marone G, Karger, Basel, 1995, pp. 161-185

• 18) Fukami H, Imajio S, Ito A, et al.:Substituted 3-phenylsulfonylquinazoline-2, 4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. Drug Des. Discov. 17:69-84, 2000

P.447 掲載の参考文献

• 1) 臼井正彦:実験的自己免疫性ぶどう膜網膜炎の発症機序について. 日眼会誌 96:1580-1607, 1992

• 2) Wacker WB, Donoso LA, Kalson CM, et al.:Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. 1. Immunol. 119:1949-1958, 1977

• 3) Faure Jp:Autoimmunity and the retina. Curr. Top. Eye Res 2:215-302, 1980
  pubmed

• 4) Pfister C, Dorey C, Vadot R, et al.:Retinal S antigen identified as the 48k protein regulating light-dependent phosphodiesterase in rods. Science 228:891-893, 1985

• 5) 高野 繁:S抗原以外の網膜可溶性特異抗原について. 眼紀 33:968-975, 1982

• 6) Wiggert B, Chader GJ:Monkey interphotoreceptor retinoid-binding protein (IRBP):isolation, characterization, and synthesis. In:The interphotoreceptor Matrix in Health and Disease, ed. by Bridges CD. Adler AJ, Liss, New York, 1985

• 7) Borst DE, Redmond TM, Elser JE, et al.:Interphotorecepter retinoid-binding protein. Gene characterization, protein repeat structure, and its evolution. 1. Biol. Chem. 264:1115-1123, 1989

• 8) Fox GM, Kuwabara T, Wiggert B, et al.:Experimental autoimmune uveoretinitis (EAU) induced by retinal interphotoreceptor retinoid-binding protein (IRBP):differences between EAU induced by IRBP and by S-antigen. Clin. Immunol. Immunol) athol. 43:256-264, 1987

• 9) Hirose S, Kuwabara T, Nussenblatt RB, et al.:Uveitis induced in primates by interphotoreceptor retinoid-binding protein. Arch. Ophthalmol. 104:1698-1702, 1986
  pubmed

• 10) Broekhuyse RM, Kuhlmann ED, Winkens HJ, et al.:Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis. I. Induction by a detergent-insoluble intrinsic protein fraction of the retinal pigment epithelium. Exp. Eye Res. 52:465-474, 1991
  pubmed

• 11) Broekhuyse RM, Kuhlmann ED, Winkens HJ:Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp. Eye Res. 55:401-411, 1992
  pubmed

• 12) Chan CC, Hikita N, Dastgheib K, et al.:Experimental melanin-protein-induced uveitis in the Lewis rat. Immunopathologic processes. Ophthalmology 101:1275-1280, 1994
  pubmed

• 13) Salinas-Carmona MC, Nussenblatt RB, Gery I:Experimental autoimmune uveitis in the athymic nude rat. Eur. J. Immunol. 12:480-484, 1982
  pubmed

• 14) de Kozak Y, Sainte-Laudy J, Benveniste J, et al.:Evidence for immediate hypersensitivity phenomena in experimental autoimmune uveoretinitis. Eur. J. Immunol. 11:612-617, 1981
  pubmed

• 15) de Kozak Y, Sakai J, Sainte-Laudy J, et al.:Pharmacological modulation of IgE-dependent mast cell degranulation in experimental autoimmune uveoretinitis. Jpn. J. Ophthalmol. 27:598-608, 1983
  pubmed

• 16) Mochizuki M, Kuwabara T, Chan CC, et al.:An association between susceptibility to experimental autoimmune uveitis and choroidal mast cell numbers. J .Immunol. 133:1699-1701, 1984

• 17) Lee CH, Lang LS, Orr EL:Changes in ocular mast cell numbers and histamine distribution during experimental autoimmune uveitis. Reg. Immunol. 5:106-113, 1993
  pubmed

• 18) 藤田浩司, 坂井潤一, 臼井正彦:実験的自己免疫性ぶどう膜網膜炎の発症における肥満細胞の関与. 眼紀 47:968-971, 1996

• 19) Smith RS, Hart PH, Coster DJ, et al.:Uveal mast cell are not required for rodent uveitis. Ophthalmic. Res. 30:388-393, 1998

• 20) Caspi RR:Experimental autoimmune uveor-etinitis-rat and mouse. In:Autoimmune Disease Models:A Guaidebook, ed. by Cohen I, Miller A, Academic Press, San Diego, 1994, pp. 57-81

• 21) Li Q, Whitcup SM, Fujino Y, et al.:The role of mast cells in endotoxin-induced uveitis. Invest Ophthalmol. Vis. Sci. 34:256-259, 1993
  pubmed

• 22) Li Q, Peng B, Whitcup SM, et al.:Endotoxin induced uveitis in the mouse:susceptibility and genetic control. Exp. Eye Res. 61:629-632, 1995
  pubmed

• 23) Saoudi A, Kuhn J, Huygen K, et al.:Th2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur. J. Immunol. 23:3096-3103, 1993
  pubmed

XIII / 基礎から臨床へ

P.455 掲載の参考文献

• 1) Kitamura Y:Heterogeneity of mast cells and phenotypic change between subpopulations. Annu. Rev. Immunol. 7:59-76, 1989
  pubmed

• 2) Kuriu A, Sonoda S, Kanakura Y, et al.:Proliferative potential of degranulated murine peritoneal mast cells. Blood 74:925-929, 1989
  pubmed

• 3) Ito A, Kataoka TR, Kim DK, et al.:Inhibitory effect on natural killer activity of microphthalmia transcription factor (MITF) encoded by the mi allele of mice. Blood 97:2075-2083, 2001
  pubmed

• 4) Ebi Y, Kasugai T, Seino Y, et al.:Mechanism of mast cell deficiency in mutant mice of mi/mi genotype:an analysis by co-culture of mast cells and fibroblasts. Blood 75:1247-1251, 1990

• 5) Ebi Y, Kanakura Y, Jippo-Kanemoto T, et al.:Low c-kit expression of cultured mast cells of mi/mi genotype may be involved in their defective responses to fibroblasts that express the ligand for c-kit. Blood 80:1454-1462, 1992

• 6) Hodgkinson CA, Moore KJ, Nakayama A, et al.:Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395-404, 1993

• 7) Takebayashi K, Chida K, Tsukamoto I, et al.:The recessive phenotype displayed by a dominant negative microphthalmia-associated transcription factor mutant is a result of impaired nuclear lucalization Potential. Mol. Cell. Biol. 16:1203-1211, 1996
  pubmed

• 8) Morii E, Takebayashi K, Motohashi H, et al.:Loss of DNA binding ability of the transcription factor encoded by the mutant mi locus. Biochem. Biophys. Res. Commun. 205:1299-1304, 1994
  pubmed

• 9) Kim DK, Morii E, Ogihara H, et al.:Different effect of various mutant MITF encoded mi Mior, or MiWh allele on phenotype of murine mast cells. Blood 93:4179-4186, 1999
  pubmed

• 10) Morii E, Ogihara H, Kim DK, et al.:Importance of leucine zipper domain of mi transcription factor (MITF) for differentiation of mast cells demonstrated using mice/mice mutant mice of which MITF Iacks the zipper domain. Blood 97:2038-2044, 2001
  pubmed

• 11) Tsujimura T, Morii E, Nozaki M, et al.:Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Blood 88:1225-1233, 1996
  pubmed

• 12) Jippo T, Ushio H, Hirota S, et al.:Poor response of cultured mast cells derived from mi/mi mutant mice to nerve growth factor. Blood 84:2977-2983, 1994

• 13) Jippo T, Morii E, Tsujino K, et al.:Involvement of transcription factor encoded by the mouse mi locus (MITF) in expression of p75 receptor of nerve growth factor in cultured mast cells. Blood 90:2601-2608, 1997
  pubmed

• 14) Tsujimura T, Hashimoto K, Morii E, et al.:Involvement of transcription factor encoded by the mouse mi locus (MITF) in apoptosis of cultured mast cells induced by removal of interleukin-3. Am. J. Pathol. 151:1043-1051, 1997
  pubmed

• 15) Adachi S, Ebi Y, Nishikawa S, et al.:Necessity of extracellular domain of W (c-kit) receptors for attachment of murine cultured mast cells to fibroblasts. Blood 79:650-656, 1992

• 16) Kim DK, Morii E, Ogihara H, et al.:Impaired expression of integrin α-4 subunit in cultured mast cells derived from mutant mice of mi/mi genotype. Blood 92:1973-1980, 1998

• 17) Jippo-Kanernoto T, Adachi S, Ebi Y, et al.:BALB/3T3 fibroblast-conditioned medium attracts cultured mast cells derived from W/W but not from mi/mi mutant mice, both of which are deficient in mast cells. Blood 80:1933-1939, 1992

• 18) Morii E, Tsujimura T, Jippo T, et al.:Regulation of mouse mast cell protease 6 gene expression by transcription factor encoded by the mi locus. Blood 88:2488-2494, 1996
  pubmed

• 19) Ogihara H, Morii E, Kim DK, et al.:Inhibitory effect of the transcription factor encoded by the mutant mi microphthalmia allele on transactivation of mouse mast cell protease 7 gene. Blood 97:645-651, 2001
  pubmed

• 20) Morii E, Jippo T, Tsujimura T, et al.:Abnormal expression of mouse mast cell protease 5 gene in cultured mast cells derived from mutant mi/mi mice. Blood 90:3057-3066, 1997

• 21) Jippo T, Lee YM, Katsu Y, et al.:Deficient transcription of mouse mast cell protease 4 gene in mutant mice of mi/mi genotype. Blood 93:1942-1950, 1999

• 22) Ge Y, Jippo T, Lee YM, et al.:Independent influence of strain difference and mi transcription factor (MITF) on the expression of mouse mast cell chymases. Am. J. Pathol. 158:281-292, 2001
  pubmed

• 23) Ito A, Morii E, Maeyama K, et al.:Systematic method to obtain novel genes that are regulated by mi transcription factor (MITF):impaired expression of granzyme B and tryptophan hydroxylase in mi/mi cultured mast cells. Blood 91:3210-3221, 1998

• 24) Kasugai T, Oguti K, Jipoo-Kanemoto T, et al.:Deficient differentiation of mast cells in the skin of mi/mi mice. Usefulness of in situ hybridization for evaluation of mast cell phenotype. Am. J. Pathol. 143:1337-1347, 1993

• 25) Morii E, Ogihara H, Oboki K, et al.:Inhibitory effect of MITF encoded by mutant mi allele on GABP-mediated transcript expression in mouse mast cells. Blood 97:3032-3039, 2001
  pubmed

• 26) Ito A, Morii E, Kim DK, et al.:Inhibitory effect of the transcription factor encoded by the mi mutant allele in cultured mast cells of mice. Blood 93:1189-1196, 1999
  pubmed

• 27) Ogihara H, Kanno T, Morii E, et al.:Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene. Oncogene 18:4632-4639, 1999
  pubmed

P.462 掲載の参考文献

• 1) 村上誠, 工藤一郎:ホスホリパーゼA2のサブタイプ. 現代医療32 (増刊I) 517-548, 2000

• 2) Murakami M, Austen KF, Arm Jp:The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase. J. Exp. Med. 182:197-206, 1995
  pubmed

• 3) Glover S, de Carvalho MS, Bayburt T, et al.:Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J. Biol. Chem. 270:15359-15367, 1995
  pubmed

• 4) Nakatani Y, Murakami M, Kudo I, et al.:Dual regulation of cytosolic phospholipase A2 in mast cells after cross-linking of Fcε-receptor. J. Immunol. 153:796-803, 1994

• 5) Nakatani Y, Tanioka T, Sunaga S, et al.:Identification of a cellular protein that functionally interacts with the C2 domain of cytosolic phospholipase A2α. J. Biol. Chem. 275:1161-1168, 2000

• 6) Enomoto A, Murakami M, Valentin E, et al.:Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipase A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells. J. Immunol. 165:4007-4014, 2000
  pubmed

• 7) Bingham CO 3rd, Murakami M, Fujishima H, et al.:Aheparin-sensitive phospholipase A2 and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D2 generation in mouse bone marrow-derived mast cells. J. Biol. Chem. 271:25936-25944, 1996
  pubmed

• 8) Murakami M, Tada K, Shimbara S, et al.:Detection of secretory phospholipase A2s related but not identical to type IIA isozyme in cultured mast cells. FEBS Lett. 413:249-254, 1997

• 9) Murakami M, Simbara S, Kambe T, et al.:The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. J. Biol. Chem. 273:14411-14423, 1998

• 10) Murakami M, Koduri RS, Enomoto A, et al.:Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J. Biol. Chem. 276:10083-10096, 2001
  pubmed

• 11) Reddy ST, Winstead MV, Tischfield JA, et al.:Analysis of the secretory phospholipase A2 that mediates prostaglandin production. in mast cells. J. Biol. Chem. 2. 272:13591-13596, 1997
  pubmed

• 12) Murakami M, Kambe T, Shimbara S, et al.:Functional association of type IIA secretory phospholipase A2 with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathways. Biol. Chem. 2. 274:29927-29936, 1999

• 13) Enomoto A, Murakami M, Kudo I:Internalization and degradation of type IIA phospholipase A2 in mast cells. Biochem. Biophys. Res. Commun. 276:667-672, 2000
  pubmed

• 14) Murakami M, Matsumoto R, Urade Y, et al.:c-kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synethase and increased IgE-dependent prostaglandin D2 generation in immature mouse mast cells. J. Biol. Chem. 270:3239-3246, 1995

• 15) Reddy ST, Tiano HF, Langenbach R, et al.:Genetic evidence for distinct roles of COX-1 and COX-2 in the immediate and delayed phases of prostaglandin synthesis in mast cells. Biochem. Biophys. Res. Commun. 265:205-210, 1999
  pubmed

• 16) Murakami M, Tada K, Nakajima K, et al.:Cyclooxygenase-2-dependent delayed prostaglandin D2 generation is initiated by nerve growth factor in rat peritoneal mast cells. Its augmentation by extracellular type II secretory phospholipase A2. J. Immunol. 159:439-446, 1997
  pubmed

• 17) Sapirstein A, Bonventre JV:Specific physiological roles of cytosolic phospholipase A2 as defined by gene knockouts. Biochim. Biophys. Acta 1488:139-148, 2000
  pubmed

• 18) Ashraf MM, Murakami M, Shimbara S, et al.:Type II phospholipase A2 is linked to cyclooxygenase-2-mediated delayed prostaglandin D2 generation by cultured mouse mast cells following FcεRI-and cytokine-dependent activation. Biochem. Biophys. Res. Commun. 229:726-732, 1996

• 19) Tada K, Murakami M, Kambe T, et al.:Induction of cyclooxygenese-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions. J. Immunol. 161:5008-5015, 1998

• 20) Kuwata H, Yamamoto S, Miyazaki Y, et al.:Studies on a mechanism by which cytosolic phospholipase A2 regulates the expression and function of type IIA secretory phospholipase A2. J. Immunol. 165:4024-4031, 2000
  pubmed

• 21) Malaviya R, Malaviya R, Jakschik BA, et al.:Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J. Biol. Chem. 268:4939-4944, 1993
  pubmed

• 22) Murakami M, Austen KF, Bingham CO 3rd, et al.:Interleukin-3 regulates developement of the 5-lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells. J. Biol. Chem. 270:22653-22656, 1995

• 23) Nakajima K, Murakami M, Yanoshita R, et al.:Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J. Biol. Chem. 272:19708-19713, 1997
  pubmed

P.470 掲載の参考文献

• 1) Laroche D, Vergnaud MC, Sillard B, et al.:Biochemical markers of anaphylactoid reactionsto drugs. A nest zesiology 75:945-949, 1991

• 2) Hirschman CA, Edelstein RA, Ebertz JM, et al.:Thiobarbiturate-induced histamine release in human skin mast cells. Anesthesiology 63:353-356, 1985

• 3) Stellato C, de Paulis A, Cirillo R, et al.:Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 74:1078-1086, 1991
  pubmed

• 4) Ihle JN, Keller J, Oronszlan S, et al.:Biologic properties of homogenous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating activity. J. Immunol. 131:282-287, 1983

• 5) Saito H, Okajima F, Molski TFP, et al.:Effects of ADP-ribosylation of GTP-binding protein by pertussis toxin on immunoglobulin E-dependent and -independent histamine release from mast cells and basophils. J. Immunol. 138:3927-3934, 1987

• 6) Liu FT, Bohn JW, Ferry E, et al.:Monoclonal dinitrophenyl-specific murine IgE antibody:preparation, isolation and characterization. J. Immunol. 124:2728-2737, 1980

• 7) Tsien RY, Pazzan T, Rink TJ:Calcium homeostasis in intact lymphocytes:cytoplasma free calcium monitored with a new intracellularly trapped fluorescent indicator. J. Cell. Biol. 94:325-335, 1982

• 8) Benyon RC, Robinson C, Church MK:Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br. J. Pharmacol. 97:898-904, 1989
  pubmed

• 9) Tasaka K, Mio M, Okamoto M:Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann. Allergy 56:464-469, 1986
  pubmed

• 10) Tedeschi A, Miadonna A, Lorini M, et al.:Receptor-operated, but not voltage-operated, calcium channels are involved in basophil leukocyte activation and histamine release. Int. Arch. Allergy Appl. Immunol. 90:109-111, 1989

• 11) Oliver JM, Seagrave J, Stump RF, et al.:Signal transduction and cellular response in RBL-2H3 mast cells. Prog. Allergy 42:185-245, 1988
  pubmed

• 12) Scatz M, Fung DL:Anaphylactic and anaphylactoid reactions due to anesthetic agents. Clin. Rev. Allergy 4:215-227, 1986

• 13) Pressman D, Siegel M, Hall LAR:The closeness of antibenzoate about haptens and the orientation of the haptens in combination. J. Am. Chem. Soc. 76:6336, 1968

• 14) Pearce FL:Functional heterogeneity of mast cells from different species and tissues. Klin. Wochensghr. 60:954-957, 1982
  pubmed

• 15) Otsu K, Nakano T, Kanakura Y, et al.:Phenotypic changes of bone marrow-derived mast cells after intraperitoneal transfer into W/Wv mice that are genetically deficient in mast cells. J. Exp. Med. 165:615-627, 1987
  pubmed

• 16) Lowman MA, Rees PH, Benyon RC, et al.:Human mast cell heterogeneity:histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J. Allergy Clin. Immunol. 81:590-597, 1988

• 17) Levy JH, Adelson D, Walker B:Wheal and flare responses to muscle relaxants in humans. Agents Actions 34:302-308, 1991
  pubmed

• 18) Lagunoff D, Martin TW, Read G:Agents that release histamine from mast cells. Annu. Rev. Pharmacol. Toxicol. 23:331-351, 1983
  pubmed

• 19) Schmutzler W, Poblete-Freundt G, Rauch K, et al.:Response to immunological or cholinergic stimulation of isolated mast cells from man, guinea pig and rat. Monogr. Allergy 11:55-59, 1981
  pubmed

P.476 掲載の参考文献

• 1) Kikuchi S, Wada O, Kurosawa M, et al.:Association between gastric cancer and H.pylori with reference to age. Gut 37:A8, 1995

• 2) Tomb JF, White O, Kerlavage AR, et al.:The complete genome sequence of the gastric pathogen H.pylori. Nature 388:539-547, 1997
  pubmed

• 3) 浅香正博:細胞傷害機序. H. Pyloriと胃粘膜病変. 第2版, 先端医学社, 東京, 1999, pp. 56-61

• 4) Garner JA, Cover TL:Binding and internalization of the H.pylori vacuolating cytotoxin by epithelial cells. Infect. Immun. 64:4197-4203, 1996

• 5) Bernard M, Burroni D, Papini E, et al.:Identification of the H.pylori VacA toxin domain active in the cell cytosol. Infect. Immun. 66:6014-6016, 1998

• 6) Noach LA, Bosma NB, Jansen J, et al.:Mucosal tumor necrosis factor-α, interleukin-1β, and interleukin-8 production in patients with H. pylori infection. Scand. J. Gastroenterol. 29:425-429, 1994

• 7) Elios MM, Manghetti M, De Carli M, et al.:T helper l effector cells specific for H.pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. 158:962-967, 1997

• 8) 川野淳, 辻晋吾:胃の炎症とmast cell. macrophageの関わり. 臨鉢消化器内科13:1353-1360, 1998

• 9) Fitzpatric LR, Decktor DL:Gastro-protective and ulcer healing profile of the mast cell stabilizer quazolast in rats. Agents Actions 33:330-336, 1991

• 10) Terashima K, Tanimura T, Shimamura H, et al.:Studies on antiulcer agents. Chem. Pharm. Bull. (Tokyo) 43:1042-1044, 1995
  pubmed

• 11) Ogle CW, Hui SC:The influence of peripheral or central administration of ondansetron on stress-induced gastric ulceration in rats. Expertientia 51:786-789, 1995
  pubmed

• 12) Karmeri F, Eliakim R, Okon E, et al.:Ketotifen and nitroxides decrease capsaicin-augmented ethanol-induced gastric damage in rats. Dig. Dis. Sci. 40:1140-1146, 1995

• 13) al-Mashhadani WM, Karim KH, al-Taie RI, et al.:Nifedipine versus cimetidine in prevention of stress-induced gastric ulcers in rats. Eur. J. Pharmacol. 192:117-121, 1991
  pubmed

• 14) Garg GP, Cho CH, Ogle CW:Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents in rats. Pharmatology 40:318-324, 1990
  pubmed

• 15) Nakajima S, Krishnan B, Ota H, et al.:Mast cell involvement in gastritis with or without H.pylori infection. Gastroenterology 113:746-754, 1997
  pubmed

• 16) 中島滋美:胃炎と胃潰瘍におけるマスト細胞の役割と動態. The. Res. 20 (Suppl. 1):91-94, 1999

• 17) Rioux KP, Wallace JL:Mast cell activation augments gastric mucosal injury through a leukotrien-dependent mechanism. Am. J. Physiol. 266:G863-G869, 1994
  pubmed

• 18) Wershil BK, Furuta GT, Wang ZS, et al.:Mast cell-dependent neutrophil and mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. Gastroenterology 110:1482-1490, 1996
  pubmed

• 19) Yamamoto J, Watanabe S, Hitose M, et al.:Role of mast cells as a trigger of inflammation in H.pylori infection. J. Physiol. Pharmacol. 50:17-23, 1999

P.483 掲載の参考文献

• 1) Garrett MH, Hooper MA, Hooper BM, et al.:Increased risk of allergy in children due to formaldehyde exposure in homes. Allergy 54:330-337, 1999
  pubmed

• 2) Wantke F, Focke M, Hemmer W, et al.:Exposure to formaldehyde and phenol during an anatomy dissecting course:sensitizing Potency of formaldehyde in medical students. Allergy 55:84-87, 2000
  pubmed

• 3) Krakowiak A, Gorski P, Pazdrak K, et al.:Airway response to formaldehyde inhalation in asthmatic subjects with suspected respiratory formaldehyde sensitization. Am. J. Ind. Med. 33:274-281, 1998
  pubmed

• 4) Tarkowski M, Gorski P:Increased IgE antiovalbumin level in mice exposed to formal-dehyde. Int. Arch. Allergy immunol. 106:422-424, 1995

• 5) Enerback L:Mast cells in rat gastrointestinal mucosa. 1. Effects of fixation. Acta. Pathol. Microbiol. Scand. 66:303-312, 1966

• 6) Fujimaki H, Kawagoe A, Bissonnette E, et al.:Mast cell response to formaldehyde 1. Modulation of mediator release. Int. Arch. Allergy. Immunol 98:324-331, 1992
  pubmed

• 7) Saneyoshi K, Nohara O, Imai T, et al.:IL-4 and IL-6 production of bone marrow-derived mast cells is enhanced by treatment with environmental pollutants. Int. Arch. Allergy. Immunol. 114:237-245, 1997
  pubmed

• 8) Sakamoto T, Doi S, Torii S:Effects of formal-dehyde, as an indoor air pollutant, on the airway. Allergol 48:151-160, 1999

• 9) Hiec-Swierczynska M, Krecisz B, Krysiak B, et al.:Occupational allergy to aldehydes in health care workers. Clinical observations. Experiments. Int. J. Occup. Med. Environ. Health 11:349-358, 1998

• 10) Fujimaki H, Shiraishi F, Katayama N:Enhan-cement of histamine release from rat peritoneal mast cells exposed to formaldehyde. Inhal Toxicol. 4:125-136, 1992

• 11) Institute of Medicine Committee on the Assessment of Asthma and indoor air.:formaldehyde. In:Clearing the Air:Asthma and lndoor Air Exposures, ed. by Institute of Medicine Committee on the Assessment of Asthma and Indoor air, National Academy Press, Washington, 2000, pp. 243-247

P.488 掲載の参考文献

• 1) Friedmann PS:Disappearance of Langerhans cells during PUVA therapy. Br. J. Dermatol. 105:219-221, 1981
  pubmed

• 2) Roberts LK, Jun BD, Gilhar A, et al.:Effect of ultraviolet radiation on Ia expression by keratinocytes. Photodermatology 6:275-286, 1989
  pubmed

• 3) Gilchrest BA, Soter NA, Stoff JS, et al.:The human sunburn reaction:histologic and biochemical studies. J. Am. Acad. Dermatol. 5:411-422, 1981
  pubmed

• 4) Morison WL, Parrish JA, Block KJ:In vivo effect of UVB on lymphocyte function. Br. J. Dermatol. 101:513-519, 1979

• 5) Imazu LE, Tachibana T, Danno K, et al.:Histamine-releasing factor(s) in sera of uraemic pruritus patients in a possible mechanism of UVB therapy. Arch. Dermatol. Res. 285:423-427, 1993

• 6) Ozdamar SO, Seckin D, Kandemir B, et al.:Mast cells in psoriasis. Dermatology 192:190, 1996
  pubmed

• 7) Parrish JA, Jaenicke KF, Morison WL:Solar Urticaria:treatment with PUVA and mediator inhibitors. Br. J. Dermatol. 106:575-580, 1982
  pubmed

• 8) Jekler J, Larko O:UVB phototherapy of atopic dermatitis. Br. J. Dermatol. 119:697-705, 1988
  pubmed

• 9) Vella Briffa D, Eady RA, James MP, et al.:Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br. J. Dermatol. 109:67-75, 1983
  pubmed

• 10) Assem ESK, Ghanem NS, Abdullah NA, et al.:Substance P and Arg-Pro-Lys-Pro-NH-C12-H25-induced mediator release from defferent mast cell subtypes of rat and guinea-pig. Immunopharmacology 17:119-128, 1989

• 11) Kurosawa M, Inamura H, Amano H, et al.:Nerve growth factor release with mast-cell-derived mediators in a patient with systemic mastocytosis after middle-wave ultraviolet irradiation. Allergy 54:994-998, 1999

• 12) Fjellner BO, Hagermark O:Histamine release from rat peritoneal mast cells exposed to ultraviolet. Acta. Derm. Venereol. (Stockholm) 62:215-220, 1982

• 13) Danno K, Fuj ii K, Tachibana T, et al.:Suppressed histamine release from rat peritoneal mast cells by ultraviolet B irradiation:decreased diacylglycerol formation as a possible mechanism. J. Invest. Dermatol. 90:806-809, 1988

• 14) Amano H, Kurosawa M, Miyachi Y:Inhibition of substance P-induced histamine release from rat peritioneal mast cells by ultraviolet light B irradiation:decreased intracellular calcium as apartial mechanism. Clin. Exp. Allergy 27:966-971, 1997

• 15) Danno K, Fujii K, Toda K, et al.:The effect of 8-methoxypsoralen plus long-wave ultraviolet (PUVA) radiation on mast cells.:PUVA suppresses degranulation of mouse skin mast cells induced by Compound 48/80 or Concanavalin A. J. Invest.Dermatol. 85:110-114, 1985
  pubmed

• 16) Toda K, Danno K, Tachibana T, et al.:Effect of 8-methoxypsoralen plus long-wave ultraviolet (PUVA) radiation on mast cells. II:In vitro PUVA inhibits degranulation of rat peritoneal mast cells induced by Compound 48/80. J. Invest. Dermatol. 87:113-116, 1986

• 17) Amano H, Kurosawa M, Miyachi Y:Inhibition of substance P-induced histamine release from rat peritoneal mast cells by 8-methoxypsoralen plus long-wave ultraviolet light irradiation:decreased intracellular calcium as a possible mechanism. Int. Arch. Allergy Immunol. 115:55-60, 1998
  pubmed

• 18) Diezel W, Meffert H, Sonnichsen N:Therapie der Psoriasis mit Hematoporphyrin und Licht. Dermatol. Monastschr. 166:793-797, 1980
  pubmed

• 19) Berns MW, McCullough JL:Porphyrin sensitized phototherapy. Arch. Dermatol. 122:871-873, 1986
  pubmed

• 20) Emtestam L, Berglund L, Angelin B, et al.:Tin-protoporphyrin and long wave length ultraviolet light in treatment of psoriasis. Lancet i:1231-1233, 1989
  pubmed

• 21) Naukkarinen A, Harvima IT, Aalto ML, et al.:Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int. J. Dermatol. 33:361-366, 1994
  pubmed

• 22) Amano H, Kurosawa M, Miyachi Y:Inhibition of substance P-induced histamine release from rat peritoneal mast cells by low doses of protoporphyrin plus long-wave ultraviolet light irradiation:decreased intracellular calcium as a possible mechanism. Clin. Exp. Allergy 28:765-771, 1998
  pubmed

• 23) Yen A, Barrett KE, Gigli I:Protoporphyrin and long-wave ultraviolet light modulate metabolic events in rat peritoneal mast cells. J. Invest. Dermatol. 98:488-493, 1992
  pubmed

P.495 掲載の参考文献

• 1) Venter JC, Adams MD, Myers EW, et al.:The sequence of the human genome. Science 291:1304-1351, 2001

• 2) Lipshutz RJ, Fodor SP, Gingeras TR, et al.:High density synthetic oligonucleotide arrays. Nat. Genet. 21:20-24, 1999
  pubmed

• 3) Nomura I, Katsunuma T, Matsumoto K, et al.:Human mast cell progenitors in peripheral blood from atopic subjects with high IgE levels. Clin. Exp. Allergy 31:1424-1431, 2001
  pubmed

• 4) Mwamtemi HH, Koike K, Kinoshita T, et al.:An increase in circulating mast cell colony-forming cells in asthma. J. Immunol. 166:4672-4677, 2001
  pubmed

• 5) Kinoshita T, Sawai N, Hidaka E, et al.:Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34+ cord blood cells. Blood 94:496-508, 1999
  pubmed

• 6) Ahn K, Takai S, Pawankar R, et al.:Regulation of chymase production in human mast cell progenitors. J. Allergy Clin. Immunol. 106:321-328, 2000
  pubmed

• 7) Tachimoto H, Ebisawa M, Hasegawa T, et al.:Reciprocal regulation of cultured human mast cell cytokine production by IL-4 and IFN-γ. J. Allergy Clin. Immunol. 106:141-149, 2000

• 8) Nakajima T, Matsumoto K, Saito H, et al.:Gene expression screening of human mast cells and eosinophils using high-density oligonu-cleotide probearrays:abundant expression of major basic protein in mast cells. Blood 98:1127-1134, 2001

• 9) Iida M, Matsumoto K, Tomita H, et al.:Selective down-regulation of high affinity IgE receptor (FcεRI) α-chain messenger RNA among transcriptome in cord blood-derived versus adult peripheral blood-derived cultured human mast cells. Blood 97:1016-1021, 2001

P.503 掲載の参考文献

• 1) Furitsu T, Saito H, Dvorak AM, et al.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 2) Irani AM, Nilsson G, Miettinen V, et al.:Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021, 1992

• 3) Kirshenbaum AS, Goff JP, Kessler SW, et al.:Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 148:772-777, 1992
  pubmed

• 4) Valent P, Spanblod E, Sperr WR, et al.:Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237-2245, 1992

• 5) Mitsui H, Furitsu T, Dvorak AM, et al.:Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90:735-739, 1993
  pubmed

• 6) Sawai N, Koike K, Ito S, et al.:Neutrophilic cell production by combination of stem cell factor and thrombopoietin from CD34+cord blood cells in long-term serum-deprived liquid culture. Blood 93:509-518, 1999
  pubmed

• 7) Koike K, Nakahata T, Takagi M, et al.:Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture. J. Exp. Med. 168:879-890, 1988
  pubmed

• 8) Kinoshita T, Sawai N, Hidaka E, et al.:Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34+cord blood cells. Blood 94:496-508, 1999
  pubmed

• 9) Sawai N, Koike K, Mwamtemi HH, et al.:Thrombopoietin augments stem cell factor-dependent growth of human mast cells from bone marrow multipotential hematopoietic progenitors. Blood 93:3703-3712, 1999
  pubmed

• 10) Kinoshita T, Koike K, Mwamtemi HH, et al.:Retinoic acid is a negative regulator for the differentiation of cord blood-derived human mast cell progenitors. Blood 95:2821-2828, 2000
  pubmed

• 11) Mwamtemi HH, Koike K, Kinoshita T, et al.:An increase in circulating mast cell colony-forming cells in asthma. J. Immunol. 66:4672-4677, 2001

• 12) Kirshenbaum AS, Goff JP, Semere T, et al.:Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood 94:2333-2342, 1999
  pubmed

• 13) Kempuraj DH, Saito H, Kaneko A, et al.:Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93:3338-3346, 1999

• 14) Nakahata T, Tsuji K, Tanaka R, et al.:Synergy of stem cell factor and other cytokines in mast cell development. In:Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function, ed. by Kitamura Y, Yamamoto S, Galli SJ, Greaves MW, et al, Raven Press, Ltd, New York, 1995, pp. 13-24

• 15) Toru H, Eguchi M, Matsumoto R. et al.:Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998
  pubmed

P.510 掲載の参考文献

• 1) Galli SJ, Wershil BK:The two faces of the mast cell. Nature 381:21-22, 1996
  pubmed

• 2) Kitamura Y:Heterogeneity of mast cells and phenotypic change between subpopulations. Annu. Rev. Immunol. 7:59-76, 1989
  pubmed

• 3) Katz HR, Stevens RL, Austen KF:Heterogeneity of mammalian mast cells differentiated in vivo and in vitro. J. Allergy Clin. Immunol. 76:250-259, 1985
  pubmed

• 4) Irani AM, Schwartz LB:Mast cell heterogeneity. Clin. Exp. Immunol 19:143-155, 1989

• 5) Barrett KE, Metcalfe DD:Mast cell heterogeneity:evidence and implications. J. Clin. Immunol. 4:253-261, 1984
  pubmed

• 6) Saito H, Hatake K, Dvorak AM, et al.:Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc. Natl. Acad. Sci. USA 85 :2288-2292, 1988
  pubmed

• 7) Furitsu T, Saito H, Dvorak AM, et al.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 8) Enerback L:Mast cells in rat gastrointestinal mucosa. 1. Effect of fixation. Acta. Pathol. Microbiol. Scand. 66:289-302, 1966

• 9) Irani AM, Bradford TR, Kopley CL, et al.:Detection of MCT and MCTc types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J. Histochem. Cytochem. 37 :1509-1515, 1989

• 10) Irani AA, Schechter NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986
  pubmed

• 11) Dayton ET, Pharr P, Ogawa M, et al.:3T3 fibroblasts induce cloned interleukin 3-dependent mouse mast cells to resemble connective tissue mast Cells in granular Constituency. Proc. Natl. Acad. Sci. USA 85:569-572, 1988
  pubmed

• 12) Levi-Schaffer F, Dayton ET, Austen KF, et al.:Mouse bone marrow-derived mast cells cocultured with fibroblasts. Morphology and stimulation-induced release of histamine, leukotriene B4, leukotriene C4, and prostaglandin D2. J. Immunol. 139:3431-3441, 1987
  pubmed

• 13) Matsuda H, Kannan Y, Ushio H, et al.:Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J. Exp. Med. 174:7-14, 1991
  pubmed

• 14) Saito H, Ebisawa M, Tachimoto H, et al.:Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350, 1996

• 15) Igarashi Y, Kurosawa M, Ishikawa O, et al.:Characteristics of histamine release from cultured human mast cells. Clin. Exp. Allergy 26:597-602, 1996
  pubmed

• 16) Toru H, Kinashi T, Ra C, et al.:Interleukin-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules. Blood 89:3296-3302, 1997
  pubmed

• 17) Toru H, Ra C, Nonoyama S, et al.:Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int. Immunol. 8:1367-1373, 1996
  pubmed

• 18) Toru H, Eguchi M, Matsumoto R, et al.:Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998
  pubmed

• 19) Nilsson G, Forsberg-Nisson K, Xiang Z, et al.:Human mast cells express functional TrkA and are a source of nerve growth factor. Eur. J. Immunol. 27:2295-2301, 1997

• 20) Kanbe N, Kurosawa M, Miyachi Y, et al.:Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells syner-gistically with stem cell factor. Clin. Exp. Allergy 30:1113-1120, 2000

• 21) Tam SY, Tsai M, Yamaguchi M, et al.:Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 90:1807-1820, 1997
  pubmed

• 22) Kanbe N, Kurosawa M, Miyachi Y, et al.:Carnoy's fixative reduces the number of chymase positive cells in immunocytochemical staining of cord-blood-derived human cultured mast cells. Allergy 53:981-985, 1998

• 23) Sonoda T, Kanayama Y, Hara H, et al.:Proliferation of peritoneal mast cells in the skin of W/Wv mice that genetically lack mast cells. J. Exp. Med. 160 :138-151, 1984
  pubmed

• 24) Nakahata T, Kobayashi T, Ishiguro A, et al.:Extensive proliferation of mature connectivetissue type mast cells in vitro. Nature 324:65-67, 1986
  pubmed

• 25) Kuriu A, Sonoda S, Kanakura Y, et al.:Proliferative potential of degranulated murine peritoneal mast cells. Blood 74:925-929, 1989
  pubmed

• 26) Kanakura Y, Sonoda S, Nakano T, et al.:Formation of mast-cell colonies in methylcellulose by mouse skin cells and development of mucosal-like mast cells from the cloned cells in the gastric mucosa of W/Wv mice. Am. J. Pathol. 129:168-176, 1987

• 27) Schwartz LB, Irani AM, Roller K, et al.:Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J. Immunol. 138:2611-2615, 1987

• 28) Benyon RC, Lowman MA, Church MK:Human skin mast cells:their dispersion, purification, and secretory characterization. J. Immunol. 138:861-867, 1987
  pubmed

• 29) Lawrence ID, Warner JA, Cohan VL, et al.:Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J. Immunol. 139:3062-3069, 1987
  pubmed

• 30) Ren S, Kanbe N, Du Z, et al.:Disialoganglioside GD3 is selectively expressed by developing and mature human mast cells. J. Allergy Clin. Immunol. 107:322-330, 2001

• 31) Kambe N, Kambe M, Kochan JP, et al.:Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes. Blood 97:2045-2052, 2001
  pubmed

P.518 掲載の参考文献

• 1) Kitamura Y, Kasugai T, Arizono N, et al.:Development of mast cells and basophils:processes and regulation mechanism. Am. J. Med. Sci. 306:185-191, 1993
  pubmed

• 2) Saito H, Ebisawa M, Sakaguchi N, et al.:Characterization of cord-blood-derived human mast cells cultured in the presence of Steel factor and interleukin-6. Int. Arch. Allergy Immunol. 107:63-65, 1995
  pubmed

• 3) Dalton R, Chan L, Batten E, et al.:Mast cell leukemia:evidence for bone marrow origin of the pathological clone. Br. J. Haematol 64:397-406, 1986
  pubmed

• 4) Horton MA, Ruck M:Characterization of human mast cells in long term culture. Blood 62:1251-1260, 1983

• 5) Butterfield JH, Weiler D, Dewald G, et al.:Establishment of an immature mast cell line from a patient with a mast cell leukemia. Leuk. Res. 12:345-355, 1988
  pubmed

• 6) Krilis SA, Warneford SG, Macpherson J, et al.:Establishment in culture and characterization of a strain with mast cell and monocytic properties from the bone marrow of a child with diffuse cutaneous mastocytosis. Blood 78:290-303, 1991
  pubmed

• 7) Barsumian EL, Isersky C, Petrino MG, et al.:IgE-induced histamine release from rat basophilic leukemia cell lines:isolation of releasing and nonreleasing clones. Eur. J. Immunol. 11:317-323, 1981
  pubmed

• 8) Siegel ML, Horwitz R, Morris TD, et al.:Isolation and characterization of Abelson murine leukemia virus-transformed mast cell lines from midgestation embryonic placenta. Eur. J. Immunol. 15:1136-1141, 1985
  pubmed

• 9) Komatsu K, Nakamura W, Kageyama K:Does weak local gamma irradiation modify the effect of CDDP on mouse mastocytoma? C.R. Seances Soo. Biol. Fil. 179:554-557, 1985

• 10) Koyasu S, Nakauchi H, Kitamura K, et al.:Expression of interleukin 2 receptors on interleukin 3-dependent cell lines. J. Immunol 134:3130-3136, 1985

• 11) Nabel G, Fresno M, Chessman A, et al.:Use of cloned populations of mouse lymphocytes to analyze cellular differentiation. Cell 23:19-28, 1981

• 12) Arora N, Min KU, Costa JJ, et at:Immortalization of mouse bone marrow-derived mast cells with Ad12-SV40 virus. Int. Arch. Allergy Immunol. 100:319-327, 1993
  pubmed

• 13) Hira K, Mitsuishi K, Kawamoto K, et al:Establishment and characterization of a murine mast cell line derived from nc/nga mice. Int. Arch. Allergy Immunol. 125:67-70, 2001
  pubmed

• 14) Dunn TB, Potter M:A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18:587-589, 1957

• 15) Vanderhoek JY, Tare NS, Bailey JM, et al.:New role for 15-hydroxyeicosatetraenoic acid. Activator of leukotriene biosynthesis in PT-18 mast/basophil cells. J. Biol. Chem. 257:12191-12195, 1982

• 16) DeVinney R, Gold WM:Establishment of two dog mastocytoma cell lines in continuous culture. Am. J. Respir. Cell. Mol. Biol. 3:413-420, 1990
  pubmed

• 17) Lazarus SC, De Vinney R, McCabe LJ, et al.:Isolated canine mastocytoma cells:propagation and characterization of two cell lines. Am. J. Physiol. 251:C935-C944, 1986
  pubmed

• 18) Eccleston E, Leonard BJ, Lowe JS, et al.:Basophilic leukaemia in the albino rat and a demonstration of the basopoietin. Nat. New Biol. 244:73-76, 1973

• 19) Krilis SA, Austen KF, Macpherson JL, et al.:Continuous release of secretory granule proteoglycans from a cell strain derived from the bone marrow of a patient with diffuse cutaneous mastocytosis. Blood 79:144-151, 1992
  pubmed

• 20) Townsend M, Macpherson J, Krilis S, et al.:Immortalization and characterization of human cell Iines with mast cell and monocytic properties. Br. J. Haematol. 85:452-461, 1993

• 21) Li L, Macpherson JJ, Adelstein S, et al.:Conditioned media from a cell strain derived from a patient with mastocytosis induces preferential development of cells that possess high affinity IgE receptors and the granule protease phenotype of mature cutaneous mast cells. J. Biol. Chem. 270:2258-2263, 1995
  pubmed

• 22) Nilsson G, Blom T, Kusche-Gulberg M, et al.:Phenotypic characterization of the human mast-cell line HMC-1. Scand. J. Immunol. 39:489-498, 1994

• 23) Xia HZ, Kepley CL, Sakai K, et al.:Quantitation of tryptase, chymase, FcεRla, fcεRIg mRNAs in human mast cells and basophils by competitive reverse transcription-polymerase chain reaction. J. Immunol. 154:5472-5480, 1995

• 24) Welker P, Grabbe J, Grutzkau A, et al.:Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology 94:310-317, 1998
  pubmed

• 25) Grabbe J, Welker P, Grutzkau A, et al.:Induction of human leukaemic mast cell differentiation by fibroblast supernatants, but not by stem cell factor. Scand. J. Immunol. 47:324-331, 1998
  pubmed

• 26) Furitsu T, Tsujimura T, Tono T, et al.:Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-1744, 1993

• 27) Tsujimura T, Furitsu T, Morimoto M, et al.:Substitution of an aspartic acid results in constitutive activation of c-leit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol. 106:377-385, 1995

• 28) London CA, Galli SJ, Yuuki T, et al.:Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27:689-697, 1999
  pubmed

• 29) Buttner C, Henz BM, Welker P, et al.:Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis:apossible explanation for divergent clinical behavior. J. lnvest. Dermatol. 111:1227-1231, 1998
  pubmed

• 30) Schechter NM, Slavin D, Fetter RD, et al.:Purification and identification of two serine class proteinases from dog mast biochemically and immunologically similar to human proteinases tryptase and chymase. Arch. Biochem. Biophys. 262:232-244, 1988
  pubmed

• 31) Varsano S, Lazarus SC, Gold WM, et al.:Selective adhesion of mast cells to tracheal epithelial cells in vitro. J. Immunol. 140:2184-2192. 1988
  pubmed

• 32) 川本恵子, 羅 智靖:肥満細胞のIgEレセプター. 臨床検査 43:751-761, 1999

• 33) Wang B, Rirger A, Kilgus O, et al.:Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI. J. Exp. Med. 175:1353-1365, 1992

• 34) Maurer D, Fiebiger E, Reininger B, et al.:Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals. J. Exp. Med. 179:745-750, 1994
  pubmed

• 35) Gosset P, Lamblin-Degros C, Tillie-Leblon I, et al.:Modulation of high-affinity IgE receptor expression in blood monocytes:opposite effect of IL-4 and glucocorticoids. J. Allergy Clin. Immunol. 107:114-122, 2001

• 36) Donnadieu E, Jouvin MH, Kinet Jp:A second amplifier function for the allergy-associated FcεRI-βsubunit. Immunity 12:515-523, 2000

P.525 掲載の参考文献

• 1) Kitamura Y, Matsuda H, Hatanaka K:Clonal nature of mast-cell clusters formed in W/Wv mice after bone marrow transplantation. Nature 281:154-155, 1979

• 2) Kitamura Y, Yokoyama M, Matsuda H, et al.:Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes. Natzare 291:159-160, 1981
  pubmed

• 3) Columbo M, Bochner BS, Marone G:Human skin mast cells express functionalβ1 integrins that mediate adhesion to extracellular matrix proteins. J. Immunol. 154:6058-6064, 1995

• 4) Guo CB, Kagey-Sobotka A, Lichtenstein LM, et al.:Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 79:708-712, 1992
  pubmed

• 5) Valent P, Bettelheim P:Cell surface structures on human basophils and mast cells:biochemical and functional characterization. Adv. Immunol. 52:333-423, 1992
  pubmed

• 6) Saeland S, Duvert V, Caux C, et al.:Distribution of surface-membrane molecules on bone marrow and cord blood CD34+hematopoietic cells. Exp. hematol. 20:24-33, 1992

• 7) Shaw S, Luce GG, Gilks WR, et al. (eds.):In:Leukocyte Typing V:White Cell Differentiation Antigens., vol1, New York, Oxford University Press, 1995, pp.16-198

• 8) Dercksen MW, Gerritsen WR, Rodenhuis S, et al.:Expression of adhesion molecules on CD34+ cells:CD34+ L-selectin+cells predict a rapid platelet recovery after peripheral blood cell transplantation. Blood 85:3313-3319, 1995
  pubmed

• 9) Tachimoto H, Hudson SA, Bochner BS:Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation. J. Allergy Clin. Immunol. 107:302-309, 2001
  pubmed

• 10) Tachimoto H, Ebisawa M, Hasegawa T, et al.:Reciprocal regulation of cultured human mast cell cytokine production by IL-4 and IFN-γ. J. Allergy Clin. Immunol. 106:141-149, 2000

• 11) Hamawy MM, Oliver C, Mergenhagen SE, et al.:Adherence of rat basophilic leukemia (RBL-2H3) cells to fibronectin-coated surfaces enhances secretion. J. Immunol. 149:615-621, 1992
  pubmed

P.533 掲載の参考文献

• 1) Ishizaka T, Isizaka K:Biology of immunoglobulin E. Molecular basis of reaginic hypersensitivity. Prog. Allergy 19:60-121, 1975

• 2) Pipkorn U, Hammarlund A, Enerback L:Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced wheal and flare response and a reduction in skin mast cell numbers and histamine content. Clin. Exp. A llergy 19:19-25, 1989

• 3) Duddridge M, Ward C, Hendrick DJ, et al.:Canges in bronchoalveolar lavage inflammatory cells in asthmatic patients treated with high dose inhaled beclomethasone dipropionate. Eur. Respir. J. 6:489-497, 1993

• 4) Sperr WR, Bankl HC, Mundigler G, et al.:The human cardiac mast cell:localization, isolation, phenotype, and functional characterization. Blood 84:3876-3884, 1994
  pubmed

• 5) Guo CB, Kagey-Sobotka A, Lichtenstein LM, et al.:Immunophenotyping and functional analysisof purified human uterine mast cells. Blood 79:708-712, 1992

• 6) Valent P, Ashman LK, Hinterberger W, et al.:Mast cell typing:demonstration of a distincthematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73:1778-1785, 1989
  pubmed

• 7) Lawrence ID, Warner JA, Cohan VL, et al.:Purification and characterization of human skin mast cells:evidence for human mast cell heterogeneity. J. Immunol. 139:3062-3069, 1987
  pubmed

• 8) Weber S, Ruh B, Kruger-Krasagakes S, et al.:Adhesion molecules on the human mast cell line HMC-1 are up-regulated during cell activation. Arch. Dermatol. Res. 287:695-698, 1995

• 9) Weber S, Babina M, Feller G, et al.:Human leukaemic (HMC-1) and normal skin mast cells express β2-integrins:characterization of β2-integrins and ICAM-1 on HMC-1 cells. Scand. J. Immunol. 45:471-481, 1997

• 10) Nilsson G, Blom T, Kusche-Gullberg M, et al.:Phenotypic characterization of the human mast cell line HMC-1. Scand. J. Immunol. 39:489-498, 1994
  pubmed

• 11) Toru H, Kinashi T, Ra C, et al.:Interleukin-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules. Blood 89:3296-3302, 1997
  pubmed

• 12) Ochi H, Hirani WM, Yuan Q, et al.:Thelper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J. Exp. Med. 190:267-280, 1999

• 13) Tachimoto H, Hudson SA, Bochner BS:Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation, J. Allergy Clin. Immunol. 107:302-309, 2001
  pubmed

• 14) Sousa AR, Lane SJ, Nakhostean JA, et al.:Increased expression of the monocyte chemoattractant protein-1 in bronchial tissue from asthmatic subjects. Am. J. Respir. Cell. Biol. 10:142-147, 1994

• 15) Alan R, York J, Boyars M, et al.:Increased MCP-1, RANTES, and MIP-1 in bronchoalveolar lavage in allergic asthmaticpatients. Am. J. Respir. Crit. Care Med. 153:1398-1404, 1996

• 16) Kurashima K, Mukaida N, Fujimura M, et al.:Increase of chemokine levels in sputum preceedes exacerbation of acute asthma attacks. J. Leukoc. Biol. 59:313-313, 1996

• 17) Lippert U, Artuc M, Grutzkau A, et al.:Expression and functional activity of the IL-8 receptor type CXCRI and CXCR2on human mast cells. J. Immunol. 161:2600-2608, 1998
  pubmed

• 18) Nilsson G, Mikovits JA, Metcalfe DD, et al.:Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/interleukin-8RB. Blood 93:2791-2797, 1999
  pubmed

• 19) Romagnani P, De Paulis A, Beltrame C, et al.:Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol. 155:1195-1204, 1999
  pubmed

• 20) Nilsson G, Butterfield JH, Nilsson K, et al.:Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 153:3717-3723, 1994
  pubmed

• 21) Ochi H, Hirani WH, Yuan Q, et al.:T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J. Exp. Med. 190:267-280, 1999

• 22) Lin TJ, Issekutz TB, Marshall JS:Human mast cells transmigrate through human umbilical vein endothelial monolayers and selectively produce IL-8 in response to stromal cell-derived factor-1α. J. Immunol. 165:211-220, 2000

• 23) Baggiolini M, Dewald B, Moser B:Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55:97-179, 1994
  pubmed

• 24) Luster AD:Mechanisms of disease:Chemokines:chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436-445, 1998

P.539 掲載の参考文献

• 1) Kalesnikoff J, Huber M, Lam V, et al.:Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14:801-811, 2001
  pubmed

• 1) Steffen M, Abboud M, Potter GK, et al.:Presence of tumour necrosis factor or a related factor in human basophil/mast cells. Immunology 66:445-450, 1989
  pubmed

• 2) Asai K, Kitaura J, Kawakami Y, et al.:Regulation of mast cell survival by IgE. Immunity 14:791-800, 2001
  pubmed

• 2) Walsh LJ, Trinchieri G, Waldorf HA, et al.:Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. USA 88:4220-4224, 1991
  pubmed

• 3) Ohkawara Y, Yamauchi K, Tanno Y, et al.:Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am. J. Respir. Cell Mol. Biol. 7:385-392, 1992
  pubmed

• 4) Bradding P, Feather IH, Howarth PH, et al.:Interleukin 4 is localized to and released by human mast cells. J. Exp. Med. 176:1381-1386, 1992
  pubmed

• 5) Bradding P, Feather IH, Wilson S, et al.:Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J. Immunol. 151:3853-3865, 1993
  pubmed

• 6) Bradding P, Roberts JA, Britten KM, et al.:Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways:evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10:471-480, 1994
  pubmed

• 7) Horsmanheimo L, Harvima IT, Jarvikallio A, et al.:Mast cells are one major source of interleukin-4 in atopic dermatitis. Br. J. Dematol. 131:348-353, 1994

• 8) Bradding P, Okayama Y, Howarth PH, et al.:Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155:297-307, 1995

• 9) Saito H, Ebisawa M, Tachimoto H, et al.:Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350, 1996

• 10) Jaffe JS, Raible DG, Post TJ, et al.:Human lung mast cell activation leads to IL-13 mRNA expression and protein release. Am. J. Respir. Cell Mol. Bio. 15:473-481, 1996

• 11) Rumsaeng V, Cruikshonk WW, Foster B, et al.:Human mast cells produce the CD4+T lymphocyte chemoattractant factor, IL16. J. Immunol. 159:2904-2910, 1997

• 12) Rumsaeng V, Vliagoftis H, Oh CK, et al.:Lymphotactin gene expression in mast cells following Fc (epsilon) receptor I aggregation:modulation by TGF-beta, IL4, dexamethasone, and cyclosporin A. J. Immunol 158:1353-1360, 1997
  pubmed

• 13) Yanagida M, Fukamachi H, Ohgami K, et al.:Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86:3705-3714, 1995
  pubmed

• 14) Sillaber C, Strobl H, Bevec D, et al.:IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J. Immunol. 147:4224-4228, 1991
  pubmed

• 15) Nilsson G, Miettinen V, Ishizaka T, et al.:Interleukin-4 inhibits the expression of Kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 84:1519-1527, 1994

• 16) Xia HZ, Du Z, Craig S, et al.:Effect of recombinant human IL-40n tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J. Immunol. 159:2911-2921, 1997

• 17) Kinoshita T, Sawai N, Hidaka E, et al.:Inter1eukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34 (+) cord blood cells. Blood 94:496-508, 1999
  pubmed

• 18) Oskeritzian CA, Wang Z, Kochen JP, et al.:Recombinant human (rh) IL-4-rnediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors. J. Immunol. 163:5105-5115, 1999

• 19) Kambe N, Kambe M, Chang HW, et al.:An improved procedure for the development of human mast cells from dispersed fetal liver cells in serum-free culture medium. J. Immunol. Methods 240:101-110, 2000
  pubmed

• 20) Kambe M, Kambe N, Oskeritzian CA, et al.:IL-6 attenuates apoptosis, while neither IL−6 nor IL-10 affect the number or protease phenotype of fetal liver-derived human mast cells. Clin．Exp. Allergy 31：1077−1085，2001
  pubmed

• 21) Du Z, Li Y, Xia H, et al.:Recombinant human granulocyte-macrophage colony-stimulating factor(CSF), but not recombinant human granulocyte CSF, down-regulates the recom-binant human stem cell factor-dependent dif-ferentiation of human fetal liver-derived mast cells. J. Immunol. 159:838-845, 1997

• 22) Toru H, Ra C, Nonoyama S, et al.:Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL4. Int. Immunol. 8:1367-1373, 1996
  pubmed

• 23) Toru H, Kinashi T, Ra C, et al.:Interleukin-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules. Blood 89:3296-3302, 1997
  pubmed

• 24) Toru H, Eguchi M, Matsumoto R, et al.:Inter. leukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998

• 25) Yamaguchi M, Sayama K, Yano K, et al.:IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells:synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor Iexpression and mediator release. J. Immunol. 162:5455-5465, 1999

• 26) Gauchat JF, Henchoz S, Mazzei G, et al.:Induction of human IgE synthesis in B cells by mast cells and basophils. Natzare 365:340-343, 1993

• 27) Pawankar R, Okuda M, Yssel H, et al.:Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilon RI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. 99:1492-1499, 1997

• 28) Bischoff SC, Dahinden CA:c-kit ligand:a unique potentiator of mediator release by human lung mast cells. J. Exp. Med. 175:237-244, 1992
  pubmed

• 29) Columbo M, Horowitz EM, Botana LM, et al.:The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J. Immunol. 149:599-608, 1992
  pubmed

• 30) Okayama Y, Petit-Frere C, Kassel O, et al.:IgE-dependent expression of mRNA for IL4 and IL-5 in human lung mast cells. J. Immunol. 155:1796-1808, 1995
  pubmed

• 31) Kanbe N, Kurosawa M, Yamashita T, et al.:Cord-blood-derived human cultured mast cells produce interleukin 13 in the presence of stem cell factor. Int. Arch. Allergy Immunol. 119:138-142, 1999
  pubmed

• 32) Echtenacher B, Mannel DN, Hultner L:Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996

• 33) Malaviya R, Ikeda T, Ross E, et al.:Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF alpha. Nature 381:77-80, 1996
  pubmed

P.548 掲載の参考文献

• 1) Venter JC, Adams MD, Myers EW, et al.:The sequence of the human genome. Science 291:1304-1351, 2001

• 2) International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001
  pubmed

• 3) Cargill M, Altshuler D, Ireland J, et al.:Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22:231-238, 1999
  pubmed

• 4) Saito H, Hatake K, Dvorak AM, et al.:Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc. Natl Acad. Sci. USA 85:2288-2292, 1988
  pubmed

• 5) Furitsu T, Saito H, Dvorak AM, et al.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 6) Church MK, Hiroi J:Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmacol. 90:421-429, 1987
  pubmed

• 7) Chen H, Centola M, Altschul SF, et al.:Characterization of gene expression in resting and activated mast cells. J. Exp. Med. 188:1657-1668, 1998
  pubmed

• 8) Kuramasu A, Kubota Y, Matsumoto K, et al.:Identification of novel mast cell genes by serial analysis of gene expression in cord blood-derived mast cells. FEBS Lett. 498:37-41, 2001
  pubmed

• 9) Duggan DJ, Bittner M, Chen Y, et al.:Expression profiling using cDNA microarrays. Nat. Genet. 21:10-14, 1999
  pubmed

• 10) Lipshutz RJ, Fodor SPA, Gingeras TR, et al.:High density synthetic oligonucleotide arrays. Nat. Genet. 21:20-24, 1999

• 11) 1ida M, Matsumoto K, Saito H, et al.:Selective down-regulation of high affinity IgE receptor (FcεRI) α-chain messenger RNA among transcriptome in cord blood-derived versus adult peripheral blood-derived cultured human mast cells. Blood 97:1016-1021, 2001

• 12) Nakajima T, Matsumoto K, Suto H, et al.:Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays:abundant expression of major basic protein in mast cells. Blood 98:1127-1134, 2001
  pubmed

• 13) Wong GW, Tang Y, Feyfant E, et al.:Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension. J. Biol. Chem. 274:30784-30793, 1999
  pubmed

• 14) Robinson C, Herbert CA, Bedwell S, et al.:The metabolism of prostaglandin D2. Evidence for the sequential conversion by NADPH and NAD+ dependent pathways. Biochem. Pharmacol. 38:3267-3271, 1989

• 15) Schwartz LB:Mast cells:function and contents. Curr. Opin. Immunol. 6:91-97, 1994
  pubmed

• 16) Humphries DE, Wong GW, Friend DS, et al.:Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400:769-772, 1999
  pubmed

• 17) Newkirk MM, Apostolakos P, Neville C, et al.:Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J. Rheumatol. 26:597-603, 1999

• 18) Hasan Q, Ruger BM, Tan ST, et al.:Clusterin/apoJ expression during the development of hemangioma. Hum, Pathol. 31:691-697, 2000
  pubmed

• 19) Craig SS, Krishnaswamy P, Irani AM, et al.:Immunoelectron microscopic localization of galectin-3, an IgE binding protein, in human mast cells and basophils. Anat. Rec. 242:211-219, 1995
  pubmed

• 20) Helmers SR:Issues in establishing primary stroke centers. JAMA 284:1647-1647, 2000
  pubmed

• 21) Sillaber C, Baghestanian M, Bevec D, et al.:The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J. Immunol. 162:1032-1041, 1999
  pubmed

• 22) Vignola AM, Riccobono L, Mirabella A, et al.:Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 158:1945-1950, 1998
  pubmed

• 23) Schulze E, Witt M, Fink T, et al.:Immunohis-tochemical detection of human skin nerve fibers. Acta Histochem. 99:301-309, 1997

• 24) De Monchy JG, Kauffman HF, Venge P, et al.:Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 131:373-376, 1985
  pubmed

• 25) Filley WV, Holley KE, Kephart GM, et al.:rdentification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet ii:11-16, 1982

• 26) Leckie MJ, ten Brinke A, Khan J, et al.:Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperre-sponsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000

• 27) Ismail EA, Rudwan M, Shafik MH:Fucosidosis:immunological studies and chronological neuror-adiological changes. Acta Paedintr. 88:224-227, 1999

• 28) Giachelli CM, Steitz S:Osteopontin:aversa-tile regulator of inflammation and biomineralization. Matrix Biol. 19:615-622, 2000

• 29) Felix CA:Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36:525-535, 2001
  pubmed

P.556 掲載の参考文献

• 1) Nakahata T, Tsuji K, Tanaka R, et al.:Synergy of stem cell factor and other cytokines in mast cell development. In:Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function, ed. by Kitamura Y, Yamamoto S, Galli SJ, et al, Raven Press, New York, 1995, pp. 13-24

• 2) Toru H, Kinashi T, Ra C, et al.:IL-4 induces homotypic aggregation of human mast cells by promoting LFA-1/ICAM-1 adhesion molecules. Blood 89:3296-3302, 1997
  pubmed

• 3) Toru H, Ra C, Nonoyama S, et al.:Induction of the high-affinity IgE receptor (FcεRI) on human mast cells by IL-4. 1nt. Immunol. 8:1367-1373, 1996

• 4) Toru H, Pawankar R, Ra C, et al.:Human mast cells produce IL-13 by high-affinity IgE cross-linking:enhanced IL-13 production by IL-4-primed human mast cells. J. Allergy Clin. immunol. 102:491-502, 1998
  pubmed

• 5) 田知本寛, 海老沢元宏, 森 和彦ほか:IL-4によるヒト培養肥満細胞のサイトカイン産生増強効果. アレルギー 46 :900, 1997

• 6) Blank U, Ra C, Miller L, et al.:Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 337:187-189, 1989
  pubmed

• 7) Lin S, Cicala C, Scharenbreg AM, et al.:The FcεRIβsubunit functions as an amplifier of FcεRIγ-mediated cell activation signals. Cell 85:985-995, 1996

• 8) Xia HZ, Du Z, Craig S, et al.:Effect of recombinant human IL-4 on tryptase, chymase, and Fcεreceptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J. Immunol. 159:2911-2921, 1997

• 9) Terada N, Konno A, Terada Y, et al.:IL-4 upregulates FcεRIα-chain messenger RNA in eosinophils. J. Allergy Clin. Immunol. 96:1161-1169, 1995

• 10) Parroncci P, Macchia D, Piccinni MP, et al.:Allergen-and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc. Natl. Acad. Sci. USA 88:4538-4542, 1991

• 11) Robinson DS, Hamid Q, Ying S, et al.:Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326:298-304, 1992
  pubmed

• 12) Hsu C, MacGlasham Jr D:IgE antibody up-regulates high affinity IgE binding on murine bone marrow derived mast cells. immunol. Lett. 52:129-134, 1996

• 13) Yamaguchi M, Lantz CS, Oettgen HC, et al.:IgE enhances mouse mast cell FcεRI expression in vitro and in vivo:evidence for a novel amplification mechanism in IgE-dependent reactions J. Exp. Med. 185:663-672, 1997

• 14) Saito, H, Nakajima T, Tachimoto H, et al.:Upregulation of FcεRIαby IgE molecules on human cultured mast cells and basophils. J. Allergy Clin. Immunol. 99:419, 1997

• 15) Valent P, Berec D, Maurer D, et al.:Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc. Natl. Acad. Sci. USA 88:3339-3342, 1991

• 16) Piela-Smith TH, Broketa G, Hand A, et al.:Regulation of ICAM-1 expression and function in human dermal fibroblasts by IL-4. J. Immunol. 148:1375-1381, 1992
  pubmed

• 17) Rousset F, Billaud M, Blanchard D, et al.:IL-4 induces LFA-1 and LFA-3 expression on Burkitt's lymphoma cell lines. Requirement of additional activation by phorbol myristate acetate for induction of homotypic cell adhesions. J. Immunol. 143:1490-1498, 1989
  pubmed

• 18) Branden H, Lundgren E:Differential regulation of LFA-1 and ICAM-1 on human primary B-lymphocytes. Cell. Immunol. 147:64-72, 1993
  pubmed

• 19) Bjorck P, Paulie S, Axelsson B:Inhibition of aggregation but enhancement of proliferation by antibodies to LFA-1. Immunology 75:122-128, 1992
  pubmed

• 20) Carlsson M, Soderberg O, Nilsson K:Interleu-kin-4 (IL4) enhances homotypic adhesion of activated B-chronic lymphocytic leukemia (B-CLL) cells via a selective up-regulation of CD54. Scand. J. Immunol. 37:515-522, 1993

• 21) Irani AMA, Schwartz LB:Mast cell heterogeneity. Clin, Exp. Allergy 19:143-155, 1989

• 22) Irani AMA, Sohechter NM, Craig SS, et al.:Two types of mast cells that have distinct neutral protease compositions.Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986

• 23) Craig SS, Sohechter NM, Schwartz LB:Ultras-tructural analysis of human T and TC mast cells identified by immunoelectron microscopy. Lab. Invest. 58:682-691, 1988

• 24) Craig SS, Schechter NM, Schwartz LB:Ultras-tructural analysis of maturing human T and TC mast cells in sitza. Lab. Invest. 60:147-157, 1989

• 25) Mitsui H Furitsu T Dvorak AM et al.:Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90:735-739, 1993
  pubmed

• 26) Furitsu T, Saito H, Dvorak AM, et al.:Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989
  pubmed

• 27) Ishizaka T, Mitsui H, Yanagida M, et al.:Development of human mast cells from their progenitors. Curr. Opin. Immunol. 5:937-943, 1993
  pubmed

• 28) Dvorak AM:Human mast cells, Ultrastructural observation of in situ, ex vivo, and in vitro sites, sources, and systems. In:The Mast Cell in Health and Disease, ed. by Kaliner MA, Metcalfe DD, Marcel Dekker, Inc, New York, 1993, pp.1-90

• 29) Dvorak AM, Massey W, Warner J, et al.:IgE-mediated anaphylactic degranulation of isolated human skin mast cells. Blood 77:569-578, 1991
  pubmed

• 30) Dvorak AM, Furitsu T, Ishizaka T l Ultrastructural morphology of human mast cell progenitors in sequential cocultures of cord blood cells and fibroblasts. Int. Arch. Allergy Immunol. 100:219-229, 1993

• 31) Levi-Schaffer F, Austen KF, Gravallese PM, et al.:Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc. Natl. Acad. Sci. USA 83:6485-6488, 1986

• 32) Tsai M, Takeishi T, Thompson H, et al.:Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc. Natl. Acad. Sci. USA 88:6382-6386, 1991

• 33) Gurish MF, Ghildyal N, McNeil HP, et al.:Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J. Exp. Med. 175:1003-1012, 1992

• 34) Ghildyal N, Mcnail HP, Gurish MF, et al.:Transcriptional regulation of the mucosal mast cell-specific protease gene, MMCP-2, by interleukin 10 and interleukin 3. J. Biol. Chem. 267:8473-8477, 1992

• 35) Eklund KK, Ghildyal N, Austen KF, et al.:Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. J. Immunol. 151:4266-4273, 1993
  pubmed

• 36) Nakano T, Sonoda T, Hayashi C, et al.:Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. J. Exp. Med. 162:1025-1043, 1985
  pubmed

• 37) Kobayashi T, Nakano T, Nakahata T, et al.:Formation of the mast cell colonies in methylcellulose by mouse peritoneal cells and differentiation of these cloned cells in both the skin and the gastric mucosa of W/Wv mice:evidence that a common precursor can give rise to both "connective tissue-type" and "mucosal" mast cells. J. Immunol. 136:1378-1384, 1986
  pubmed

• 38) Gurish MF, Pear WS, Stevens RL, et al.:Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-comitted progenitor. Immunity 3:175-186, 1995

• 39) Toru H, Eguchi M, Matsumoto R, et al.:Interlukin-4 promotes the development of tryptase and chymase double positive human mast cells accompanied by cell maturation. Blood 91:187-195, 1998

• 40) Schwartz LB, Irani AM, Roller K, et al.:Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J. Immuno. 138:2611-2615, 1987

P.566 掲載の参考文献

• 1) Galli SJ:New concepts about mast cell. N. Engl. J. Med. 328:257-265, 1993
  pubmed

• 2) Gordon JR, Burd PR, Galli SJ:Mast cells as a source of multifunctional cytokines. Immunol. Today 11:458-464, 1990
  pubmed

• 3) Saito H, Ebisawa M, Tachimoto H, et al.:Selective growth of human mast cells induced by steel factor, IL6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350, 1996

• 4) Okayama Y, Church MK:Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int. Arch. Allergy Immunol. 97:216-225, 1992
  pubmed

• 5) Irani AA, Schechto NM, Craig SS, et al.:Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986

• 6) Pelaia G, Vatrella A, Marsico SA, et al.:New perspectives in asthma treatment. Allergy 55 (Suppl. 61):60-66, 2000

• 7) Wiederrecht G, Lam E, Hung S, et al.:The mechanism of action of FK-506 and cyclosporin A. Ann. NY. Acad. Sci. 696:9-19, 1993
  pubmed

• 8) Shichijo M, Inagaki N, Nakai N, et al.:The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin. Exp. Allergy 28:1228-1236, 1998
  pubmed

• 9) Matsuoka T, Hirata M, Tanaka H, et al.:Prostaglandin D2 as a mediator of allergicasthma. Science 287:2013-2017, 2000

• 10) Weston MC, Peachell PT:Regulation of human mast cell and basophil function by cAMP. Gen. Pharmacol. 31:715-719, 1998
  pubmed

• 11) Shichijo M, Inagaki N, Kimata M, et al.:Role of cyclic 3', 5'-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells. J. Allergy Clin. Immunol. 103:S421-S428, 1999
  pubmed

• 12) Kimata M, Shinchijo M, Miura T, et al.:Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin. Exp. Allergy 30:501-508, 2000

• 13) Garman SC, Kinet Jp, Jardetzky TS:Crystal structure of the human high-affinity IgE receptor. Cell 95:951-961, 1998
  pubmed

• 14) Suzuki H, Takei M, Yanagida M, et al.:Early and late events in FcεRI signal transduction in human cultured mast cells. J. Immunol. 159:5881-5888, 1997

• 15) Kimata M, Shinchijo M, Miura T, et al.:Ca2+ and protein kinase C signaling for histamine and sulfidoleukotrienes released from human cultured mast cells. Biochem. Biophys. Res. Commun. 257:895-900, 1999

• 16) Kimata M, Inagaki N, Kato T, el al.:Roles of mitogen-activated protein kinase pathways for mediator release from human cultured mast cells. Biochem. Pharmacol. 60:589-594, 2000

• 17) Toru H, Ra C, Nonoyama S, et al.:Induction of the high-affinity IgE receptor on human mast cells by IL-4. Int. Immunol. 8:1367-1373, 1996
  pubmed

• 18) Yamaguchi M, Sayama K, Yano K, et al.:IgE enhances Fcε receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells:synergistic effect of IL-4 and IgE on human mast cell Fcε receptor I expression and mediator release. J. immunol. 162:5455-5465, 1999

• 19) 田知本寛, 海老澤元宏, 斎藤博久:ステロイド・免疫抑制剤とマスト細胞. アレルギーの領域4:1213-1220, 1997

P.572 掲載の参考文献

• 1) Aloe L, Levi-Montalcini R:Mast cells increase in tissue of neonatal rats injected with nerve growth factor. Brain Res. 133:358-366, 1977
  pubmed

• 2) Matsuda H, Koyama H, Sato H, et al.:Role of nerve growth factor in cutaneous wound healing:accelerating effects in normal and healing-inpaired diabetic mice. J. Exp. Med. 187:297-306, 1998

• 3) Matsuda H, Switzer J, Coughlin MD, et al.:Human basophilic cell differentiation promoted by 2. 5S nerve growth factor. Int. Arch. Allergy Appl. Immunol. 86:453-457, 1988
  pubmed

• 4) Matsuda H, Coughlin MD, Bienerstock J, et al.:Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc. Natl. Acad. Sci. USA 85:6508-6512, 1988

• 5) Matsuda H, Kannan Y, Ushio H, et al.:Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow. J. Exp. Med. 174:7-14, 1991
  pubmed

• 6) Kawamoto K, Okada T, Kannan Y, et al.:Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Blood 86:4638-4644, 1995
  pubmed

• 7) Tanaka A, Sato H, Matsuda H, et al.:Nerve growth factor can inhibit transforming growth factor-β 1-induced apoptosis of rat peritoneal mast Cells. In:Kinases and Phosphatases in Lymphocyte and Nezaronal Signaling. ed. by Yakura H, Springer-Verlag, Tokyo, 1997, pp. 363-364

• 8) Aloe L:The effect of nerve growth factor and its antibody on mast cells in vivo. J. Neuroimmunol. 18:1-12, 1988
  pubmed

• 9) Sawada J, Itakura A, Tanaka A, et al.:Nerve growth factor functions as a chemoattractant for mast cells through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathway. Blood 95:2052-2058, 2000
  pubmed

• 10) Tanaka A, Arai K, Kitamura Y, et al.:Matrix metalloproteinase-9 production, a newly indentified function of mast cell progenitors, is down regulated by c-kit receptor activation. Blood 94:2390-2395, 1999

• 11) Kawamoto K, Aoki J, Tanaka A:Nerve growth factor activates mast cells through the collaborative interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets. (Submitted)

• 12) Tam SY, Tsai M, Yamaguchi M, et al.:Expression of functional Trk A receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 90:1807-1820, 1997

• 13) Nilson G, Forsberg-Nilsson K, Xiang Z, et al.:Human mast cells express functional Trk A and are a source of nerve growth factor. Eur. J. Immunol. 27:2295-2301, 1997

• 14) Xiang Z, Nilsson G:IgE receptor-mediated release of nerve growth factor by mast cells. Clin. Exp. Allergy 30:1379-1386, 2000
  pubmed

• 15) Welker P, Grabbe J, Grutzkau A, et al.:Effects of nerve growth factor and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology 94:310-317, 1998
  pubmed

• 16) Welker P, Grabbe J, Gibbus B, et al.:Nerve growth factor-beta induces mast cellmarker expression during in vitro culture of human umbilical cord blood cells. Immunology 99:418-426, 2000

• 17) Kanbe N, Kurosawa M, Miyachi Y, et al.:Nerve growth factor prevents apoptosis of cord blood-derived human cultured mast cells synergistically with stem cell factor. Clin. Exp. Allergy 30:1113-1120, 2000
  pubmed

P.582 掲載の参考文献

• 1) Ehrlich P:Beitrage zur kenntnis der Anilinfar-bungen und ihrer Verwendung in der mikros-kopischen Technik. A rch. Mikr. Anat. 131263-277, 1877

• 2) Kirshenbaum AS, Goff JP, Kessler SW, et al.:Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+pluripotent progenitor cells. J. Immunol, 148:772-777, 1992
  pubmed

• 3) Howkins KA, Claman HN, Clark RAF, et al.:Increased dermal mast cell proliferation in progressive systemic sclerosis:a link in chronic fibrosis?. Ann. Intern. Med. 102:182-186, 1985

• 4) Walls AF, Roberts JA, Godfrey RC, et al.:Histochemical heterogeneity of human mast cells:disease-related differences in mast cell subsets recovered by bronchoalveolar lavage. Int. Arch. Appl. Immunol. 92:233-241, 1990
  pubmed

• 5) Dayton ET, Caulfield Jp, Hein A, et al.:Regulation of the growth rate of mouse fibroblasts by IL-3-activated mouse bone marrow-derived mast cells. J. Immunol. 142:4307-4313, 1989
  pubmed

• 6) Levi-Schaffer F, Kupietzky A:Mast cells enhance migration and proliferation of fibroblasts in vitro wound. Exp. Cell. Res. 188:42-49, 1990
  pubmed

• 7) Rubinchik E, Levi-Schaffer F:Mast cell activation is fibrogenic for 3T3 fibroblasts. J. Allergy Clin. Immunol. 93:193, 1994

• 8) Abe M, Kurosawa M, Igarashi Y, et al.:Influence of IgE-mediated activation of cultured human mast cells on proliferation and type I collagen production by human dermal fibroblasts. J. Allergy Clin. Immunol. 106:S72-S77, 2000
  pubmed

• 9) Jordana M, Befus A, Newhouse MT, et al.:Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax 43:552-558, 1988
  pubmed

• 10) Abe M, Kurosawa M, Ishikawa O, et al.:Effect of mast cell-derived mediators and mast cellrelated neutral proteases on human dermal fibroblast proliferation and type I collagen production. J. Allergy Clin. Immunol. 106:S78-S84, 2000
  pubmed

• 11) Schwartz LB, Lewis RA, Austen KF:Tryptase from human pulmonary mast cells. Purification and characterization. J. Biol. Chem. 256:11939-11943, 1981
  pubmed

• 12) Cairns JA, Walls AF:Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997
  pubmed

• 13) Hartmann T, Ruoss SJ, Raymond WW, et al.:Human tryptase as a potent, cell-specific mitogen:role of signaling Pathways in synergic responses. Am. J. Physiol. 262:L528-L534, 1992
  pubmed

• 14) Abe M, Kurosawa M, Ishikawa O, et al.:Mast cell tryptase stimulates both human dermal fibroblast proliferation and type I collagen production. Clin. Exp. Allergy 28:1509-1517, 1998
  pubmed

• 15) Needleman BW, Choi J, Burrows-Mezu A, et al.:Secretion and binding of transforming growth factorβby scleroderma and normal dermal fibroblasts. Arthritis Rheum. 33:650-656, 1990

• 16) Gruschwitz M, Muller PU, Sepp N, et al.:Transcription and expression of transforming growth factor type beta in the skin of progressive sclerosis:amediator of fibrosis?. J. Invest. Dermatol. 94:197-203, 1990
  pubmed

• 17) Broekelmann TJ, Limper AH, Colby TV, et al.:Transforming growth factorβ 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 88:6642-6646, 1991

• 18) Kanbe N, Kurosawa M, Nagata H, et al.:Cord blood-derived human cultured mast cells produce transforming growth factorβ1. Clin. Exp. Allergy 29:105-113, 1999

• 19) Kanbe N, Kurosawa M, Nagata H, et al.:Prodution of fibrogenic cytokines by cord blood-derived cultured human mast cells. J. Allergy Clin. Immunol. 106:S85-S90, 2000